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Abstract 
Multiple sclerosis (MS) is an inflammatory, autoimmune disorder of the central nervous 
system (CNS) with considerable heterogeneity in clinical outcome and a leading cause of 
disability in young adults. The disease is caused by interplay of genetic and environmental 
factors and recent evidence suggests a role for an adverse lipid profile (low HDL, increased 
LDL and triglycerides) and comorbidity in MS clinical course. This thesis therefore 
investigates the etiological role of the serum lipid profile and comorbidity in the onset and 
progression of the disease. 
A literature review on the role of vascular comorbidities in the onset and progression of MS 
showed a potential association of vascular comorbidities with MS risk and disability 
progression. However, the number of prospective studies was sparse, thus precluding 
ascription of causality. It was therefore recommended that future studies of the frequency and 
effects of vascular comorbidities on MS risk and disability should be prospective and 
objective where relevant. A literature review on the frequency of commonly reported 
autoimmune comorbidities in MS and the contribution of interferon-beta (IFN-β) to the 
frequency of thyroid autoimmunity and dysfunction in MS patients identified a consistent 
increase in the risk of clinical thyroid disorder, inflammatory bowel disease and psoriasis 
among people with MS compared to a comparator population. It also appears that IFN-β 
therapy is associated with higher occurrence of thyroid autoimmunity and dysfunction 
compared to IFN-β naive MS patients. It was recommended that future studies should have a 
population-based design with large sample size and a concurrent control to minimize 
heterogeneity due to differences in study design. 
The Tasmanian MS Longitudinal Study was used to examine the association between serum 
lipid profile and disability, progression in disability and time to relapse in a cohort with 
established disease. A cohort of 178 MS patients was followed for a total of 2.5 years and 
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serum samples and other data were obtained at each biannual review. Among 141 relapsing–
remitting MS patients, neither body mass index (BMI) nor any of the lipid-related measures 
were associated with the hazard of relapse. In relation to disability, higher levels of total 
cholesterol (TC), apolipoprotein B (ApoB) and apolipoprotein B to apolipoprotein A-I ratio 
(ApoB/ApoA-I ratio) were associated with a greater disability. In addition, a significant 
independent effect of BMI on disability was observed. This suggests that clinicians should 
monitor and treat adverse lipid profiles and BMI. Importantly, a higher TC/HDL ratio was 
associated with faster accrual of disability, suggesting that lipid lowering interventions may 
be of benefit for people with MS.  
The Tasmanian MS Longitudinal Study was also used to examine whether the frequency of 
comorbidities was higher in MS patients compared to the Australian population and whether 
comorbidities were associated with clinical disability and relapse. It was found that age-
standardised prevalence of hypertension, dyslipidaemia, psoriasis, eczema, asthma and 
anaemia was significantly higher in the MS cohort compared to the general Australian 
population and that reporting overweight/obesity and dyslipidaemia was associated with 
significantly higher disability. However, there was no significant association with annual 
change in disability. In the relapse analysis, rheumatoid arthritis and anaemia were associated 
with increased risk of relapse.  
The final set of analyses was conducted using the Ausimmune Longitudinal Study 
(AusLong), an internationally unique cohort with a first clinical diagnosis of demyelination, 
which has been followed annually up to five year review.  The association between serum 
lipids and conversion to clinically definite MS (CDMS), time to relapse and annualised 
change in disability was investigated. It was found that higher BMI and triglycerides were 
associated with increased risk of relapse while none of the serum lipid-related variables were 
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significantly associated with conversion to CDMS. In addition, higher BMI and TC/HDL 
ratio was associated with a higher annualised change in clinical disability. 
In summary, this thesis presents a number of epidemiological studies suggesting that 
improving the lipid profile, decreasing BMI into the healthy range and increasing physical 
activity may reduce the risk of comorbidity and modulate the accumulation of disability. 
Further, long-term monitoring and treatment of lipid profile and comorbidities in MS is 
recommended in order to prevent increased morbidity as people age with their MS. We 
examined reverse causality, and this cannot be completely ruled out in these observational 
studies. Regardless of the direction of some associations, the findings of this thesis are 
important from a clinical perspective, and the increased awareness of this issue may assist in 
an improved management of the disease. 
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Chapter 1 Epidemiology and clinical characteristics of MS 
 
1.1 Preface 
This Chapter gives a general background of multiple sclerosis, its geoepidemiology, clinical 
features, clinical course, risk factors, pathogenesis and immunomodulatory treatment. 
Information is also provided on serum lipid classification, metabolism and associated 
diseases.  This is to provide succinct literature on MS relevant for understanding of the thesis. 
1.2  General overview 
Multiple sclerosis (MS) is an autoimmune, inflammatory disorder of the central nervous 
system (CNS) with considerable heterogeneity in outcome and a leading cause of physical, 
mental and visual disability in young adults.
1
 Although genetic susceptibility explains the 
clustering of MS within families
2
, it cannot fully explain the geoepidemiological variations in 
MS frequency
3
 and the changes in risk factors associated with migration
4
 or MS disease.
5
 
Further, the observation that concordance rates in monozygotic twins are considerably less 
than 100% shows that MS is a complex disease, in which multiple environmental and 
lifestyle risk factors act together in a genetically susceptible individual to cause the disease.
6-8
 
A number of aetiological factors have been identified to play a role in MS susceptibility and 
disease progression. Among the aetiological factors associated with MS, low sun exposure or 
ultraviolet radiation (UVR) exposure,
9
 low 25-hydroxyvitamin D (25(OH)D),
10
 infection with 
Epstein-Barr virus,
11
 and cigarette smoking
12
 stand out because of the strength of supporting 
evidence. In relation to the genetics of MS, both HLA (Human Leukocyte Antigen) and non-
HLA
13
 regions have been significantly associated with increased risk and progression of the 
disease.  
Increasing evidence also suggests that serum lipids and comorbidities are associated with the 
disease course of MS.
14, 15
 Serum lipids have been associated with clinical disability,
14, 16
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progression of disability
14, 16
 and disease activity on magnetic resonance imaging.
16
 
Comorbidities have been associated with the clinical course of MS,
17
 disability progression,
15
 
health-related quality of life,
18
 and increased mortality.
19
  
MS has a highly variable inter and intra-personal clinical course, both in pattern and rate of 
deterioration.
1
 While there is a marked female to male sex ratio of the disease
10
, this seems to 
be increasing
20
 with generally no difference in the severity of the disease between the male 
and female.
21
 The typical age of onset of MS is in the third and fourth decades of life but the 
burden of disease is most marked in the fifth to seventh decades.
1
  
In the study of the geoepidemiology of MS, one of the most striking features observed has 
been a positive latitudinal gradient in incidence
22, 23
 and prevalence
24
 but recent studies have 
underlined an attenuation of the gradient in MS incidence.
25
 Conversely, studies continue to 
report increasing incidence and prevalence of MS
26, 27
 with increase in the sex ratio over 
time.
23, 28
 This raises the question whether the latitudinal gradient is a real 
geoepidemiological feature or an artefact and whether the increase in incidence is a real effect 
or due to alteration in diagnostic criteria and ascertainment. Month of birth (MOB) has 
previously been described as a risk factor for MS and hypothesised to be related to maternal 
vitamin D levels during pregnancy
29, 30
 but this effect has not been consistently shown.
31, 32
 
There is currently no cure for MS. Available immunomodulatory therapy may help reduce the 
number of relapses, severity of symptoms and reduce the progression of disability to improve 
the quality of life of people with MS. Since the advent of disease-modifying drugs (DMDs) 
for MS, studies have been carried out to assess their effect on disease outcome.
33, 34
 While 
they are effective in reducing relapses, their effect on long-term disability is largely 
unknown.
34, 35
 It is therefore expedient to critically assess whether their extensive use is 
warranted. 
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In summary, the scope of this thesis will investigate the role of the serum lipids and 
comorbidities in the onset and progression of MS. This Chapter is intended to provide a 
general overview and critical examination of the epidemiology of MS, its clinical course and 
features, risk factors associated with the disease and those that operate in disability 
progression, pathophysiology and immunomodulatory treatment of the disease. This is to 
provide succinct literature on MS relevant for understanding of the thesis.  
1.3 The epidemiology of MS 
1.3.1 Increasing incidence and prevalence of MS  
MS affects more than 2.5 million individuals worldwide
36
, with higher incidence and 
prevalence in women than men.
10
 The prevalence of MS in Australia in 2010 was 21,283 
people and at the rate of 95.5 per 100,000 people. The incidence and prevalence of MS have 
been reported to vary geographically.
24, 37
 High prevalence areas of the world (prevalence of 
≥30 per 100,000) include New Zealand, Israel, south-eastern Australia, northern parts of 
Europe, North America and southern Canada. In many of these geographical areas, 
prevalence is more than 100 per 100,000 with a highest reported estimate of 300 per 100,000 
in the Orkney Islands. Medium prevalence areas (5-30 per 100,000) include southern Europe, 
most of Australia, Ukraine, southern United States, Central and South America. Low 
prevalence areas (<5 per 100,000) include Africa, Asia and South America.
23, 38
 This 
geographic variation in MS frequency may be explained in part if not all by both differences 
in environmental factors as well as racial differences.  
Accumulating epidemiological studies on MS suggest a trend of increasing incidence over the 
last few decades which partly explains the observed increase in prevalence.
39-43
 However, it 
remains to be clarified whether these increased rates reflect a real increase in MS incidence or 
merely due to temporal changes which can be linked to changes in diagnosis and treatment 
such as earlier diagnosis, alterations in diagnostic criteria and better case ascertainment.
39, 44
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In Newcastle, Australia, there has been a significant progressive increase in the incidence rate 
of MS, increasing from 1.2 to 2.4 per 100,000 population between 1950–1959 and 1986–
1996 and a significant increase in the age-standardized prevalence from 19.6 and 59.1 per 
100,000 population between 1961 and 1996.
45
 Similarly, in Hobart, Australia, the age-
standardized incidence increased from 2.2 per 100,000 to 3.7 per 100,000 between 1951-1961 
and 2001-2009 and the crude prevalence increased from 32.5 per 100,000 in 1961 to 125.2 
per 100,000 in 2009.
46
 
In Canada
47
, the incidence rate has increased from 5.2 to 22.3 between 1985–1989 and 1990–
2004. In Sassari province of Sardinia, the incidence has increased from 1.1 to 5.8 between 
1965–1969 and 1995–1999.40 Increased incidence rates have also been reported in France44, 
Netherlands
48
, Japan,
39
 Finland,
49
 Norway
43, 50
 and Italy.
51
 
In addition to a meta-analyses of MS prevalence and incidence, Koch-Henriksen and 
Sorensen
23, 25
 examined cases of incidence studies that had been repeated after some years or 
decades in the same population. These authors reported that the repeated surveys showed a 
progressive increase in incidence with time.
23, 25
 However the increase in incidence was not 
universal. For instance, in the population of Olmsted County, Minn., USA, whose registry 
depends on the Mayo Clinic, the incidence rates of MS appear to have been stable rather than 
increasing over the past 20 years.
42
 Similarly, the trend of incidence in Orkney,
52, 53
 
Shetland
52, 54
 and Gothenburg, Sweden
55
 has been relatively stable or decreasing. 
Although improvements in diagnostic accuracy could be responsible for the reported 
increased incidence, the marked increase over time cannot be explained by alterations in 
ascertainment or diagnostic criteria alone. For instance in northern Japan, the diagnostic 
criteria have not been changed since 2000 and therefore the trend of increased incidence 
observed after this period strongly suggests a possible real increased risk of MS.
39
 In 
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Sardinia, where the population is relatively genetically homogeneous and stable, repeated 
surveys have shown increasing disease incidence. The time scale of these changes tends to 
suggest changes in environmental factors.
40
 
In summary, evidence from available data shows an increased incidence (leading to increased 
prevalence) of MS over the last few decades but this increase is not universally found. The 
increase overrides changes in diagnostic methods, access to care and ascertainment which 
suggest real increase in the risk of MS. Understanding why these changes occurred would 
shed light on the causes of MS.  
1.3.2 Latitudinal gradient of incidence and prevalence of MS 
Early in the study of the epidemiology of MS, one of the most striking hallmarks of the 
disease was a latitudinal distribution of MS, with increasing latitudinal gradient in incidence 
and prevalence
56
 in both the northern and southern hemispheres. For instance in Australia, 
studies have established strong relationship between MS frequency and latitude, with the 
prevalence of MS reported to be more than six times higher in Hobart, Tasmania, which is in 
the south compared to tropical Queensland in the north.
57-59
 Also, the incidence and 
prevalence of MS in Hobart is almost twice that of Newcastle and Perth.
59, 60
 Similarly, in 
New Zealand, studies have demonstrated a robust association between MS frequency and 
latitude, with the prevalence of MS increasing three-fold from the Auckland (in the North) to 
Otago ( in the South).
61
 
While latitudinal gradients have also been demonstrated in North America,
62
 Japan and 
Europe,
63
 this has not been universally found. Other studies have found no significant 
association between MS prevalence and latitude in Argentine Patagonia,
64
 Canada
65
 and 
Norway.
66
 Also, studies in Sardinia
67
 have reported higher prevalence than expected for their 
latitudes, while studies in Norway
68
 have found a lower prevalence than expected for their 
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latitudes. Evidence also suggests that the gradient of MS incidence may be decreasing.
5, 69, 70
 
This has led some authors
56, 62, 69
 to suggest that the gradient is not real.  
In an effort to investigate this issue and to provide evidence for or against the existence of a 
latitudinal gradient of MS frequency, data from individual studies have been combined and 
analysed using meta-analyses. Zivadinov and colleagues
71
 in the first meta-analysis of MS 
frequency, combined data from 22 incidence and 69 prevalence estimates published between 
1980 and 1998. They reported a highly significant latitudinal gradient for the crude 
prevalence which was attenuated for the age and sex- standardised prevalence and the effect 
on incidence disappeared after age-adjustment. Alonso and Hérnan
22
 undertook a meta-
analysis of MS incidence, including 38 age-standardised incidence estimates between 1966 
and 2007. These authors reported that higher latitude was associated with higher MS 
incidence, but this latitudinal gradient was attenuated after 1980. They concluded that the 
gradient which was present in older incidence studies is decreasing. 
Recently, Koch-Henriksen and Sørensen published two meta-analyses
23, 25
 of MS prevalence 
and incidence, reporting a clear trend of latitudinal gradient of incidence in Australia and 
New Zealand but without a significant latitudinal gradient of prevalence. In Western Europe 
and North America, the authors reported modest latitudinal gradient of prevalence but no 
association was found between incidence and latitude even when the search was restricted to 
surveys published before 1980 or 1970. In 2011, Simpson and colleagues
24
 conducted a more 
comprehensive meta-analysis of MS prevalence studies, including 650 prevalence estimates 
from 321 peer-reviewed studies in 59 countries between 1923 and 2009. These authors found 
a significant positive association between age-standardised prevalence and latitude. Further, 
these authors noted exceptions to the gradient in the Italian region and northern Scandinavia, 
which they suggested are explicable by genetic and behavioural-cultural variations. These 
authors argued that the meta-analyses by Koch-Henriksen and Sørensen
23
 had significant 
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methodological shortcomings for reporting no association between latitude and prevalence, or 
incidence after adjusting for study prevalence year in Australasia.  
In addition, some migration studies
72
 if not all have reported that persons migrating from 
lower to higher latitude after the age of puberty are thought to carry their former high risk 
with them, while those that migrate prior to puberty seem to have the risk associated with the 
new area to which they migrated.
69
 This finding has been replicated by an Australian study.
73
 
In summary, evidence from the systematic reviews examined above shows that the latitudinal 
gradient of incidence and prevalence is a real geoepidemiological feature and not a 
manifestation of poor methodology. However, this gradient is not universally found and the 
intensity of the gradient may be decreasing, which has been suggested to be due to increasing 
incidence of MS in lower latitudes or regions closer to the equator.
22
  
1.3.3 Age of onset and sex ratio of MS frequency  
The mean age of MS onset ranges from 28 to 31 years. The onset of MS can occur as late as 
the seventh decade, although rarely. The mean age of onset is a few years earlier for women 
than for men.
74
 Those who have the type of MS that starts with relapses (relapsing-remitting 
(RR) MS) tend to have an earlier onset, averaging 25 to 29 years. Those with RRMS may 
convert to a progressive phase at a mean age of 40 to 49 years.
75
 The mean age of onset for 
those whose onset is progressive rather than relapsing is substantially later, generally around 
40 years of age.
76
 For the definitions of the types of MS clinical course mentioned under this 
section, see section 1.4.2. 
A well-noted feature of MS is the characteristic pattern of higher susceptibility in females 
compared to males. In relation to this feature, recent studies have suggested that the sex ratio 
of MS appears to be dynamic, thus varying significantly over time.
23
 While in the past it was 
shown that there are two women for every man with a diagnosis of MS,
3
 most recent studies 
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have reported a sex-ratio of about three women for every man, especially in patients 
diagnosed with RRMS.
3
 
 In a large population-based study from Canada, the female to male sex ratio increased 
significantly from 1.9:1.0 to 3.2:1.0 for those born in 1931–1940 and for those in born 1976–
1980 respectively.
28
 In Denmark
77
, the sex ratio increased from 1.3:1.0 in 1950 to 2.0:1.0 in 
2005. In Wales
27
, the sex ratio increased from 1.8:1.0 in 1985 to 4.3:1.0 in 2007. In Iran
78
, the 
sex ratio increased from 2.0:1.0 in 2002 to 3.1:1.0 in 2008 and in Japan
79
, the sex ratio 
increased from 1.2:1.0 in 1972 to 2.9:1.0 in 2004.  
In a meta-analysis by Simpson and colleagues, the global prevalence sex ratio increased from 
1.4:1.0 in 1949 to 2.3:1.0 in 2009, but this did not reach statistical significance (p<0.12) in 
this sample size.
24
 However, there was a statistically significant increase in the prevalence 
sex ratio over time in Australasia (p<0.023) and the UK region (p<0.003).
24
 This increasing 
trend has been noted by another recent meta-analysis showing that the worldwide sex ratio of 
MS has been substantially increasing over the last century.
23
 In another systematic review by 
Alonso and Hernan, for each five-year period, the male-to-female incidence ratio increased 
6% on average, from a predicted mean sex ratio of 1.4 in 1955 to 2.3 in 2000. Recent increase 
in female incidence of MS has also been reported in France,
44
 in Norway,
50
 in Australia,
45
 
and Germany
80
. In conflict with the above finding, Boström and colleagues
81
 reported a 
stable sex ratio trend in Sweden. Simpson and colleagues also did not find any change in the 
sex ratio in greater Hobart over time.
46
 Data from high MS prevalence areas, such as New 
Zealand, has also shown sex ratio stability over time.
61
 This increase in female preponderance 
mainly affected patients with relapsing onset MS. (RRMS). Interestingly, female sex has also 
been shown to vary with latitude
82
 and that the rate at which MS prevalence increases with 
decreasing UVB was also higher in females than in males.
83
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In summary, many studies reported an increasing trend of the sex ratio in MS and only few 
studies documented a stable sex ratio over time. It is therefore apparent that the sex ratio is 
increasing but this is not universally found. This increasing sex ratio of MS parallels MS 
incidence and a key driver for the worldwide increasing prevalence of this devastating 
disease. The rapid increase in the female preponderance occurring over a century is 
suggestive of environmental exposure to which only females are susceptible rather than 
genetic cause which requires time. A relative increase in smoking in women has been 
proposed to partly explain the increasing sex ratio in women.
23, 84
 However this was mainly 
driven by a decline of smoking among men.
85
 Other factors such as older age at birth, 
reduced offspring number and reduced UV radiation in the first trimester of pregnancy have 
been suggested to contribute to the increasing sex ratio of MS. Further studies are needed to 
provide evidence as to what environmental factors are influencing the sex ratio. 
1.3.4 Month of birth effect in MS 
The MOB or season of birth effect describes the relationship between MOB and subsequent 
or future risk of MS. In the northern hemisphere, people born in spring months (March, April, 
May) have been reported to have slightly increased risk of MS and those born in winter 
(November, December, January) have a reduced risk.
29, 86, 87
 A recent meta-analysis 
replicated a significant excess of MS risk in those born in April (1.07, p=0.002) and May 
(1.11, p=0.0006), and a reduced risk in those born in October (ratio 0.94, p=0.004) and 
November (0.88, p=0.0002).
30
 
Similar to the pattern in the northern hemisphere, two studies conducted in the southern 
hemisphere reported risk of MS with MOB. In Australia, Staples and colleagues
88
 observed 
an increased risk of MS for those born in early summer (November-December) compared 
with those born in early winter (May-June) given that the seasons are reversed between the 
two hemispheres. In Brazil, Becker and colleagues
32
 demonstrated that births in the spring 
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(October, November & December) showed an increased risk of MS, whereas births in the 
autumn (April, May & June) had lower risk. Conversely, no month of birth effect has been 
reported in some studies in both hemispheres.
89, 90
 
The probability of being born in the spring is positively correlated with latitude, whereas the 
probability of being born in the winter is negatively correlated. A recent meta-analysis on the 
subject also showed a latitudinal variation in the month of birth effect. 
30
 This season of birth 
effect was recently demonstrated to be a manifestation of UV exposure of the mother during 
early pregnancy.
88
 
In challenge of this finding, Fiddes and colleagues
91
 reported that the relationship between 
MOB and risk of MS may be false positive finding because studies have not controlled for 
year and place of birth. However, a study that showed a significant MOB effect in MS risk by 
Staples and colleagues
88
 did adjust for region of birth and year of birth. In another study 
conducted in Sardinia, where cases were matched with family members as controls, an MOB 
effect was again observed.
92
 
In summary, evidence from the studies examined suggests that there may be a true 
relationship between MOB and future MS risk. More studies are however needed that 
adequately adjusted for confounders including year of birth and region of origin in order to 
accurately estimate the magnitude of this effect.  
1.4 Clinical features and clinical course of MS 
1.4.1 Clinical signs and symptoms 
MS has no unique clinical signs and symptoms, but some are highly characteristic of the 
disease. Sign and symptoms of MS may vary depending on the part of the central nervous 
system affected. The onset is often polysymptomatic where patients usually manifest 
heterogeneous group of signs and symptoms. The most common symptoms of MS include 
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sensory symptoms in limbs or face, vision loss (unilateral visual loss, diplopia), ataxia 
(difficulties with coordination and balance), and acute or subacute muscle weakness and 
spasms. Additional signs and symptoms that may develop with the disease course include 
fatigue, pain, gait disturbance and balance problems, Lhermitte’s sign (electric shock-like 
sensations that run down the back and/or limbs upon flexion of the neck), dysarthria 
(problems in speech), vertigo, bladder and bowel dysfunction, acute transverse myelopathy, 
dysphagia (problems in swallowing), tremor and seizures.
93, 94
 
Progression of the disease after onset may eventually lead to accumulation of disability. A 
number of measures have been created to clinically assess disability progression and 
symptom severity. Some of these include the Expanded Disability Status Scale (EDSS), 
Multiple Sclerosis Severity Score (MSSS) and Scripps Neurologic Rating Scale (NRS). The 
EDSS is the gold standard in assessing physical disability in MS, which utilises a ten-point 
disease severity scale from 0 (normal) to 10 (death due to MS).
95
 The EDSS is limited, in that 
it has a limited sensitivity and non-linear scale. MSSS is a useful measure of MS severity, 
which partially corrects for the limitation of the EDSS. The MSSS is a cross-sectional 
measure of disability progression, as it uses the EDSS and takes disease duration into 
account.
96
 
1.4.2 Clinical course of MS 
In 1996, a unified categorisation of MS clinical course was published.
97
 In that publication, 
the clinical course of MS was characterized as: relapsing-remitting, secondary progressive, 
primary progressive and progressive-relapsing MS. Since then, an increased understanding of 
MS and its pathology prompted a re-examination and revision of the disease phenotypes in 
2013.
97-99
 The newer characterization of MS phenotypes was dependent on consideration of 
clinical relapse rate, imaging findings and disease progression. Progressive relapsing MS has 
been eliminated from the clinical course descriptions and clinically isolated syndrome has 
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been added.
98
 This is to provide objective criteria and to ensure accurate separation or 
description of the phenotypes.
98, 99
 This is particularly crucial for the purpose of design and 
recruitment of clinical trials, management and treatment decision-making, prognostication 
and communication.
98, 99
  
The clinical course of MS has been categorized into four clinical subtypes based on the core 
phenotype characteristics of relapsing and progressive disease. The clinical subtypes now 
include clinically isolated syndromes (CIS), relapsing-remitting MS (RRMS), secondary-
progressive MS (SPMS) and primary-progressive MS (PPMS). 
1.4.2.1 Clinically isolated syndromes (CIS) 
CIS is the first clinical presentation of a disease that demonstrates characteristics of 
inflammatory demyelination isolated in time that could possibly convert to definite MS, but 
has yet to meet the diagnostic criteria for MS.
99, 100
 Common presentations of CIS include 
optic neuritis, a brainstem and/or cerebellar syndrome and spinal cord syndrome.
100
 
The core requirement for the diagnosis of MS is the objective demonstration of dissemination 
of lesions in the CNS in both space and time, based upon either clinical findings alone or a 
combination of clinical and MRI findings. Also, for individuals with CIS to become definite 
MS patients, they may have to develop a second exacerbation or relapse.
100, 101
  
For patients with CIS who have MRI lesions at baseline, the chance of developing definite 
MS is about 60% to 80% by 10 years, and CIS patients who have a normal baseline MRI 
have a 20% chance of developing MS within 10 years.
100
 
1.4.2.2 Relapsing-remitting MS (RRMS) 
RRMS is the most predominant form of the disease, accounting for more than 80% of cases. 
The relapsing-remitting form is characterised by unpredictable relapses followed by 
remissions.
94, 102
 A relapse is defined as the acute or subacute appearance or reappearance of 
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a neurological abnormality typical of an acute inflammatory demyelinating event in the 
central nervous system (lasting at least 24 hours), immediately preceded by a stable, 
improving, or slowly progressive neurological state for 30 days, in the absence of fever, 
known infection, concurrent steroid withdrawal, or externally derived increases in body 
temperature.
102, 103
 Most patients with RRMS will eventually enter a secondary-progressive 
phase.  
1.4.2.3 Secondary progressive MS (SPMS) 
A subset of persons with RRMS will after some amount of time convert to a progressive form 
of disease, featuring a steady accrual or progression to increased disability and worsening of 
function. Relapses can be seen during the early stages of SPMS, but are uncommon as the 
disease further progresses. Because there are no established criteria or predictors to determine 
when RRMS converts to SPMS, the diagnosis of SPMS is made retrospectively.
99, 104
 The 
conversion from RRMS to SPMS usually takes 10 to 20 years after disease onset. In one 
study, the median time from CIS to the development of SPMS was 19 years, while the 
median time from MS diagnosis to SPMS was 12 years.
105
 
1.4.2.4 Primary progressive MS (PPMS) 
PPMS is characterized by progressive accumulation of disability from disease onset without 
any relapses or remission.
104
 The PPMS form of the disease may account for about 10-15% of 
MS cases at disease onset.
104, 106
 A common clinical presentation of PPMS is a spinal cord 
syndrome with spastic paraparesis. PPMS patients have a more even sex distribution than 
RRMS and tend to have a worse prognosis for ultimate disability in comparison with patients 
who have RRMS.
107
  
1.5 Environmental, lifestyle, genetic factors in MS onset and progression 
1.5.1 Sun exposure and MS 
One explanation proposed for the observed association of MS with latitude is that exposure to 
sunlight may be protective, either because of an effect of ultraviolet radiation (UVR) directly 
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or via UVR-induced production of vitamin D.
5
 The protective effect of UVR-induced 
immunosuppression, direct or indirect via vitamin D, on MS is a plausible explanation of the 
gradient as ambient UVR levels decrease with increasing latitude.
108
 In line with this 
hypothesis, a number of studies have found an inverse relationship between sun exposure, 
serum levels of vitamin D and the risk or disease course of MS.
83, 109-112
 
Sun exposure and risk of MS was investigated in the EnvIMS study.
113
 A total of 1660 MS 
patients and 3050 controls from Italy and Norway were included in the multinational case-
control study to estimate the association between MS and measures of sun exposure in 
specific age periods. They reported significant association between infrequent summer 
outdoor activity and increased MS risk in Norway and Italy. The association was strongest 
between the ages of 16 and 18 years in Norway (OR: 1.83, 95% CI: 1.30–2.59) and between 
birth and age 5 years in Italy (OR 1.56, 95% CI: 1.16–2.10). In Italy, a significant association 
was also found during winter (OR 1.42, 95% CI: 1.03–1.97). 
In one of the pioneering case-control studies conducted by van der Mei and colleagues
109
 to 
investigate whether past high sun exposure is associated with a reduced risk of MS, 136 MS 
cases and 272 controls were randomly drawn from the community and matched on sex and 
year of birth. The authors reported a dose-response relationship between MS and decreasing 
sun exposure when aged 6-15 years. Higher sun exposure when aged 6-15 years was 
associated with a decreased risk of MS (OR: 0.31, 95% CI: 0.16 - 0.59). 
Islam and colleagues
114
 also studied the role of childhood sun exposure on the risk of MS in 
79 pairs of identical twins where only one of the twins had MS. They found that the twin who 
developed MS had significantly lower sun exposure during childhood compared to the co-
twins without MS. The risk of MS was substantially lower (OR: 0.40, 95% CI: 0.19 - 0.83) 
for the twin who spent more time in the sun compared with the co-twin. 
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1.5.2 Vitamin D and MS 
There are two major forms of vitamin D. These are ergocalciferol and cholecalciferol. The 
physiologically active form is 1,25-dihydroxyvitamin D (1,25(OH)2D) and the circulating 
metabolite used for assessment of vitamin D status is 25-hydroxyvitmain D (25(OH)D.
115
 
Vitamin D has been known for its role in calcium homeostasis, brain development and 
function, cardiovascular and musculoskeletal health, anti-neoplastic properties, regulation of 
insulin production, anti-inflammatory properties and immunomodulatory effects.
116
 A 
number of prospective studies have shown that low vitamin D intake
117
 or serum vitamin D 
status
110
 are associated with increased risk of developing MS. In a prospective, nested case-
control study among more than 7 million US military personnel, the risk of MS among the 
whites significantly decreased with increasing levels of 25(OH)D (Odds Ratio (OR) for a 50 
nmol/L increase in 25(OH)D: 0.59; 95% CI: 0.36-0.97).
110
 
Consistent with this evidence, a prospective cohort study using the Nurses' Health Study 
(NHS; 92,253 women followed from 1980 to 2000) and Nurses' Health Study II (NHS II; 
95,310 women followed from 1991 to 2001) examined the direct relationship between dietary 
vitamin D intake and risk of MS and reported that the risk of developing MS was 
significantly reduced for women in the highest quintile of total vitamin D intake at baseline 
compared to those in the lowest (Relative Risk (RR): 0.67; 95% CI: 0.40 - 1.12; p-trend 
0.03).
117
 
A number of studies were also conducted to investigate the relationship between vitamin D 
and clinical course of MS – relapse and disability. Simpson and colleagues118 conducted a 
prospective cohort study of 145 participants with RRMS followed from 2002 to 2005 to 
investigate whether higher levels of serum 25(OH)D measured every six months were 
associated with a lower risk of relapses in people with MS. In that study, there was an inverse 
linear relationship between 25(OH)D levels and the hazard of relapse over the subsequent six 
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months, with hazard ratio (HR) of 0.91 per 10nmol/L increase in 25(OH)D level (HR: 0.91; 
95% CI: 0.85–0.97; p=0.006). 
To determine whether serum concentrations of serum vitamin D status predict disease activity 
and prognosis in patients with a clinically isolated syndrome, 465 patients were followed up 
for 5 years clinically and by magnetic resonance imaging.
119
 From analysis of the results, 
higher vitamin D levels predicted reduced MS activity and a slower rate of progression. A 50-
nmol/L increment in average serum vitamin D levels within the first 12 months predicted a 
57% lower rate of new active lesions (p<0.001), 57% lower relapse rate (p=0.03), 25% lower 
yearly increase in T2 lesion volume (p<0.001), and 0.41% lower yearly loss in brain volume 
(p=0.07) from 12 to 60 months. In analyses using dichotomous vitamin D levels, values 
greater than or equal to 50 nmol/L at up to 12 months predicted lower disability (EDSS score: 
-0.17; p=0.004) during the subsequent four years. 
Smolders and colleagues investigated the association between serum levels of 25(OH)D and 
1,25-dihydroxyvitamin D (1,25(OH)2D), and clinical MS severity as expressed by EDSS 
score and relapse rate. They reported that low 25(OH)D levels were associated with high 
EDSS scores and high 25(OH)D levels were associated with a high chance of remaining 
relapse-free.
120
 In a study by Thouvenot and colleagues, a retrospective cohort analysis was 
performed in 181 MS patients without previous vitamin D supplementation. Disability 
(EDSS) was assessed in relation to vitamin D levels. From the analysis, there was a negative 
correlation between vitamin D level and EDSS score (r= –0.33, p<0.001). 
A longitudinal study by Soilu-Hanninen and colleagues followed MS patients and healthy 
controls for 12 months and measured their level of serum vitamin D every three months and 
at the time of MS relapse. They reported that there was a significantly lower serum vitamin D 
level during MS relapse than in remission.
121
 Similarly, a case-control by Soilu-Hanninen 
confirmed that serum vitamin D levels were significantly lower in MS relapse than in 
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remission.
122
 In the same line, Smolders and colleagues in a cross-sectional study reported 
that a high serum vitamin D level was associated with a high chance of remaining relapse-
free.
120
  
However, a case-control study by Nikanfar reported that there was no significant association 
between serum vitamin D levels and disability in MS patients (r= −0.08, p=0.280).123 Another 
study by Hatamian and colleagues showed no significant relationship between EDSS score 
and serum vitamin D levels in people with MS (p=0.35), after adjusting for covariates.
124
 
Randomised clinical trials investigating the potential therapeutic benefits of vitamin D in MS 
patients were conflicting.
125-127
 A systematic review of randomized, double-blind, placebo-
controlled trials examining the clinical efficacy of vitamin D in MS was conducted by 
Pozuelo-Moyano and colleagues.
128
 Five clinical trials were included in the review.  Out of 
the five clinical trials included in the review, four of the trials showed no evidence of 
beneficial effect of vitamin D on any clinical outcome of MS measured and one showed a 
significant inverse relationship between vitamin D and number of T1 enhancing lesions on 
brain magnetic resonance imaging. Evidence from these studies was limited by small study 
sizes, heterogeneity of dosing, form of vitamin D tested and clinical outcome measured.  
In summary, sun exposure and vitamin D were associated with the risk and disease course of 
MS. Measurement of sun exposure is subject to measurement error and recall bias since 
studies rely on subjects to approximate past sun exposure. Further, measurement of 25 (OH) 
D levels is subject to measurement error and systematic bias and this error increases with 
increasing 25(OH)D level. Although studies have demonstrated a fairly consistent inverse 
relationship between sun exposure/vitamin D and MS risk and disease course, randomised 
controlled trials on the efficacy of vitamin D to modulate the risk and progression of MS are 
inconsistent. Even though vitamin D supplementation appears to be a promising treatment 
worthy of further exploration, the paucity of published randomised controlled trials, small 
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study sizes and use of different doses in studies makes the evidence for vitamin D as a 
treatment for MS inconclusive. A number of large trials are now being conducted which will 
hopefully address some of these concerns. 
 
1.5.3 Cigarette smoking 
Several epidemiological studies have demonstrated a link between cigarette smoking and 
subsequent development of MS and rapid progression of the disease. Cigarette smoking may 
be seen as an important risk factor for MS given that it is relatively easily modified and could 
provide insights into the pathogenesis of the disease.
129
  
In 2009, a large case–control study by Hedstrom and colleagues demonstrated that cigarette 
smoking was associated with increased risk of MS. Smokers of both sexes had an increased 
risk of developing MS compared to never-smokers (OR: 1.4, 95% CI: 1.2–1.7 for women, 
and OR: 1.8, 95% CI: 1.3–2.5 for men).130 This finding was replicated by a larger cohort 
study of 277,777 male Swedish construction workers that assessed the risk of MS associated 
with cigarette smoking. Ever-smoking was associated with an increased risk for MS 
compared with never-smoking (RR: 1.9; 95% CI: 1.4–2.6).131  
A meta-analysis was conducted by Hawkes to assess the relationship between smoking and 
risk of MS. The meta-analysis of six studies showed significantly increased susceptibility to 
MS in smokers compared to non-smokers, with overall odds ratio ranging from 1.25 to 
1.51.
132
 As a follow-up to the earlier meta-analysis, Handel and colleagues conducted a meta-
analysis using a total of 14 articles, representing 3,052 cases and 457,619 controls. They 
reported that smoking was associated with 48% increased risk of MS (RR: 1.48, 95% CI: 
1.35–1.63, p<0.001). 
In MS disease course, a relationship has been established between cigarette smoking and 
disability progression. Smoking has also been associated with increased risk of early 
 
 
19 
 
progression from clinical isolated syndrome (CIS) to clinically definite MS
133
 and conversion 
from RRMS to secondary-progressive disease.
134, 135
 In a prospective Tasmanian cohort 
study, Pittas and colleagues
136
 followed 203 MS patients for a median of 909 days and 
smoking data were collected at baseline and six-monthly reviews. In a dose–response fashion, 
smoking was positively associated with the progression of clinical disability measured as 
MSSS (p=0.001). Similar results were found when EDSS was used as the clinical disability 
outcome. In addition, smoking was associated with an increased risk of a progressive course 
at MS onset rather than a relapsing-remitting course. However, smoking during the cohort 
period was not associated with the hazard of relapse (HR: 0.94; 95% CI: 0.69–1.26). 
In a study aimed at investigating the effects of smoking on disability progression and disease 
severity in a cohort of 895 patients with clinically definite MS, the risk of reaching EDSS 
score milestones of 4 was 34% higher in  in ever-smokers compared to never-smokers (1.34 
(95% CI: 1.12–1.60) and a milestone 6 was 25% higher in ever-smokers compared to never-
smokers (1.25 (95% CI: 1.02–1.51).137 Similarly, current smokers showed 64% increased risk 
of reaching EDSS scores of 4 (1.64 (95% CI: 1.33–2.02) and 49% increased risk of reaching 
EDSS scores of 6 (1.49 (95% CI: 1.18–1.86) compared with non-smokers. This study 
demonstrated that regular smoking may be associated with more severe disease and faster 
disability progression. 
To replicate and establish a relationship between cigarette smoking and MS progression, 
Healy and colleagues
134
 conducted a large cross-sectional survey with 1,465 MS patients and 
a subsequent longitudinal follow-up for an average of 3.29 years. From the analysis, current 
smokers had significantly worse disability at baseline than never-smokers as measured by 
EDSS (p<0.001) and MSSS (p<0.001). In longitudinal analyses, progression from RRMS to 
secondary-progressive disease occurred faster in smokers than in never smokers (HR: 2.50, 
95% CI: 1.42, 4.41). In addition, compared to never-smokers, smokers had a faster rate of 
 
 
20 
 
increase in the T2 lesion volume (p=0.017) and a faster rate of decrease in brain parenchymal 
fraction (p=0.021). 
 
Not all studies found a significant relationship between smoking and MS progression. For 
instance, a cross-sectional Dutch survey of 364 patients with MS by Koch and colleagues 
found no effect of cigarette smoking on disease progression or accumulation of disability.
138
  
Also, a meta-analysis of four studies by Handel and colleagues showed a trend towards 
significant association between smoking and increased risk of secondary-progressive disease 
from RRMS (RR: 1.88, 95% CI: 0.98–3.61, p=0.06) but with considerable heterogeneity.139 
In summary, the majority of the current epidemiological data suggest that cigarette smoking 
is associated with increased MS susceptibility and progression of the disease. A dose–
response effect with higher consumption of cigarettes resulting in increased susceptibility and 
progression of clinical disability was reported in some studies. The overall magnitude of 
effect of smoking on MS susceptibility or disease course was small but the prevalence is 
substantial making the population attributable fraction (PAF) relatively high (PAF: 40.8%; 
95% CI: 27.3–60.1)140 suggesting that smoking prevention efforts are worthwhile. Further 
studies evaluating the effect of smoking on the risk and course of established MS may shed 
light on the underlying disease mechanisms which may provide new insights for the better 
management and prevention of MS. 
1.5.4 Epstein-Barr virus (EBV) and MS  
Many infectious agents have been identified to be associated with MS etiology and 
pathogenesis. The most consistent findings were in relation to past infection with EBV and a 
history of infectious mononucleosis (IM) and levels of some EBV markers.
116
 Although EBV 
infection in the general population has been described as being ubiquitous, evidence from 
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systematic reviews and meta-analyses have consistently demonstrated a positive relationship 
between EBV and MS risk and disease course. 
Infectious mononucleosis (IM), a frequent clinical manifestation of primary EBV infection 
during adolescence or adulthood, has been consistently associated with the risk of developing 
MS.
141
 It has been consistently demonstrated that a history of infectious mononucleosis had a 
positive relationship with the subsequent occurrence of MS and this symptomatic 
manifestation of EBV infection beyond the immunotolerant phase earlier in life is an 
independent risk factor contributing to the cause of MS.
142
.  
Thacker and colleagues
143
 in 2006 conducted a systematic review and meta-analysis of 11 
case–control studies and 3 cohort studies to assess the role of a history of IM as a risk of MS. 
From the meta-analysis, the combined relative risk of MS after history of IM from the 14 
studies was 2.3 (95% CI: 1.7–3.0; p<0.001). As an extension of this work, Handel and 
colleagues
11
 identified articles published since the original meta-analysis investigating MS 
risk following IM. A total of 18 articles were included in this study, representing 19,390 MS 
cases and 16,007 controls. From the results, history of IM was strongly associated with more 
than two-fold increased risk of MS (RR: 2.17; 95% CI: 1.97–2.39; p<0.001). 
Several studies have been conducted investigating the association between the risk of MS and 
serological parameters of EBV. For instance, Ascherio and Munger
144
 investigated the risk of 
MS in EBV seronegative versus seropositive subjects by reviewing 13 epidemiological 
studies. They reported an odds ratio of 0.06 (95% CI: 0.03–0.13, p<0.001) indicating that the 
risk of MS in the EBV seronegative individuals is many folds lesser than that of the EBV 
positive individuals. As a follow-up to this work, Pakpoor and colleagues
145
 conducted a 
meta-analysis of 22 epidemiological studies aiming to investigate the association between 
MS and EBV. The authors reported that the odd ratio for developing adult MS in EBV 
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seronegatives was significantly lower compared to the EBV seropositive  individuals (OR: 
0.18; 95% CI: 0.13–0.26). 
A more recent systematic review and meta-analysis of the seroepidemiological association 
between EBV and risk of MS by Almohmeed and colleagues
146
 included 39 studies in 
systematic review and meta-analysis. The meta-analysis showed a significant higher 
seropositivity to anti-EBNA IgG (OR: 4.5; 95% CI: 3.3–6.6, p<0.001) and anti-VCA IgG 
(OR: 4.5; 95% CI: 2.8–7.2, p<0.001) in cases compared to controls. No significant difference 
in seropositivity to anti-EA IgG was found (OR: 1.4; 95% CI: 0.9 –2.1, p<0.09). 
In the disease course of MS, changes in MRI and changes in disability are the main 
exhibitions of progression, while relapse considered a measure of disease activity. The 
progression of disability in MS is mainly measured by EDSS or MSSS. In a longitudinal 
study by Simpson and colleagues
147
 to investigate the relationship between anti-EBV IgG 
titers and MS clinical course, a prospective cohort of 198 clinically definite MS patients of 
the Tasmanian MS Longitudinal study was used. They found that neither antibodies to EBNA 
nor VCA was associated with the hazard of relapse. There was no evidence that higher anti-
EBV-EBNA IgG or anti-EBV-VCA IgG levels were associated with level of or change in 
disability. 
Similarly, in a study by Farrell and colleagues
148
 to investigate disease activity, EBNA-1 IgG 
correlated with change in EDSS (r= 0.3, p=0.035). Further, gadolinium-enhancing lesions on 
MRI correlated with EBNA-1 IgG (r= 0.33, p<0.001). EBNA-1 IgG also correlated with 
change in T2 lesion volume (r=0.27, p=0.044). 
A study was also conducted to determine the immune responses to EBV candidate viral 
triggers of MS in patients with CIS, and to evaluate their potential value in predicting 
conversion to MS.
149
 There was a correlation between immune responses to EBNA1 and 
EDSS and T2 lesions during follow-up. In a univariable Cox regression model, increased 
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EBNA1-specific IgG responses predicted conversion to MS (HR: 2.2; 95% CI: 1.2-4.3 
p=0.003). In other studies, lesion volume or number of lesions measured by MRI has been 
associated with antibody levels to EBNA1.
148-150
 Another important viral marker, viral capsid 
antigen (VCA) has also been associated with a greater atrophy in total brain and increased 
lesion volume in MRI image.
151
 
Although EBV infection is ubiquitous, epidemiological studies have established a 
relationship between EBV and MS risk and disease progression. The temporal relationship 
that exists between infection with EBV in adulthood or development of antibodies against 
EBV antigens year before disease onset, supports an etiological role of EVB in MS. 
However, further studies are warranted to investigate whether this relationship is causal. 
1.5.5 Genetic susceptibility  
There is substantial genetic epidemiological evidence supporting a role of genetic risk factors 
in the development of MS. Genetic studies of twins, sibling and adoptees have helped to 
distinguish between environmental and genetic cause of the disease. In these twin studies, the 
risk of developing MS for identical twins (genetically identical) varies between 15% and 39% 
in different populations. The risk of developing MS for fraternal twins (50% of genetic 
component in common) is about 3% to 5% which approaches the recurrence rate in other 
biological siblings.
6, 7, 152
  
Another distinguished feature of the genetic susceptibility of MS is the marked familial 
aggregation. While MS is not hereditary disease, having a first-degree relative such as a 
sibling or parent with MS does substantially increase a person’s risk of developing the 
disease. Nearly 10% to 20% of MS patients have another relative with MS.
153-155
 First-degree 
relatives of an MS patient are 18 to 36 times more likely to acquire MS compared with the 
general population.
153, 154
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The frequency of familial MS varies from 3% to 23% in different studies. One well-designed 
population study of 8,205 Danish patients with MS found that the relative lifetime risk of MS 
was increased sevenfold (95% CI: 5.8-8.8) among first-degree relatives (n = 19,615).
156
 The 
excess familial lifetime risk for first-degree relatives was 2.5% (95% CI: 2.0-3.2) added to 
the sporadic absolute risk of MS in Danish women and men of 0.5% and 0.3%. These 
sporadic rates from the Danish population are among the highest in the world. 
Further evidence for genetic susceptibility in MS comes from half-sibling, stepsibling and 
adoptees studies.
155, 157, 158
 Age-adjusted full-sibling (50% of genome in common) risk is 
reported to be 3.1%, while half-sibling (25% of genome in common) risk in the same families 
was 1.89%, which is significantly lower and around half of the risk for full siblings.
157
 In 
addition, the risk of MS in stepsiblings who share no genetic component was 
indistinguishable from that of the general population.
157
 From these studies, it could be 
concluded that the risk of MS increases for the family members of MS patients who have 
more genes in common. 
Data from whole-genome association studies indicate that the risk of developing MS is 
associated with certain class I and class II alleles of the major histocompatibility complex 
(MHC) on chromosome 6p21.
159-161
 Variations in the HLA-DRB1 gene are thought to be the 
strongest genetic risk factors for developing MS. Variations in several HLA genes have been 
associated with increased MS risk, but one particular variant of the HLA-DRB1 gene, called 
HLA-DRB1*15:01, is the most strongly linked genetic factor. 
Systematic attempts to identify linkage in multiplex families have confirmed that variation 
within the major histocompatibility complex (MHC) exerts the greatest individual effect on 
risk.
161
 When susceptibility has been fine-mapped to an extended HLA Class II haplotype 
DQA1*0102 DQB1*0602 DRB1*1501 DRB5*0101, the estimated relative risk ranged 
between 2 and 4.
162
 The three candidate risk genes of this haplotype, HLADRB1*1501 
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(encoding HLA-DR2b), HLADRB5*0101 (encoding HLADR2a) and HLADQB1*0602 
(encoding HLA-DQ6), are so tightly linked that they are almost invariably inherited 
together.
163
 The association is strongest in northern Europeans, but is seen in virtually all 
populations with a notable exception in some Mediterranean populations where MS is 
associated with DR4.
162
 
Apart from HLADRB1*15, there are other risk increasing alleles. For instance, 
HLADRB1*17 increases the risk of MS but to a lesser extent when compared to 
HLADRB1*15.
162, 164
 When inherited together, HLADRB1*14 completely abrogates any risk 
associated with HLADRB1*15. The relative risk of MS for carrying the HLA-DRB1*15 
allele is about three. A combination of HLADRB1*14 and HLADRB1*15 reduces the 
relative risk to approximately one.
162
 Epistasis, (complex gene–gene interactions) has also 
been indicated to occur in the HLA region. For example, HLA-DRB1*08 which has a modest 
effect, more than doubles the risk associated with HLA-DRB1*15.
162
 In addition, 
HLADRB1*01 and HLADRB1*10 protect against MS but only in the presence of HLA-
DRB1*15 that operate from the other chromosome—that is in trans162, 165, 166, although 
reports from Sweden suggest that HLADRB1*01 may be protective on its own.
167
  
The HLADRB1 gene belongs to a family of genes called the human leukocyte antigen (HLA) 
complex. The HLA genomic region encodes the MHC, a key protein complex involved in 
identification of the body's own proteins from proteins made by foreign invaders (MHC Class 
I), as well as in antigen presentation (MHC Class II). Each HLA gene has many different 
normal variations, allowing each person's immune system to react to a wide range of foreign 
proteins.  
Several genome-wide association studies have provided genome-wide significant support for 
several non-HLA MS risk genes.
168-170
 Among these are IL7R, IL2R, CLEC16A
171-173
, CD58 
173
, CD226
171
, KIF1B
174
, KIF21B
175, 176
, CD6
177
, IRF8
177
, TNFRSF1A 
177
, and two loci on 
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chromosome 12 and 20, which have been suspected to relate to the genes CD40 and 
CYP27B1
178
, TYK2 and STAT3.
179
 Strikingly most of these molecules are associated with 
immune function.  
1.6 Serum lipids: Lipoprotein classification, metabolism, and role in MS 
1.6.1 Lipoproteins 
Lipoproteins are complex aggregate of spheroidal macromolecules of lipids and proteins. 
Lipoproteins function as transporter molecules for lipids such as cholesterol and triglycerides, 
for fat and other fat soluble nutrients like vitamins A, K, D and E. Lipoproteins also function 
in regulating lipid synthesis and catabolism and maintaining cholesterol homeostasis.
180
 
Cholesterol like all the other fats and fat-soluble vitamins are not water-soluble and are 
insoluble in blood, hence the requirement to be carried in “packages” called lipoproteins. 
They transport lipids from the blood to various tissues (adipose and other cells) and different 
organs (liver) for energy utilization, lipid deposition, steroid hormone production, and bile 
acid formation.
181, 182
 Lipoproteins consist of a hydrophobic core containing phospholipid, 
fat-soluble antioxidants and vitamins, and cholesteryl ester, and a hydrophilic coat that 
contains free cholesterol, phospholipid and protein molecules referred to as apolipoprotein.
182
 
Lipoproteins consist of the following parts: 
 A core of fats (triglycerides), cholesterol esters (cholesterol linked to fatty acids), and 
fat-soluble vitamins. 
 A monolayer membrane of phospholipids and small amounts of free cholesterol. 
 Proteins called “apoprotein” which may be “integral” apoproteins (apoA or apoB) 
penetrating as a transmembrane protein through the monolayer membrane, compared 
to the “peripheral” apoproteins (apoC or apoE) that are on the outer surface of the 
phospholipid membrane. 
27 
Apoproteins determine the overall structures and metabolism of lipoproteins, and the 
interactions with receptor molecules in liver and peripheral tissues. Lipoproteins are 
classified or distinguished from each other by size, relative densities of the aggregates on 
ultracentrifugation, relative mobility on electrophoresis on agarose gels, composition and 
function.
181, 182
 The densities of these lipoproteins are related to the relative amounts of lipids
to proteins in the complex. The higher the protein content the higher the density of the 
lipoprotein. By density, chylomicrons are the lowest in density followed by the chylomicron 
remnants, very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low 
density lipoprotein (LDL), and high density lipoproteins (HDL). According to the 
nomenclature based on the relative mobility on electrophoresis on agarose gels, HDL, VLDL 
and LDL corresponds to α, preβ and β lipoproteins respectively. 
There are 5 distinct lipoproteins: In increasing order of density, these are 
 Chylomicrons: They are the largest lipoproteins and transport exogenous lipid (mainly
triglycerides) from intestine to all cells.
 VLDL: transport endogenous lipid (mainly triglycerides) from liver to cells.
 IDL: they are transient and formed during the conversion of VLDL to LDL. They are
not normally present in plasma.
 LDL: they are formed from VLDL and carry cholesterol to cells
 HDL: they transport cholesterol from cells back to liver (reverse cholesterol
transport). These lipoprotein can be further divided by density into HDL2 and HDL3
Each lipoprotein contains a specific content of protein, triglyceride, cholesterol and 
cholesterol ester (table 1.1). From table 1.1 below, the large chylomicron molecules and 
VLDL are the main carriers of triglyceride in blood compared to the IDL, LDL and HDL 
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molecules carrying predominantly cholesterol ester. Triglyceride molecules consist of one 
glycerol molecule attached by an ester bond to 3 fatty acid molecules. Triglycerides form the 
basis of our energy stores of fatty acids and may provide fuel for beta-oxidation to generate 
ATP. Cholesterol ester is cholesterol esterified to one fatty acid molecule and is essentially 
the mechanism by which cholesterol is transported to various cells for use in cell membranes. 
The integrity and stability of cell membranes is dependent on the relative content of these 
fatty acids and cholesterol. Cholesterol is also the precursor of many hormones including 
Cortisol, Aldosterone, Testosterone and Oestrogen, all vital to optimal health. 
 
Table 1.1: Physical properties and lipid compositions of lipoprotein classes 
 Chylomicron VLDL IDL LDL HDL 
Density (g/ml) < 0.94 0.94-1.006 1.006 – 1.063 1.006-1.063 1.063-1.210 
Diameter (Å) 6000-2000 600 250 250 70-120 
Protein 1% 10% 10% 20% 50% 
Triglyceride 85% 55% 10% 13% 6% 
Cholesterol 2% 7% 11% 10% 7% 
Cholesterol 
ester 
3% 18% 50% 48% 40% 
Phospholipids 8% 20% 29% 24% 46 
Table reproduced from Saba and Oridupa
183
. 
1.6.2 Apoproteins 
The protein components of lipoproteins are called apoproteins (apo). They are synthesized in 
the liver, intestine, brain and other tissues. The apoproteins have important roles in lipid 
transport and metabolism. They have specific structural domains that are recognized by cell 
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receptors. Apoproteins have amphipathic α-helixes that are thought to be essential for 
apoprotein-phospholipid interaction.
180
 
The affinities of the apoproteins for the surface components of the lipoprotein change during 
lipoprotein metabolism. Apoproteins often diffuse from one lipoprotein and bind to another. 
Only apoprotein B (apoB48 & apoB100) are non-exchangeable and therefore maintains its 
association with the lipoprotein during the cycle of lipoprotein metabolism.  
ApoA is the major apoprotein associated with HDL. ApoA-I and apoA-II are activators of 
lecithin-cholesterol acyltransferase (LCAT) and hepatic lipase respectively. ApoB100 is the 
predominant apoprotein found with LDL and it is the ligand for LDL receptor. The ratio of 
apoA to apoB has been used as a risk of cardiovascular disease risk. Table 1.2 summarizes 
the main types of apoproteins, lipoproteins associated with and their function. ApoE has three 
isoforms (E2, E3, and E4). ApoE is a ligand for hepatic chylomicron and VLDL remnant 
receptor and for LDL receptor. ApoE is also synthesized in the brain and involved in lipid 
homeostasis. ApoD are mainly associated with HDL and may function as multiple ligand 
protein. 
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Table reproduced from Saba and Oridupa
183
. 
  
1.6.3 Serum lipid synthesis and metabolism 
Lipids are derived exogenously from food or synthesized endogenously in the body. The 
exogenous pathway starts with the intestinal absorption of dietary cholesterol and fatty acids. 
The endogenous pathway starts in the liver. The mechanisms regulating the amount of dietary 
cholesterol and fatty acids that is absorbed are unknown.  
1.6.3.1 Chylomicron 
Chylomicron is an endogenously synthesized lipoprotein that transports dietary lipids to 
peripheral tissues and the liver. Within the intestinal cells, free fatty acids released from 
dietary fats by digestion combine with glycerol to form triglycerides, and cholesterol is 
esterified by cholesterol acyltransferase (ACAT) to form cholesterol esters. Inside the jejunal 
enterocytes, triglycerides, cholesterol, phospholipids and ApoB48, are then assembled to form 
chylomicrons. Chylomicrons enter the circulatory system through the thoracic duct. 
Table 1.2: Classes of apoproteins, their molecular weight and functions 
 Apoprotein  Molecular 
weight 
 Lipoprotein  Function 
Apo A1 28,100 HDL Lecithin cholesterol acyltransferase (LCAT) 
activation. Main structural protein. Binds 
ABCA1 on macrophages 
Apo A2 17,400 HDL Enhances hepatic lipase activity 
Apo A4 46,000 CM  
Apo AV(5) 39,000 HDL Enhances triacylglycerol uptake 
Apo B48 241,000 CM Derived from Apo B100 – lacks the LDL 
receptor 
Apo B100 512,000 LDL, VLDL Binds to LDL receptor 
Apo C1 7,600 VLDL, CM Activates LCAT 
Apo C2 8,900 VLDL, CM Activates lipoprotein lipase 
Apo C3 8,700 VLDL, CM Inhibits lipoprotein lipase 
Apo D 33,000 HDL Associated with LCAT, progesterone 
binding 
Apo E 34,000 HDL At least 3 forms. Binds to LDL receptor 
Apo(a) 300,000-
800,000 
LDL, Lp(a) Linked by disulfide bond to apo B100 and 
similar to plasminogen 
Apo H, J, L   Poorly defined functions 
Apo M  HDL Transports sphingosine-1-phosphate 
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The main apoprotein of chylomicron is Apo B48, but Apo CII and Apo E are acquired in the 
lymph and plasma as the chylomicrons enter the circulation. Lipoprotein lipase (LPL) 
through the Apo CII cofactor hydrolyses the core triglycerides to free fatty acids and 
glycerol, a process that yields chylomicron remnant particles. The free fatty acids are then 
used as an energy source by muscle cells or stored in adipose tissue. The chylomicron 
remnants enriched in cholesterol, ApoB and ApoE then bind rapidly to hepatic chylomicron 
remnant receptors (LDL-receptor-related protein), for which apoE is a high affinity ligand. 
Within the hepatic cells the cholesterol is utilized and the apoprotein catabolized. Thus, 
chylomicron facilitates the delivery of triglycerides to muscles and adipose tissue and 
cholesterol to the liver.
184
 
The liver has a central role in the endogenous cholesterol synthesis and metabolism. The 
endogenous pathway of serum lipid metabolism begins with the synthesis of VLDL by the 
liver. VLDL is a large particles containing a core of triglycerides (synthesized from fatty acid 
and glycerol) and cholesterol esters (synthesized locally or derived from chylomicron 
remnants). VLDL also consists of apoCII which acts as a cofactor for lipoprotein lipase, 
apoCIII which inhibits this enzyme, and apoB100 and apoE which serve as ligands for the 
apoB100 and ApoE receptor respectively.
184, 185
 
In peripheral tissues, lipoprotein lipase hydrolyses the triglyceride core of nascent VLDL 
particles to free fatty acids and glycerol. The free fatty acids released by lipolysis can be 
either used as substrates by skeletal muscle or myocardium, or can be taken up by adipose 
tissue and then reassimilated into triglyceride for storage. 
During lipolysis, the triglyceride core of the VLDL particle is reduced, generating VLDL 
remnant particles called IDL. VLDL remnants can either be cleared from the circulation by 
the apoB100/ apoE receptors or further hydrolysed by the endothelial enzyme hepatic lipase to 
LDL by losing triglyceride and apoE.
184, 185
 
 
 
32 
 
1.6.3.2 LDL 
LDL is produced by VLDL catabolism and not directly secreted from hepatocytes of the 
liver. LDL particles are concentrated with cholesterol and cholesterol esters and depleted of 
triglycerides and containing only apoB100. They are the major carriers of the total plasma 
cholesterol.  
LDL can be taken up by both hepatic and non-hepatic tissues. Within these tissues or cells, 
LDL particles are broken down by lysosomes to release cholesterol. This cholesterol 
internalized by non-hepatic cells is used in steroid hormone production, cell membrane 
synthesis or stored in the esterified form. In the liver, cholesterol is converted to bile acids 
and secreted into the intestinal lumen.
186
 The internalization of LDL is regulated by cellular 
cholesterol requirements through negative feedback control of apoB100 and apoE receptor 
expression. Cells in positive feedback cholesterol balance suppress apoB100 and apoE 
receptor expression.
186
  
Although most of the plasma LDL is removed by LDL receptors, if plasma cholesterol is 
excessive, LDL particles can infiltrate tissues by passive diffusion and can cause damage as 
in atheroma formation. Alternatively, LDL is removed through the scavenger cell pathway 
which only recognises chemically modified LDL as in oxidised LDL. 
Decreased activity of HMG CoA reductase, the enzyme that controls the rate of de novo 
cholesterol synthesis by the cell, leads to a decrease in cell cholesterol, increased expression 
of apoB100 and apoE receptors, and enhanced uptake of cholesterol from the circulation 
thereby reducing the plasma cholesterol concentration. Statin drugs inhibit this rate-limiting 
enzyme to reduce biosynthesis cholesterol. 
Chemically modified LDL such as oxidized LDL can also enter macrophages and some other 
tissues through the unregulated scavenger receptor. This pathway can result in excess 
accumulation of intracellular cholesterol and the formation of foam cells, which contribute to 
the formation of atheromatous plaques. 
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1.6.3.3 HDL 
HDL is associated with reverse cholesterol transport, a series of enzymatic reactions that 
stimulate the transport of intracellular cholesterol from non-hepatic tissues back to the liver 
for elimination as bile salts or biliary cholesterol.
187
 HDL is cardio-protective because of the 
reverse cholesterol transport system, increased atherosclerotic plaque stability, protection of 
LDL from oxidation and maintaining the integrity of the vascular endothelium. 
During chylomicron and VLDL lipolysis, apoproteins in their phospholipid surface coats (apo 
AI, apo AII, apo CII) are released and can be used to form HDL in serum. HDL particles can 
also be secreted de novo from hepatocytes and jejunal enterocytes. HDL consists of free 
cholesterol, phospholipids, apoE with apoA as the predominant apoprotein. 
HDL acquires free cholesterol from tissue sites and other lipoproteins as the nascent HDL 
particles contain relatively little cholesterol. This cholesterol acquisition is stimulated by 
adenosine triphosphate-binding cassette protein 1 (ABC1). ApoA-I on the surface of HDL 
plays a central role in this process. It serves as a signal transduction protein to mobilize 
cholesterol esters from intracellular pools. After diffusion of free cholesterol onto HDL, the 
cholesterol is esterified to cholesterol esters by lecithin cholesterol acyltransferase (LCAT), a 
plasma enzyme that is activated primarily by apoA-I. This esterified cholesterol is either 
directly transported to the liver by HDL or transferred to LDL, VLDL and chylomicron 
remnants for delivery to the liver for excretion in bile or taken up for steroid hormone 
synthesis. Cholesterol ester transfer protein (CETP) is involved in these processes. HDL also 
contains other enzymes including paraoxonase which has antioxidant role.  
By a similar mechanism, HDL can act as an acceptor for cholesterol released during lipolysis 
of triglyceride containing lipoproteins. Cholesterol efflux regulatory protein also appears to 
play an important role in the uptake of cellular cholesterol by HDL by promoting the transfer 
of intracellular cholesterol to the cell membrane.
188, 189
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1.6.3.4 Lipoprotein (a) 
Lipoprotein (a) often shorten as Lp(a) is a unique macromolecular lipoprotein which consists 
of LDL covalently bound to apoprotein(a) or apo(a) by a disulphide bridge.
190, 191
 They are 
believed to be assembled extracellularly, either in circulation or at the surface of the 
hepatocytes.
192
 The function or metabolic fate of Lp(a) has been elusive probably because of 
its similarity to LDL.
193
 An elevated level of Lp(a) has been shown to be an independent risk 
factor for cardiovascular disease.
193, 194
 This may be due to its high affinity for the arterial 
wall and athero-thrombogenic properties.
191, 193, 195
 Interestingly, lipoprotein-lowering drugs 
such as statins do not significantly alter or reduce Lp(a) levels.
193
 However, nicotinic acid 
(LDL-apheresis) has been reported to have moderate efficacy.
196
 
1.6.4 Disorders of lipid metabolism 
1.6.4.1 Familial hypercholesterolemia 
This is usually an inherited autosomal dominant disorder. The inheritance of one mutant gene 
that encodes for the LDL receptor results in impaired LDL catabolism and 
hypercholesterolemia.
197
 Depending on the type of mutation, there may be reduced synthesis 
of LDL receptor, failure of transport of the synthesized receptor to the Golgi complex within 
the cell, defective LDL binding or inadequate expression or defective recycling of the LDL 
receptor at the cell surface.
198
 
Clinically, familial hypercholesterolemia is characterized by a high total cholesterol and LDL 
cholesterol level from birth, a propensity to tendon xanthomata, and early onset coronary 
heart disease.
197, 198
 It affects about 1 in 500 people in most populations.
198
 The associated 
impairment in function of these receptors results in reduced clearance of LDL particles from 
the circulation and an elevation in plasma LDL cholesterol. There is also increased uptake of 
modified LDL by the macrophage scavenger receptors, resulting in macrophage lipid 
accumulation and foam cell formation.
199
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Individuals heterozygous for an LDL receptor mutation express half the normal number of 
functional receptors on their cell surface. Their cells bind, internalize, and degrade plasma 
LDL at half the normal rate. This produces a twofold elevation in plasma LDL cholesterol 
concentration (300 to 500 mg/dl). The excess plasma LDL cholesterol deposits in tendons 
and arterial walls, forming tendon xanthomas and atherosclerotic plaques (30).
198
 
1.6.4.2 Familial combined hyperlipidaemia  
Familial combined hyperlipidaemia may be inherited as an autosomal dominant lipid 
disorder. Others have argued that it may involve multiple susceptibility genes.
200
 In affected 
families, some individuals may experience high triglyceride levels, some high cholesterol 
levels and some may experience both. In many cases, familial combined hyperlipidaemia 
may be caused by overproduction of hepatically derived apoB100 associated with VLDL or a 
decrease in its catabolism.
200
 About 0.5 per cent of the European population is affected, and 
there is an increased incidence of coronary artery disease in family members. Familial 
combined hyperlipidaemia is thought to cause up to 10% of the coronary heart disease 
occurring before the age of 60 years.
201
  
1.6.4.3 Familial hypoalphalipoproteinemia 
Familial hypoalphalipoproteinemia is an autosomal dominant disorder that has been linked to 
premature coronary heart disease (CHD) and stroke.
202, 203
 Affected individuals and their 
relatives have low levels of high density lipoprotein-cholesterol and apoprotein A. The defect 
appears to be due to mutations in the apoA-I gene.
204
  
1.6.4.4 Familial HDL deficiency and Tangier disease 
Familial HDL deficiency is an autosomal dominant disorder associated with very low serum 
HDL concentrations and premature CHD.
205, 206
 Tangier disease is an autosomal co-dominant 
condition. Homozygotes have elevated plasma triglyceride levels and HDL deficiency and 
heterozygotes have HDL cholesterol and apoA concentrations about half that of normal 
individuals.
206, 207
 The defect in both familial HDL deficiency and Tangier has been 
 
 
36 
 
associated with mutations in the ATP-binding cassette transporter (ABC1), the gene that 
encodes for the cholesterol efflux regulatory protein.
205, 208
 
HDL mediated cholesterol efflux from macrophages and intracellular lipid trafficking are 
impaired in this disorder, leading to the presence of foam cells throughout the body and 
hepatosplenomegaly, peripheral neuropathy, and frequently premature coronary disease.
207, 
209
 
1.6.4.5 Abetalipoproteinemia (Bassen-Kornzweig Syndrome) 
Abetalipoproteinemia (ABL) is a rare Mendelian disorder of lipid metabolism caused by a 
mutation in the gene encoding the microsomal triglyceride transfer (MTTP) protein.
210
 MTTP 
is an endoplasmic reticulum protein that transfers triglycerides, cholesteryl esters, and 
phospholipids to apoB100 in the hepatocyte and apolipoprotein apoB48 in the enterocyte. 
The mutation in MTTP prevents apoB100 and apoB48 from combining with triglycerides to 
form VLDL and chylomicrons, respectively.
210
 The absence of functioning chylomicrons 
inhibits effective lipid absorption in the intestines leading to hypolipidaemia, fat 
malabsorption, and neurologic disorders. The absence of VLDL results in the accumulation 
of triglycerides within hepatocytes and results in significant steatosis.
210, 211
 
Consequently, patients with ABL exhibit intestinal lipid malabsorption, low plasma lipid 
levels, hepatic steatosis, and neurological and ophthalmological symptoms.
210
 
Unless treated, abetalipoproteinemic subjects develop gastrointestinal, neurological, 
ophthalmological, and haematological abnormalities.
211
 
1.6.5 The role of lipids in the aetiology of MS 
The role of serum lipids in the aetiology of MS will be described in Chapter two. 
1.7 Pathogenesis of MS 
MS is a heterogeneous disorder characterised by variable clinical course. The major 
pathologic mechanisms that cause the clinical manifestations include inflammation, 
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demyelination and axonal degeneration.
94, 212
 Early in the disease course, MS involves 
recurrent bouts of CNS inflammation that results in damage to the myelin sheath surrounding 
axons as well as extensive axonal loss. Histologic examination reveals foci of severe 
demyelination, decreased axonal and oligodendrocyte numbers, and gliotic scarring. The 
exact cause of inflammation remains unclear, but an autoimmune response directed against 
CNS antigens is suspected.
213
 
It is believed that early in the disease course, disruption of the blood-brain barrier (BBB) at 
active lesion points facilitates increased permeability and the migration of inflammatory cells 
from the periphery into the CNS.
214, 215
 T cells are widely considered to be primary effectors 
of the autoimmune CNS inflammation that characterizes MS.
216, 217
 In MS, it has been 
proposed that autoreactive T cells from the periphery become activated by presentation of 
antigens,
218
 which may include myelin basic protein, proteolipid protein and myelin 
oligodendrocyte glycoprotein.
219, 220
 Upon antigen presentation, naive T cells bearing the 
CD4-I- surface marker may differentiate into effector subsets including Thl, Th2 and Thl7.
221
 
T-cell subtypes with particular relevance in MS pathogenesis include T helper-1 (Thl), Th17, 
superantigen reactive yô and CD8+ cells generally considered to mediate inflammation with 
resultant neurodegeneration.
216, 217
 Functional deficits among regulatory T cells (Tregs) allow 
proinflammatory cytokine products to tip the balance of intrinsic damage and repair 
mechanisms in favour of inflammation and subsequent neurodegeneration.
216, 217
 
Proinflammatory cytokines stimulate the activation/proliferation of additional T cells, B cells 
and macrophages, stimulate MHC class II expression on antigen-presenting cells, reduce 
production of anti-inflammatory cytokines and enhance cytolytic activity of CD8+ cells, 
macrophages and certain natural killer (NK) cells.
219, 222
 The proinflammatory cytokines IL-2, 
IL-12, IL-17, IL-23, tumour necrosis factor-α and osteopontin are considered pivotal 
mediators of CNS inflammation in MS.  
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Activated T-cell migration across the BBB is facilitated by chemokines and activated matrix 
metalloproteinases (MMPs) such as MMP-9 and MMP-2, which destabilize tight junctions 
and disrupt the BBB basement membrane.
223
 Increased BBB permeability that can often be 
visualized as gadolinium-enhancing (Gd+) lesions on MRI scans is associated with MS 
disease initiation and subsequent relapses.
219
 Leukocyte migration breaks down the BBB and 
leaves the CNS vulnerable to cellular, myelin or axonal damage from an array of otherwise 
restricted substances (e.g. demyelinating antibodies).
219
 Macrophages and certain NK cells 
recruited with the help of proinflammatory molecules become effectors of demyelination, 
with further axonal damage occurring independently of myelin loss.
224, 225
 
Microglia within the CNS are normally supportive of neuronal function, but may become 
activated by proinflammatory molecules to release MMPs, additional proinflammatory 
mediators and myelinotoxic free radicals such as nitric oxide and glutamate, leading to 
multiple neurotoxic effects, as well as enhanced phagocytotic activity.
226-229
 Conversely, glial 
cells, along with endothelial cells, can play a role in promoting recovery from stress and 
injury through secretion of neurotrophic factors such as brain-derived neurotrophic factor, 
neurotrophin-3 and nerve growth factor (NGF).
230
  
1.8 Diseases modifying therapies (DMTs) in MS 
1.8.1 Treatment with DMTs 
To date, MS has no cure. Current management of the disease include symptomatic and 
supportive care and the use of disease-modifying therapies (DMTs). The therapies are used to 
reduce the occurrence of relapse, severity of symptoms and reduce the progression of 
disability.  
Currently approved DMTs for MS in Australia include intramuscular interferon beta-1a 
(IFNβ-1a IM; Avonex), subcutaneous interferon beta-1a (IFNβ-1a SC; Rebif), interferon 
beta-1b (IFNβ-1b; Betaseron; Extavia), glatiramer acetate (GA; Copaxone), natalizumab 
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(NZ; Tysabri), fingolimod (FG; Gilenya), teriflunomide (TF; Aubagio) and dimethyl 
fumarate (DF; Tecfidera).
231
 Conceptually, MS is considered an autoimmune inflammatory 
demyelinating disease and therefore DMTs formulated for the disease are anti-inflammatory, 
immunomodulatory or immunosuppressive in nature. The DMTs are more effective early in 
the disease course, when there is active inflammation, than in later stages of MS which is 
typically less inflammatory and more degenerative. 
Below we provide an overview of Australian DMTs, focusing on their possible mode of 
action, the available evidence in terms of efficacy and known adverse effects and their 
possible treatment implications. 
1.8.1.1 Interferon-β 
The first-line disease modifying agents approved for use in treating RRMS are those derived 
from interferon-β, a pro-inflammatory antiviral and anti-tumour cytokine produced by 
immune cells.
232
 The three interferon-β medications available in Australia, Betaseron, 
Avonex and Rebif, are each recombinant forms of human interferon-β. 
Interferon-β balances the expression of pro-inflammatory and anti-inflammatory agents in the 
brain, probably by increasing expression and concentration of anti-inflammatory agents while 
down-regulating the expression of proinflammatory cytokines. It reduces the trafficking and 
number of inflammatory cells that cross the BBB.
232
 The precise mechanism by which IFNβ 
achieves its anti-inflammatory and immunomodulatory effects is yet unclear. However 
several modes of action have been proposed, including inhibition of T-cell activation and 
proliferation; apoptosis of autoreactive T cells; induction of regulatory T cells; inhibition of 
leukocyte migration across the blood-brain barrier; cytokine modulation; and potential 
antiviral activity.
233
 
The efficacy of interferon beta-1b (Betaseron) was investigated in a double-blind, placebo-
controlled trial of 372 patients with RRMS. After two years, treatment with high-dose IFNb-
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1b (1.17/year) or low-dose IFNb-1b (0.84/year) significantly reduced the annual rate of 
relapse compared to the compared to placebo group (1.27/year).
234
 However, there was no 
significant change in disability in this trial. At five-year follow-up, there was about 33 
percent reduction in the annual exacerbation rate in the high-dose interferon beta-1b group 
compared to the placebo group over five years although this was not statistically significant. 
There was no significant progression of lesion burden in the high-dose interferon beta-1b 
group (at 4 years, p=0.917) compared to the placebo group (p=0.0001).
235
  
To study the efficacy of interferon beta-1a (Avonex), 301 RRMS patients were randomized 
into a double-blinded, placebo-controlled, multicentre phase III trial.
236
 Over 2 years, 
compared to the placebo-group, interferon beta-1a treatment produced a significant delay in 
time to sustained disability progression (p=0.02). The annual exacerbation rate was 
significantly (p=0.002) lower in interferon beta-1a-treated patients (0.61 per year) compared 
to placebo-treated patients (0.90 per year) and a significantly lower number and volume of 
gadolinium-enhanced brain lesions on MRI was observed in patients treated with interferon 
beta-la compared to placebo-treated patients (p =0.02). 
The randomized, multicentre, double-blind, placebo-controlled PRISMS trial also assessed 
the benefit of interferon beta-1a (Rebif) in 560 RRMS patients.
237
 After two years there was a 
significant beneficial effect of treatment (27% 95% CI: 14-39) on relapse rate compared to 
placebo group (33% 95% CI: 21-44) and MRI outcome measures. Treatment also reduced the 
MRI lesion burden (number) in both low and high-dose treatment groups (1.2% & and 3%) 
compared placebo group (10.9%) and 1-point EDSS progression rate (p<0.05) was reduced in 
the treatment arm compared to placebo arm. When patients initially receiving placebo were 
randomized to interferon-beta-1a while others continued their original treatment in the two 
years extension study, outcomes were better for patients treated for 4 years than for patients 
in crossover groups.
238
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In a comparative trial, the relative efficacy of Rebif and Avonex were compared in the 
EVIDENCE trial of 667 RRMS patients randomly assigned to one of these drugs.
239
 From the 
study, the frequency of relapse and the mean number of active MRI lesions was fewer in 
Rebif compared to Avonex. However Rebif was more frequently associated with adverse 
effect than Avonex. 
The INCOMIN prospective, randomised, multicentre comparative study compared the 
efficacy of interferon beta-1b and interferon beta-1a in 188 patients with RRMS for two 
years.
240
 Over the period of 2 years, interferon beta-1b was found to be more effective than 
interferon beta-1a, with 24% of individuals administered interferon beta-1b remaining 
relapse-free compared with individuals given interferon beta-1a (relative risk of relapse (RR): 
0.76; 95% CI: 0.59-0.9; p=0.03). Similarly, 40% of patients who received interferon beta-1b 
remained free from new T2 lesions on MRI compared to those who received interferon beta-
1a (RR 0.6, 95% CI: 0.45-0.8; p<0.0003). Converse to the INCOMIN study, a Danish 
multicentre, controlled, open-label, randomized trial comparing the efficacy of interferon 
beta-1a (Rebif) with interferon beta-1b (Betaseron) in 310 patients with RRMS, found that 
there was no difference in the efficacy between the two treatments.
241
 Interferon-β may be 
associated with adverse effect including fever, flu-like symptoms, Injection site reaction, 
Myalgia and Abnormal liver function tests (LFT).
242
 
1.8.1.2 Glatiramer acetate 
Glatiramer acetate (GA), also known as copolymer 1 or Copaxone is a random polypeptide 
made up of four amino acids. The exact mechanism of action is not known but have been 
reported to involve binding to major histocompatibility complex molecules and consequent 
competition with various myelin antigens for their presentation to T cells and induction of 
specific suppressor cells of the T helper 2 type that migrate to the brain and lead to in situ 
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bystander suppression. It has also been shown that GA-reactive Th2 cells secrete 
neurotrophins, important for neuronal survival and for axonal protection.
243, 244
 
The efficacy of glatiramer acetate was reported in a large multicentre, randomized, double-
blind, placebo-controlled trial of 251 RRMS patients. At two years, patients treated with 
glatiramer acetate had a significantly reduced relapse rate compared to placebo group 
(annualized rates = 0.59 for GA and 0.84 for placebo; p=0.007) and significantly more 
patients receiving GA reported reduction in 1-point EDSS worsening compared those 
receiving placebo (p=0.037). There was however no significant change in EDSS 
progression.
245
 Another double-blind, placebo-controlled, randomized trials with 239 RRMS 
patients found that glatiramer acetate treatment led to a significant reduction in the total 
number of enhancing lesions compared with placebo (-10.8, 95% CI: -18.0, -3.7; p=0.003). 
The relapse rate was also significantly reduced by 33% for GA-treated patients (p=0.012).
246 
Glatiramer acetate may be associated with adverse effect including injection site reaction and 
post-injection systemic reactions.
242
 
1.8.1.3 Fingolimod 
Fingolimod also known as FTY720 (Gilenya) is derived from a metabolite of the fungus 
Isaria sinclairii. The mechanism of action in MS is not completely understood. As a 
sphingosine analogue, fingolimod modulates the sphingosine-1-phosphate receptor on 
lymphocytes and alters lymphocyte migration, resulting in sequestration of lymphocytes in 
lymph nodes.
247, 248
  
The FREEDOMS trial verified the efficacy of fingolimod in a 24-month, double-blind, 
randomized, placebo-controlled study of 1272 RRMS patients.
249
 They reported a 
significantly reduced annualized relapse rate in fingolimod-treated group compared to 
placebo group (p<0.001). Also, treatment with fingolimod significantly reduced the risk of 
disability progression over the 24-month period (p=0.02). The TRANSFORMS trial, a 12-
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month, double-blind, comparative study randomly assigned 1292 RRMS patients to receive 
either oral fingolimod or interferon beta-1a. At 12 months, the annualized relapse rate was 
significantly lower in fingolimod-treated groups than in the interferon group (p<0.001). There 
were no significant differences in progression of disability.
250
 Although there is evidence 
from the trials that fingolimod is effective for reducing the frequency of relapse, this was 
associated with adverse events and life-threatening infections.
249, 250
 Fingolimod may also be 
associated with lymphopenia, macular oedema, bradycardia and Abnormal LFT.
242
 
1.8.1.4 Dimethyl fumarate  
Dimethyl fumarate, also called BG-12 is an oral formulation and second-generation fumaric 
acid.
251
 A study of BG-12 in the CONFIRM placebo-controlled trial (1430 RRMS patients) 
reported that treatment with BG-12 significantly reduced the relapse rate and improved 
neuroradiologic outcomes compared to the placebo. There was no significant reduction in 
disability progression however.
252
 In the DEFINE  placebo-controlled trial of BG-12 among 
1200 patients with RRMS, treatment with BG-12 was associated with significant reduction in 
the annualized rate of rate relapse, the rate of disability progression, and the number of 
lesions on MRI compared to placebo.
253
 Dimethyl fumarate may be associated with adverse 
effect including lymphopenia, flushing, abdominal pain, and diarrhoea.
242
 
1.8.1.5 Teriflunomide  
Teriflunomide is the active metabolite of the pro-drug leflunomide that exhibits anti-
inflammatory, anti-proliferative, and immunosuppressive effects.
254
 In a randomized placebo-
controlled trial involving 157 RRMS and 29 SPMS patients, oral teriflunomide was effective 
in reducing MRI lesions compared to placebo.
255
 In the TEMSO placebo-controlled trial of 
1088 patients with RRMS, teriflunomide significantly reduced the annualized relapse rate, 
MRI evidence of disease activity and disability progression (at the higher dose) compared to 
placebo.
256
 However teriflunomide could be associated with adverse effects.
255, 256
 Adverse 
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effects of teriflunomide therapy may include lymphopenia, rash, alopecia, Abnormal LFT, 
diarrhoea, nausea and Peripheral neuropathy.
242
 
1.8.1.6 Alemtuzumab  
Alemtuzumab is a humanised anti-CD52 monoclonal antibody which causes depletion and 
repopulation of B lymphocytes and T lymphocytes. The CARE-MS I trial was a comparative 
evaluation of the efficacy of alemtuzumab and interferon beta-1a (Rebif) in 581 RRMS 
patients.
257
 At two years, alemtuzumab was more effective in reducing the rate of relapse 
accompanied with a better MRI outcome compared to interferon beta-1a. However, there was 
no significant difference in sustained accumulation of disability. CARE-MS II comparative 
trial evaluated 667 RRMS patients with least one relapse while on interferon beta-1a or 
glatiramer.
258
 At two years, alemtuzumab significantly reduced the relapse rate and sustained 
accumulation of disability compared to interferon beta-1a but without significant difference 
in MRI outcomes. Alemtuzumab may be associated with adverse effect of infection and 
secondary autoimmunity including immune thrombocytopenia.
257, 258
 
1.8.1.7 Mitoxantrone  
Mitoxantrone is an anthracenedione used as an antineoplastic agent in prostate cancer and 
acute leukaemia and now approved for use in secondary-progressive MS and RRMS.
259
 The 
MIMS trial of mitoxantrone was a randomised, double-blind, placebo-controlled study of 194 
patients with either RRMS or SPMS for 24 months. At 24 months, treatment with 
mitoxantrone was associated with significantly reduced progression of disability and clinical 
exacerbations compared to placebo.
260
 However, treatment with mitoxantrone did not reduce 
MRI outcome measure significantly.
261
 A systematic review and meta-analysis confirmed the 
positive effect of the drug on disability progression and also reduction in annualised relapse 
rate.
262
 The use of mitoxantrone may be however associated with serious cardiac toxicity.
259
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1.8.1.8 Natalizumab 
Natalizumab (Tysabri) is a humanized monoclonal antibody that inhibits leukocyte migration 
across the blood-brain barrier by binding to the α4 subunit of α4β1 and α4β7 integrins which 
are expressed on the surface of activated T-cells, thus reducing inflammation in central 
nervous system.
263, 264
 To evaluate the efficacy, tolerability and safety of natalizumab in the 
treatment of RRMS patients, a systematic review and meta-analysis by Pucci and colleagues 
pooled efficacy data from the AFFIRM (942 RRMS patients)
265
 and SENTINEL (1171 
RRMS patients)
266
 randomized placebo-controlled trials.
264
 Over two years period, treatment 
with natalizumab reduced the risk of sustained progression of disability by 42 percent (HR: 
0.58; 95% CI, 0.43 to 0.77; p<0.001) and reduced the risk of relapse by 59% (HR: 0.41, 95% 
CI: 0.34 - 0.51; p<0.001) compared to placebo. Significant adverse events associated with 
natalizumab include fatigue and hypersensitivity reactions.
264
 Of more serious concern is the 
association of natalizumab treatment with a risk of developing progressive multifocal 
leukoencephalopathy.
263
 
1.8.2 Is the use of disease-modifying therapies in MS justified? 
MS is a complex disorder that results in the accumulation of progressive disability and 
impaired quality of life in the vast majority of cases.
94
 The economic and personal burden of 
MS increases with level of disability, with the average annual cost of illness increasing from 
$37,000 p.a. for mild disability to $65,000 p.a. for those with severe disability
267
 with overall 
costs of illness in Australia exceeding $1 billion per year.
268
 The principal costs among 
persons with mild disability are the costs of MS disease-modifying therapies (DMTs).
267
  
To date, MS has no cure. Drugs used in the management of the disease are disease-modifying 
therapies (DMTs). The therapies may help reduce the number of relapse, severity of 
symptoms and retard the progression of disability 
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Since 1993, treatments with DMTs have been available for MS
269
 and as of 2014 there are 
nine approved DMTs for relapsing-remitting MS in Australia. The crucial questions that 
remain to be answered is whether the wide use of DMTs over the last 20 years affected the 
natural history of the disease- that is, whether the DMTs is effectively reducing the duration 
and number of relapses and long-term disability progression. 
DMTs are known to be effective in reducing relapses by 30-80% and significantly reducing 
disease activity shown on magnetic resonance imaging.
270
 Studies have shown associations of 
relapses with disability, quality of life,
271
 cost,
272
 and mortality. 
231
 However, the relationship 
between relapses and subsequent disability progression is a hotly debated topic
273
, with no 
clear association found in some longitudinal studies
273
 but with some associations shown in 
other studies.
274
 
The effect of DMTs on long-term disability progression or quality of life is largely unknown. 
There are some studies that have attempted to examine the long-term effects of DMTs. Some 
population-based studies have shown no effects from DMTs on disability progression over a 
mean follow-up of five years compared to untreated controls.
275
 Other studies have shown 
that early in follow-up (3-5 years), there are apparent reductions in the risk of converting to 
definite MS and level of disability progression among those who started therapy early rather 
than delaying the start of treatment.
33
 Long-term follow-up of the pivotal beta-interferon 
study demonstrated that, at 16 years there were no differences in disability between those 
who had been originally randomised to placebo for two years and then offered active 
treatment and those randomised to active treatment from the start
34
; other trial extensions 
have shown associations of treatment persistence and early treatment with long-term 
disability outcomes.
276
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Thus, while there is some evidence of both short and long-term benefits of the DMTs, the 
results are conflicting and the methods ad hoc for disability or wholly absent for other aspects 
of clinical course. Definitive conclusions are precluded by limitations of these studies, which 
include large numbers of patients lost to follow-up, uncontrolled open-label treatment with 
unblinded and retrospective assessment of clinical events. Consequently, a more systematic 
clinical trials and studies with longer study duration are required to assess the long-term 
effects of DMTs on MS disability progression. However, this is considered impractical and 
possibly unethical. 
1.9 Structure of thesis 
This thesis is partly by publication. Chapter 2 presents a review on the vascular comorbidities 
in the onset and progression of MS. Data is also reviewed on how vascular comorbidities may 
influence MS clinical disability and other aspects of the disease course. Chapter 3 presents a 
review on the frequency of autoimmune comorbidities in MS and how immunomodulatory 
therapies may influence their occurrence. Chapter 4 presents the results of the analysis on the 
associations between serum lipids, apolipoproteins and disability in MS in a prevalent cohort. 
Chapter 5 presents the results of the analysis on the associations between serum lipids, 
apolipoproteins, body mass index and relapse in MS. Chapter 6 presents the results of the 
analysis on the relationship between lipid-related variables, conversion to clinically definite 
MS, time to relapse and progression in disability in a cohort of people with a first clinical 
diagnosis of demyelination. Chapter 7 presents the results of the analysis of the frequency of 
comorbidities and their associations with clinical disability and relapse in MS. Chapter 8 
presents a summary of the main findings, discussion and future research. 
 
 
48 
 
1.10 Postscript 
This Chapter has provided some key information about MS, which will help to understand 
the rest of the thesis. The next Chapter is a review of the literature on the role of vascular 
comorbidities in the onset and progression of MS. 
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Chapter 2 Vascular comorbidities in the onset and progression of 
multiple sclerosis 
 
2.1 Preface 
The manuscript presented in this chapter has been published. The typeset version of the 
manuscript as it appeared in the journal is in Appendix 2A. The text of this chapter is the 
same as the published version. In writing this review, relevant articles were retrieved by a 
variety of methods. Firstly, PubMed, Google Scholar and Web of Knowledge were 
comprehensively searched using the following terms: ‘‘multiple sclerosis’’ and ‘‘obesity’’, 
‘‘multiple sclerosis’’ and ‘‘body mass index’’, ‘‘multiple sclerosis’’ and ‘‘type 2 diabetes’’, 
‘‘multiple sclerosis’’ and ‘‘hypertension’’, ‘‘multiple sclerosis’’ and ‘‘coronary heart 
disease’’, ‘‘multiple sclerosis’’ and ‘‘myocardial infarction, ‘‘multiple sclerosis’’ and 
‘‘stroke’’, ‘‘multiple sclerosis’’ and ‘‘Atrial fibrillation’’, ‘‘multiple sclerosis’’ and 
‘‘cerebrovascular disease’’, ‘‘multiple sclerosis’’ and ‘‘lipid, ‘‘multiple sclerosis’’ and 
‘‘cholesterol.” In addition, a snowballing method was used by retrieving articles back in time 
by identifying new papers that the key articles cited. Lastly, citation tracking was used 
(reverse snowballing), where Web of Knowledge was used to retrieve articles forward in time 
by identifying new papers who cited the key articles. 
2.2 Abstract 
Vascular comorbidities are common in the general population and are associated with adverse 
health outcomes. In people with multiple sclerosis (MS), an increasing amount of evidence 
suggests that vascular comorbidities are also common, but an association with MS risk and 
disability has not been conclusively established. This review aims to critically examine 
published data on the relationship between vascular comorbidities (including vascular risk 
factors) and MS. The evidence suggests an increased risk of MS in people with a high BMI 
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during childhood or adolescence but not adulthood. People with established MS appear to 
have a slightly increased risk of cardiovascular disease and a greater proportion of people 
with MS die from cardiovascular disease, which has important implications for clinicians 
trying to identify risk factors for cardiovascular disease and reviewing treatment options. In 
relation to whether vascular comorbidities influence MS clinical disability or other aspects of 
the disease course, the key finding was that having type-2-diabetes, hypertension, 
dyslipidaemia or peripheral vascular disease at any point in the disease course may be 
associated with a greater progression in disability. Additionally, a negative effect of high 
cholesterol and triglycerides and positive effect of higher HDL (high density lipoprotein) 
levels on acute inflammatory activity was observed on magnetic resonance imaging. The 
results of the published clinical trials of statins as an intervention in MS were however 
conflicting and care need to be taken when treating people with MS with statins. Taken 
together, the literature seems to indicate a potential association of vascular comorbidities with 
MS risk and disability, but the number of prospective studies was sparse, thus precluding 
ascription of causality. We therefore recommend that future studies of the frequency and 
effects of vascular comorbidities on MS risk and disability should be prospective and 
objective where relevant. 
2.3 Introduction 
Multiple sclerosis (MS) is a disorder of the central nervous system (CNS) with autoimmune, 
inflammatory and neurodegenerative components which may influence each other or 
alternatively may have independent natural histories. Although the typical age of onset of MS 
is in the third and fourth decades of life, the burden of disease is most marked in the fifth to 
seventh decades.
1
 MS affects more than 2.5 million individuals worldwide
2
, with higher 
incidence and prevalence in women than men.
3
 MS has a highly variable inter and intra-
personal clinical course, both in pattern and rate of deterioration.
1
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In relation to aetiology, MS is a complex disease in which multiple environmental and 
lifestyle risk factors act together in a genetically susceptible individual to cause the disease.
4
 
Environmental and lifestyle risk factors include low sunlight exposure and vitamin D, 
cigarette smoking and exposure to Epstein-Barr virus.
3-5
 However it is not entirely clear 
whether the same factors also modulate disease progression and whether the putative factors 
that modulate the inflammatory components of the disease are the same as those that 
potentially modulate the neurodegenerative components. In the last several years, vascular 
risk factors and vascular comorbidities such as obesity, dyslipidaemia, type-2 diabetes and 
cardiovascular disease have been associated with MS onset and disease progression.
4, 6
 In line 
with this background, MS has been proposed to have, in part, a vascular basis due to its 
shared pathophysiology with these comorbidities, including endothelial dysfunction,
7
 
inflammation,
8
 and cardiovascular autonomic dysfunction.
9
  
In this review, we examine the current literature on the relationship between cardiovascular 
risk factors including obesity, hypertension, dyslipidaemia, type-2 diabetes, and 
cardiovascular disease with MS risk, disability progression and mortality. Throughout the 
text, the term vascular comorbidity refers to cardiovascular risk factors and diseases. 
2.4 Obesity and MS 
2.4.1 Prevalence of obesity in people with MS and comparison with healthy 
populations 
The prevalence of obesity in people with MS has been investigated in several studies. For 
example, in a large study of persons with MS (n=8,983), 31.3% of participants were 
classified as overweight and 25% as obese.
10
 A study of 123 women with MS from Oregon 
found 47.5% of participants to be overweight and 25.8% were obese.
11
 In a study of by Pilutti 
and colleagues
12
, 36.3% of the 168 MS patients were overweight and 32.7% were obese. In a 
24-month longitudinal study of 269 individuals with relapsing-remitting MS (RRMS), 24.0% 
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and 28.3% were classified as overweight and obese respectively.
13
 Similarly, a study by 
Marrie and colleagues
14
 reported that nearly half had high BMI at MS onset, with 26.4% 
being overweight and 23.8% being obese.  
A number of studies compared the prevalence of high BMI to a control population. A study 
by Khurana and colleagues
15
 found that 4339 veterans with MS had a slightly higher age and 
sex-adjusted prevalence of overweight than veterans in general (42.3% vs. 39.6%, 
respectively) but a lower adjusted prevalence of obesity (20.1% vs. 33.1%). In contrast, other 
case-control studies were not able to detect any difference in BMI between MS cases and 
controls, though these studies were relatively small (sample size ranging from 16 to 68) 
compared to that of Khurana and colleagues.
16-18
 Two other studies even reported a lower 
BMI in MS cases than controls.
16, 19
 Overall, there is currently no evidence that the 
prevalence of overweight and obesity in MS is higher than that of the general population.  
The use of self-reported height and weight may have led to underestimation of overweight 
and obesity in these investigations.  
2.4.2 Obesity and MS risk 
Table 2.1 provides an overview of the studies that have examined the association between 
BMI and MS risk. It shows that a number of prospective and case-control studies have 
observed an association between BMI in childhood
20, 21
 and adolescence
22, 23
 and MS risk; 
however no associations have been found between BMI in adulthood and MS risk.
22, 23
 
Interestingly, the two studies that examined childhood BMI both found that the association 
was only present in females and not in males, both showing a clear dose-dependent 
relationship between childhood BMI in females and subsequent MS risk.
20, 21
 In addition, two 
studies found a dose-response relationship between BMI and MS when BMI was measured at 
age 18 and 20
22, 23
 but no association was observed when BMI was measured in adulthood.
22, 
23
 Certainly having an association with exposure prior to disease onset is potentially 
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supportive of a causal directionality, but it is interesting and perhaps disruptive to a causal 
interpretation that the BMI-MS association does not track forward to later adulthood. It may 
be that by this age other factors that occur among all adults in their later decades of life 
nullify any appreciable differences in BMI between MS cases and other adults.   
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Table 2.1: Studies examining obesity and risk of multiple sclerosis 
Author (year) Study 
information 
Number of 
MS patients 
/total cohort 
Age BMI 
Measured 
Main findings 
Munger and 
colleagues, 
(2013)20 
Cohort study 
(1930-1983) 
 
774/302,043 7 years 
 
1. Girls: BMI z-score (HR =1.20, (95% CI: 1.10-1.30), p<0.001) 
2. Boys: BMI z-score (HR =1.12, (95% CI: 0.99-1.28), p>0.05) 
13 years 1. Girls: BMI z-score (HR =1.18, (95% CI: 1.08-1.28), p<0.001) 
2. Boys: BMI z-score (HR =1.10, (95% CI: 0.97-1.25), p>0.05) 
Langer-Gould 
and colleagues, 
(2013)21 
Cohort study 
(2007-2009) 
 
75/913,097 2-18 years Girls:  Normal weight: OR =1(ref), Overweight :  OR =1.58 (95% CI: 0.71-3.50), 
Moderate obesity:  OR=1.78 (95% CI: 0.70-4.49), Extreme obesity: OR=3.76 (95% CI: 
1.54-9.16), p-trend=0.005 
Boys:  Normal weight: OR = 1 (ref), Overweight : OR =1.80 (95% CI: 0.83-3.93), 
Moderate obesity: OR=0.89 (95% CI: 0.30-2.64), Extreme obesity: OR=0.82 (95% CI: 
0.19-3.56), 
p-trend=0.93 
Hedstrom  
and colleagues, 
(2012)23 
Case-control 
study (2005-
2011) 
1571/3,371 
 
20 years 
 
Normal weight (BMI): 18.5-21, OR=1(ref), 21-23, OR=1.1 (95% CI: 0.9-1.2), p=0.5, 
 23-25, OR=1.2 (95% CI: 1.0-1.5), p=0.03 
Overweight (BMI) : 25-27, OR =1.4 (95% CI: 1.1-1.8), p=0.2, 27-29, OR =2.2 (95% 
CI: 1.6-3.0), p=1x10-6 
Obese(BMI):>30, OR  =2.2 (95% CI: 1.5-3.0), p=9x10-6, p-trend=2x10-10 
>20 years No association between current/adult BMI and MS risk (data not shown) 
Munger and 
colleagues, 
(2009)22 
Cohort study 
(1976-2003) 
 
593/238,371 18 years Normal weight (BMI): 18.5-21, RR=1(ref), 21-23, RR =1.13 (95% CI: 0.91-1.40),  
23-25, RR =0.97 (95% CI: 0.72-1.31) 
Overweight(BMI): 25-27, RR =1.44 (95% CI: 0.87-2.39) 27-29, RR =1.40 (95% CI: 
0.92-2.14) 
Obese(BMI): >30, RR  =2.25 (95% CI: 1.50-3.37), p-trend<0.001 
25-55 years Normal weight(BMI): 18.5-21, RR=1(ref), 21-23, RR =0.87 (95% CI: 0.69-1.10),  
23-25, RR =1.00 (95% CI: 0.78-1.29) 
Overweight(BMI) : 25-27, RR =1.23 (95% CI: 0.93-1.62), 27-29, RR =0.79 (95% CI: 
0.30-2.12) 
Obese (BMI): >30, RR  =0.91 (95% CI: 0.46-1.79), p-trend=0.88 
Normal: 18.5 to 24.9Kg/m2, Overweight:25 to 29.9Kg/m2, Obese:≥30Kg/m2 
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A substantial limitation of these studies was the fact that they were unable to adjust for sun 
exposure and/or 25-hydroxyvitamin D serum levels. It is well known that individuals with 
high BMI have less sun exposure and lower vitamin D levels.
24
 
25
 In part, this may be due to 
changes in behaviour and the effects of increased adiposity on systemic vitamin D 
availability. Low sun exposure and vitamin D levels are now established risk factors for 
MS.
26-28
 It is therefore feasible that the observed associations between childhood/adolescence 
BMI and MS may be explained by the fact that cases had less sun exposure and lower serum 
vitamin D levels. That said, there are a number of deleterious effects of obesity that might 
independently contribute to MS risk, such as increased oxidation and dyslipidaemia, so both 
BMI and sun/vitamin D are worthy covariates to assess in studies of MS risk and disability 
progression. Importantly, the absence of association between adult BMI and the risk of MS is 
interesting and seems to suggest that some aspects of early life or adolescence may be critical 
in determining the risk of MS. 
2.4.3  Obesity and MS disability 
Three studies examined the association between BMI and disability. In the first study, 269 
individuals with RRMS were prospectively followed for 24 months and participants reported 
information about their BMI and level of disability as measured by the Patient Determine 
Disease Steps (PDDS), a self-reported variant of EDSS.
13
 Higher BMI at baseline was 
associated with a higher PDDS at 12 months (β: +0.06, p<0.05), but BMI at 12 months was 
not significantly associated with PDDS at 24 months (β: -0.04, p>0.05). In the second study 
by Marrie and colleagues
10, PDDS was grouped into mild (EDSS≤3; n= 1,318), moderate  
(EDSS 4.5-5.5; n=350) and severe (EDSS≥6; n=707) disability. No significant association 
was observed between BMI and disability, because among those with mild, moderate and 
severe disability, 24.0%, 27.7% and 25.6% were obese, respectively (OR=1.09 (95% CI: 
0.90-1.33) for moderate vs. mild disability; OR=0.99 (95% CI: 0.86-1.14) for severe vs. mild 
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disability; ptrend=0.11). In our own work,
29
 BMI was measured objectively and disability 
assessed by EDSS. We found that BMI was independently associated with higher EDSS (p = 
0.013). In another study where we investigated the associations between BMI and relapse in 
MS in cohort of 141 participants with relapsing–remitting MS, BMI was not associated with 
the hazard of relapse.
30
 
The fact that two studies used self-reported height and weight to calculate BMI is a potential 
limitation, because it is well known that those who are more overweight are more likely to 
under-report their weight.
31
 This under-reporting could bias an association toward the null, 
though the fact that the Pilutti study found a significant effect of baseline BMI and disability 
at 12 months despite a self-reported BMI may just indicate the absence of effect. Regardless, 
additional studies are needed to assess any association, ideally measuring BMI objectively. 
We could not identify any studies that examined disability longitudinally to determine 
whether obesity could be related to a more rapid change in disability. Certainly such an 
analysis would greatly improve upon the capacity to assess the veracity of the associations 
demonstrated with previous retrospective and cross-sectional designs, though the logistics 
required do complicate implementation. A blended method, prospectively collecting data on 
early and mid-adulthood BMI and making use of medical records for childhood BMI may 
allow a more feasible design without being too logistically onerous. 
2.4.4 Potential biological mechanisms 
The mechanisms by which obesity might impact upon MS risk are not yet known. As 
mentioned, part or all of the association between childhood/adolescence BMI and MS risk 
could be confounded by other factors such as sun exposure and vitamin D. If there were to be 
an independent effect of obesity, then the mechanism may be related to the lipid pathway, as 
obese people are known to have a more adverse lipid profile compared to those of normal 
weight.
32, 33
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It is also possible that there is a shared pathway between vitamin D and lipids.
34, 35
 While 
serum lipids are prone to oxidation and inflammation in the vascular endothelium, vitamin D 
is known to exert immunomodulatory and antioxidant effects on the immune system.
36
 The 
connection between vitamin D and lipids is not unexpected, as vitamin D synthesis starts in 
the skin from a cholesterol precursor, 7-dehydrocholesterol, and it is thought that higher 
serum vitamin D levels may improve the plasma lipid profile.
17
 In line with these findings, 
patients that began using statins in order to improve their cholesterol profile experienced an 
increase in serum vitamin D levels.
37
  
An alternative hypothesis is that the effects of obesity are mediated by a low-grade chronic 
inflammatory state. There is evidence that adipose tissue secretes inflammatory factors 
collectively known as adipokines that influence immune system functioning, including 
leptin
38
 and interleukin-6,
39
 which has been shown to reduce regulatory T-cell activity
40, 41
 
and promote an inflammatory T helper 1 cell response
42
 thought to be responsible for the 
autoimmune inflammation, development and progression of MS.
43
 
2.4.5 Summary: Obesity and MS 
Collectively, the results from the studies on BMI and MS suggest that weight status during 
early life may be important in determining subsequent MS risk. In relation to the question of 
whether obesity is associated with disability or a change in disability, studies are required that 
measure BMI objectively and prospectively.  
2.5 Type-2 Diabetes and MS 
2.5.1 Prevalence of Type-2 Diabetes in people with MS and comparison with healthy 
populations 
We could not identify any studies that examined T2D and the risk of MS to determine 
whether T2D is more prevalent prior to the onset of MS. However a number of studies 
compared T2D frequencies in people with MS and healthy controls. In a study by Hussein 
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and Reddy
44
, the prevalence of T2D among a cohort of 1,206 MS patients was significantly 
higher (prevalence: 6.75%; 95% CI: 6.74-6.76), p=0.005) than in the general population. A 
study by Kang and colleagues reported that the prevalence of T2D in a group of 898 MS 
patients was 8.6%, this was 1.5-times higher than that of the 4,490 randomly matched 
controls without MS (OR: 1.5; 95% CI: 1.1-1.2; p<0.01).
45
 However, in a study by Marrie 
and colleagues, the age-adjusted prevalence of T2D in patients with MS was similar to that of 
the general population (7.62 vs. 8.31%; prevalence ratio 0.91; 95% CI: 0.81-1.03).
46
 Fleming 
and Blake compared T2D frequencies among MS and non-MS cases admitted to hospital, 
finding the prevalence of T2D was lower in MS cases (3.08 per 100 discharges) compared to 
controls (6 per 100 discharges).
47
  
A retrospective study by Sternberg and colleague also showed no difference in the prevalence 
of T2D between MS patients and non-MS patients indicated by the lack of difference in the 
use of anti-diabetic drugs between the two groups.
8, 48
 Plasma glucose level was however 
significantly lower in MS patients compared to non-MS patients
8
 and also lower in disease 
modifying therapies naive (DMTs-naive) MS patients compared to MS patients on disease 
modifying therapies,
48
 showing that the chronic use of pharmacological agents by MS 
patients may be associated with increased plasma glucose levels and also associated with the 
risk of T2D in MS patients. 
The heterogeneity of the findings reported could also be due to differences in study design 
used in these investigations that is, hospital-based versus population-based studies. From 
these inconsistent results, there is no convincing evidence that the prevalence of T2D is 
higher among people with MS compared to the general population, and thus no evidence 
indicative of an association between T2D and MS risk.  
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2.5.2 Type-2 Diabetes and MS disability 
The relationship between T2D and disability in MS was investigated by Marrie and 
colleagues. In this study,
6
 they examined whether T2D was associated with the time to 
different ambulatory disability endpoints in a large population of 8,983 MS patients enrolled 
in the North American Research Committee on MS Registry (NARCOMS). Compared with 
MS patients who did not report T2D, individuals with MS who developed T2D at any point 
during their disease course had a 29% increased risk of early gait disability (hazard ratio 
(HR): 1.29; 95% CI: 1.13-1.48), a 28% increased risk of requiring unilateral assistance (HR: 
1.28; 95% CI: 1.11-1.49) and a 56% increased risk of requiring bilateral assistance (HR: 1.56; 
95% CI: 1.30-1.88).  
In another study using the NARCOMS registry, Marrie and Cutter
49
 also assessed the effect 
of T2D on the development of visual disability using the Vision subscale of Performance 
Scales (PSV) which is scored ordinally as 0 (normal), 1 (minimal), 2 (mild), 3 (moderate), 4 
(severe), or 5 (total disability). They reported that developing T2D at any point in the disease 
course was associated with a 35% (HR: 1.35 (1.15-1.58) increased risk of mild visual 
disability, a 41% (HR: 1.41 (1.12-1.78) increased risk of moderate visual disability and a 
54% increased risk of visual disability (HR: 1.54 (1.04-2.28). 
These results are in line with a non-MS systematic review and meta-analysis by Wong et al 
reporting that diabetes is associated with increased physical disability compared to people 
without diabetes in the general population
50
 which in part, may be due to the complications of 
diabetic neuropathy which is characterised by muscle weakness and significant autonomic 
dysfunction.
51
 These results are suggesting that T2D comorbidity is associated with a worse 
progression in disability. The lack of consistently higher prevalence of T2D in people with 
MS does not preclude any potential association with disability progression, given the distinct 
pathways for inflammatory and neurodegenerative mechanisms.  
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2.5.3 Summary: Type-2 Diabetes and MS 
Data on the prevalence of T2D in MS patients is limited and the findings are inconsistent. 
The result on the relationship between T2D and disability suggest that people with MS who 
also have T2D may have a worse progression in disability compared to people with MS 
without T2D. Further studies are required to confirm this finding, however.  
2.6 Hypertension and MS 
2.6.1 4.1 Prevalence of hypertension in people with MS and comparison with healthy 
populations  
The frequency of hypertension in MS patients has been investigated by a number of studies. 
For instance, in a study of 898 MS patients by Kang and colleagues, the prevalence of 
hypertension was higher in the MS patients compared to the control group (OR: 1.40; 95% 
CI: 1.10-1.70).
45
 In a cross-sectional study of 1142 male veteran MS patients, LaVela and 
colleagues reported higher prevalence of hypertension in MS patients compared to general 
veteran population (46.7% versus 41.2%, p<0.001) and the general population (46.7% versus 
20.9%, p<0.001).
52
 However, in a study using the NACORMS registry, Marrie and 
colleagues reported that 30.1% of 8983 MS participants reported being hypertensive which 
was similar to the rate expected for the general population.
6
 In another study of 430 MS 
patients by Marrie and colleagues, the age-adjusted prevalence of hypertension in the MS 
patients was similar to that of the general population (MS: 20.8% versus general population: 
22.5% [PR: 0.9; 95% CI: 0.78-1.06]). Studies reporting actual blood pressure values recorded 
similar values in MS patients compared to controls.
8, 48, 53
 Sternberg and colleagues also 
reported that there was no significant difference in the use of antihypertensive drugs between 
MS and non-MS patients. Lower prevalence of hypertension was also reported by some 
studies.
19, 54
 For example, in study of 8281 MS patients by Jadidi and his colleagues, the 
frequency of hypertension was  in MS patients compared to the matched controls (0.42% 
versus 0.68%).
54
 Similarly, Allen and colleagues reported lower prevalence of hypertension 
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in 9949 hospitalised MS patients compared to non-MS hospitalised controls(18.3% versus 
29.3%, p<0.05).
19
 Lower prevalence of hypertension in MS patients compared to controls 
have been reported in other studies.
8, 47
   
The data available on the prevalence of hypertension in MS is inconsistent and there is no 
convincing trend of evidence that the prevalence of hypertension is higher in MS patients 
compared to the general population or healthy controls. This may be due to differences in 
demographic and clinical characteristic between studies, including differences in exposure to 
pharmacological agents in MS. 
2.6.2 Hypertension and MS disability 
Marrie and colleague investigated the relationship between hypertension and disability in 
MS.
6
 They examined whether hypertension was associated with the time to different 
ambulatory disability endpoints using the NARCOMS registry. Compared with MS patients 
who did not report hypertension, individuals with MS who developed hypertension at any 
point during their disease course had a 29% increased risk of early gait disability (HR: 1.29; 
95% CI: 1.20-1.39), a 25% increased risk of requiring unilateral assistance (HR: 1.25; 95% 
CI: 1.15-1.36) and a 17% increased risk of requiring bilateral assistance (HR: 1.56; 95% CI: 
1.05-1.31).  
Using the NARCOMS registry, Marrie and Cutter
49
 also assessed the effect of hypertension 
on the development of visual disability using the Vision subscale of Performance Scales 
(PSV). Developing hypertension at any point in the disease course was associated with 32% 
(HR: 1.32 (1.20-1.46) increased risk of mild visual disability, 31% (HR: 1.31 (1.13-1.51) 
increased risk of moderate visual disability and 16% increased risk of visual disability (HR: 
1.16 (0.89-1.51). 
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These results suggest that hypertension as comorbidity in MS patients may be associated with 
a worse progression in disability. These findings are consistent with data from non-MS 
studies which have reported significant association between hypertension and disability in the 
general population.
55, 56
 
2.6.3 Summary: hypertension and MS 
We found no convincing evidence of higher prevalence of hypertension in MS patients 
compared to matched controls. However, there is some evidence to suggest that MS patients 
who develop hypertension at any point in the disease course may experience faster 
progression in clinical disability. 
2.7 Cardiovascular diseases and MS 
Cardiovascular diseases are common in the general population
57
 and are associated with 
many adverse health outcomes, including reduced functional status
58
, severity of the primary 
disease,
57, 59
 reduced quality of life
59, 60
 and increased mortality
60
. If cardiovascular diseases 
were also common in MS and were associated with disability, then this could partly explain 
the highly variable inter and intra-personal clinical course observed in MS. Despite their 
potential importance, little information exists about the prevalence of cardiovascular diseases 
in MS, how the prevalence is changing over time, and how they affect treatment decisions, 
treatment responses or health outcomes in MS. 
2.7.1 Cardiovascular diseases and mortality in people with MS and comparison with 
healthy populations 
To the best of our knowledge, no study has been conducted that examined the whether the 
occurrence of cardiovascular disease prior to MS onset was associated with MS risk.  
However, mortality due to cardiovascular disease in individuals with MS has been 
investigated by a number of studies. In Denmark, Koch-Henriksen and colleagues
61
 reported 
that individuals with MS had a 34% increased risk of death from cardiac and vascular disease 
compared to the general population (standardised mortality ratio [SMR]:1.34; 95% CI: 1.02-
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1.71). In another Danish study, Bronnum-Hansen and colleagues
62
 reported a 32% increased 
risk for MS patients of dying from cardiovascular disease compared to the general population 
(SMR: 1.32; 95% CI: 1.22-1.43). Lalmohamed and colleagues reported a stronger effect, with 
a 2.4-fold increased risk of death from cardiovascular disease compared to gender-matched 
referent subjects. However Hirst and colleagues
63
 reported that MS patients had a 6% 
increased risk of death from cardiovascular diseases which was not statistically different from 
the general population (p=0.22).  
These studies collectively suggest an association between cardiovascular diseases and 
mortality in people with MS.     
2.7.2 MS and risk of cardiovascular diseases  
Table 2.2 provides a summary of the studies that have examined the association between MS 
and risk of cardiovascular disease. Two studies reported a higher risk of myocardial 
infarction in MS cases than matched controls.
54, 64
 However a third study reported a lower 
prevalence of myocardial infarction in MS cases than controls.
19
 MS cases have been found 
to have a higher risk of heart failure,
54, 64
 stroke
19, 54, 64
 or cerebrovascular disease
45
 and 
peripheral vascular disease
6, 45
 when compared to matched controls. Coronary heart disease 
has also been found to be more frequent in MS cases compared to controls.
45, 54
 The 
prevalence of ischemic heart disease was higher in MS cases compared to controls
65
 in some 
studies but lower in others.
19
 In a study by Fleming and Blake
47
, the frequencies of acute 
myocardial infarction, heart failure, atrial fibrillation and cerebrovascular disease were lower 
in MS cases than matched hospitalised controls.  
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Table 2.2: Studies examining occurrence of cardiovascular diseases in people with multiple sclerosis 
Author (year) Study 
information 
MS 
patients 
Control group Main findings 
Jadidi and 
colleagues, 
(2013)54 
Case-control 
(1987-2009) 
8,281 76,640 matched 
Controls 
1. Myocardial infarction: IRR=1.85 (95% CI: 1.59-2.15) 
2. Heart failure: IRR=1.97 (95% CI: 1.52-2.56) 
3. Atrial fibrillation: IRR=0.63 (95% CI: 0.46-0.87) 
4. Stroke:  IRR=1.71 (95% CI: 1.46-2.00) 
 
Kang and 
colleagues, 
(2010)45 
Case-control 
(2007) 
898 4490 matched 
controls 
1. Hypertension: OR =1.40 (95% CI: 1.1-1.7) 
2. Peripheral vascular disease: OR =6.60 (95% CI: 4.00-11.00) 
3. Cerebrovascular disease: OR =3.70 (95% CI: 2.90-4.10) 
 
Christiansen 
 and colleagues, 
(2010)64 
Case-control 
(1977-2006) 
13,963 66,407 matched 
controls 
One year follow-up:  
1. Myocardial infarction: IRR=1.84 (95% CI: 1.28-2.65),  
2. Heart failure: IRR=1.92 (95% CI: 1.27-2.90)  
3. Stroke: IRR=1.69 (95% CI: 1.42, 2.71) 
2-30 year follow-up: 
1. Myocardial infarction: IRR=1.10 (95% CI: 0.97-1.24)  
2. Heart failure: IRR=1.53 (95% CI: 1.37-1.71)  
3. Stroke: IRR=1.23(95% CI: 1.10-1.38) 
 
Allen and 
colleagues, 
(2008)19 
Case-control 
(2005-2011) 
9,949 
 
19,898 matched 
controls 
 
1. Myocardial infarction : OR=0.78 (95% CI: 0.64-0.96) 
2. Ischemic stroke: OR=1.66 (95% CI: 1.33-2.09) 
3. Haemorrhagic stroke: OR=1.14 (95% CI: 0.76-2.32) 
4. Ischemic heart disease: OR=0.58 (95% CI: 0.51-0.66) 
 
Fleming & 
Blake,(1994)47 
Case-control 
(1989) 
 
7,168 7,168 matched 
controls 
1. Coronary heart disease: 3.81% in MS and 10.69% in control group (p<0.05) 
2. Atrial fibrillation: 2.66% in MS and 6.60% in control group (p<0.05) 
3. Cerebrovascular disease: 1.86% in MS and 2.58% in control group (p<0.05) 
4. Hypertension: 7.42% in MS and 15.95% in control group (p<0.05) 
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Marrie and 
colleagues, 
(2010)6 
Cohort study 
(2006) 
 
8,983  Bilateral assistance to walk 
1. Hypertension: HR=1.17 (95% CI: 1.05-1.31) 
2. Coronary heart disease: HR=0.99 (95% CI: 0.80-1.23) 
3. Peripheral vascular disease: HR=1.87 (95% CI: 1.35-2.60) 
 
Marrie and 
colleagues, 
(2011)49 
   Severe visual disability  
1. Hypertension: HR=1.16 (95% CI: 0.89-1.51) 
2. Coronary heart disease: HR=1.20 (95% CI: 0.80-1.80) 
3. Peripheral vascular disease: HR=1.90 (95% CI: 1.11-3.23) 
 
Marrie and 
colleagues, 
(2013)65 
Case-control 
(1984-2005) 
2366 11,786 matched 
controls 
Ischemic heart disease 
1. Aged 20–44 years: Prevalence ratio (PR)=1.87 (95%CI:1.65-2.12) 
2. Aged 45–59 years: PR=1.21 (95%CI:1.08–1.35) 
3. Age ≥60 years: PR=0.81 (95%CI:0.70–0.92)  
 
1. Aged 20-44 years: Incidence ratio (IRR)= 2.01 (95%CI:0.94-4.30) 
2. Aged 45-59 years: IRR=1.33 (95%CI:0.95-1.86) 
3. Age ≥60 years: IRR=1.04 (95%CI:0.69-1.56) 
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Differences in patients’ demographic and clinical characteristics between studies could 
contribute to the inconsistencies in the results. For instance, in the studies by Jadidi and 
colleagues
54
 and that of Christiansen et al., 
64
 they used newly diagnosed MS patients and 
reported higher incidence of cardiovascular disease in MS patients compared to matched 
controls. One of the factors that may account for this is the activation of the sympathetic 
autonomic nervous system which is potentiated by heightened inflammation at the initial 
stages of the disease.
9, 66, 67
 However, the study by Fleming and Blake
47
 reported contrasting 
results, since it was conducted in elderly MS patients (≥65 years of age), where inflammation 
is low, and the sympathetic autonomic function is severely dysfunctional. Secondly, 
differences in the use or exposure to DMTs of MS and other pharmacological agents between 
studies may also contribute to the varied results since studies have shown that the use of 
pharmacological agents in MS may be associated with increased risk of cardiovascular 
diseases.
68, 69
 
In summary, current evidence suggests that people with MS may be at a slightly increased 
risk of cardiovascular diseases than matched controls. To what extent this is reflective of any 
causal mechanisms or just a common set of predictors for MS and cardiovascular disease 
can’t be discerned from these study methods. 
2.7.3 Cardiovascular disease and MS disability 
Marrie and colleagues evaluated the association between the presence of vascular 
comorbidities and the time to different ambulatory disability endpoints in 8,983 MS patients 
from the NARCOMS Registry.
6
 Participants reporting one or more vascular comorbidities at 
MS diagnosis had an increased risk of ambulatory disability, and the risk increased with the 
number of vascular comorbidities reported. A single vascular comorbidity at diagnosis was 
associated with 51% increased risk of early gait disability (HR: 1.51; 95% CI: 1.41-1.61) 
while two vascular comorbidities were associated with a 228% increased risk of early gait 
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disability. A single vascular comorbidity at any point in the disease course was also 
associated with 58% increased risk of early gait disability (HR: 1.58; 95% CI: 1.48-1.68). 
Similarly, compared with MS patients who did not report peripheral vascular disease, 
individuals with MS who developed peripheral vascular disease at any point in the disease 
course had a 29% increased risk of early gait disability (hazard ratio (HR): 1.29; 95% CI: 
1.20-1.39), a 25% increased risk of requiring unilateral assistance (HR: 1.25; 95% CI: 1.15-
1.36) and a 17% increased risk of requiring bilateral assistance (HR: 1.56; 95% CI: 1.05-
1.31). However, compared with MS patients who did not report coronary heart disease, 
individuals with MS who developed coronary heart disease had similar ambulatory disability. 
Using the NARCOMS registry, Marrie and Cutter also assessed the effect of vascular 
comorbidities on the development of visual disability.
49
 They reported that developing 
peripheral vascular disease at any point in the disease course was associated with 45% (HR: 
1.45 (1.14-1.80) increased risk of mild visual disability, 63% (HR: 1.63 (1.17-2.27) increased 
risk of moderate visual disability and 90% increased risk of visual disability (HR: 1.90 (1.11-
3.23). Similarly, coronary heart disease was associated with 27% (HR: 1.27 (1.09-1.46) 
increased risk of mild visual disability, 45% (HR: 1.45 (1.16-1.80) increased risk of moderate 
visual disability and 20% increased risk of visual disability (HR: 1.20 (0.80-1.80). 
Another study using the NARCOMS Registry assessed the association between pre-existing 
comorbidity and the severity of disability at diagnosis.
70
 Using PDDS, participants were 
classified as having mild, moderate or severe disability. Among participants enrolled within 
two years of diagnosis, the adjusted odds ratio of moderate vs. mild disability at diagnosis 
increased in participants with a vascular comorbidity (OR: 1.51; 95% CI: 1.12-2.05). 
However, the odds ratio of severe vs. mild disability was not statistically different for 
participants with a vascular comorbidity (OR: 1.06; 95% CI: 0.77-1.44).  
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Further, a population-based study by Tinghog and colleague examined whether the presence 
of cardiovascular comorbidities increases the risk for disability pension in people with MS. 
From the results, the presence of cardiovascular comorbidity in MS patients (4,519) had no 
significant influence on the risk for disability pension.
105
 
Taken together, this data suggests that having a cardiovascular disease at diagnosis or at any 
point in the disease course may be associated with a worse progression in disability compared 
to those without a cardiovascular comorbidity. As with MS risk, however, whether this 
reflects a causal mechanism or just shared predictors is unclear.  
2.7.4 Potential biological mechanisms 
There are some potential hypotheses for the biological mechanisms underlying the 
relationship between cardiovascular disease and progression in disability. Firstly, vascular 
comorbidities are associated with increased peripheral inflammation and could act to increase 
disease progression by activating the inflammatory cascade. Elevated levels of inﬂammatory 
markers in MS are associated with an excess activation of cellular and humoral components 
of the immune system which may increase inﬂammatory demyelination and 
neurodegeneration. The neurodegeneration which manifests in disability progression in MS 
evokes neuronal and axonal loss which leads to brain atrophy and cognitive decline.
71-73
 
Secondly, it has been proposed that the chronic inflammatory process that characterises MS 
pathogenesis may contribute to the aetiogenesis and dysfunction of the cerebral 
endothelium.
7, 72
 Serum proinflammatory cytokines such as TNF-α and IFN-γ, which are 
elevated before clinical exacerbations of MS, can activate the cerebral endothelial cells 
(CECs) and alter their anatomical distribution and activity leading to the disruption of the 
blood-brain barrier as evidenced by a decrease expression of endothelial tight junction 
proteins of the CECs. Dysfunction of the CECs and permeability of the blood-brain barrier 
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causes adherence and trans-endothelial migration of T-lymphocytes and monocytes to the 
CNS with destructive and often neurodegenerative consequences.
7, 74
 
2.7.5 Summary: cardiovascular disease and MS 
On the whole, the prevalence of cardiovascular disease and the risk of death from 
cardiovascular disease appear to be higher in people with MS compared to the general 
population. Whether cardiovascular comorbidities are already frequent prior to the onset of 
MS is not completely known since only few studies have been published in this area.
15
 More 
case-control or ideally prospective study designs are needed to assess this. Importantly, 
whether present at diagnosis or later in the disease course, cardiovascular diseases may be 
associated with a faster accumulation of disability. Having two or more cardiovascular 
diseases, which independently cause impairment, could act in concert to increase disability in 
MS patients.
70 
 
While MS in itself may not cause cardiovascular disease, patients with MS may be subject to 
the risk of cardiovascular diseases because of co-occurring conditions such as dyslipidaemia, 
depression, neurological impairment or physical disability, which make them less physically 
active than the general population. Physical inactivity would be expected to increase the risk 
of cardiovascular diseases. Consequently some MS patients may die from cardiovascular 
diseases even without a direct relation to the disease.  
2.8 Lipids and MS 
Apart from adipose tissue, the brain is the most cholesterol-rich organ in the body,
75
 with 
cholesterol forming about 80% of the intact myelin
76
. Lipids play important roles in the 
central nervous system and their transport through the blood-brain barrier have been 
demonstrated in normal physiological conditions
77, 78
 and during breakdown of the blood-
brain barrier in MS.
79
 To maintain cholesterol homeostasis in the body
80
 and the CNS
81, 82
 
there are antioxidant defence systems and mechanisms to regulate lipid metabolism. 
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Notwithstanding, the brain is believed to be particularly susceptible to oxidative damage and 
lipid dysregulation
83-85
 due to its high content of lipids and high oxygen consumption, as well 
as a less effective antioxidant defence system compared with other tissues.
85
 Dysregulation 
and oxidation of lipids are closely linked to the development of several neurodegenerative 
disorders including Alzheimer’s and Parkinson’s disease.86, 87  
2.8.1 Lipids in people with MS and comparison with healthy populations 
We could not identify any studies that examined the risk of MS in people with dyslipidaemia 
(HDL below 1.3mmol/L, LDL above 4.1 mmol/L, triglycerides above 2.3 mmol/L). However 
a number of studies were found which compared lipid profiles between MS cases and 
controls. Table 2.3 provides a summary of the studies that examined the lipid profile in 
people with MS compared with healthy populations. Generally, a more adverse lipid profile 
among MS cases was observed in some studies, but this was not consistently found. For 
example, some studies have shown significantly elevated total cholesterol in people with MS 
compared to healthy controls,
8, 88, 89
 while other studies found no difference in total 
cholesterol levels.
18, 90, 91
 Similarly some studies reported higher LDL levels in people with 
MS compared with healthy controls
89
 while other studies did not find any significant 
difference in LDL levels.
8, 18, 88
 Likewise, HDL concentrations have been found to be higher 
in MS cases compared with controls
8, 88, 91
, but other studies did not find any significant 
differences.
18, 89
 Triglycerides levels were also higher in MS cases compared to healthy 
control in some studies but did not find any significant differences.
18, 88-91
  A study by 
Sternberg and colleagues which compared the lipid profile difference between MS patients 
who were on disease modifying therapies (DMTs-users) and DMTs-naïve demonstrated a 
significantly higher HDL in DMTs-users compared to DMTs-naïve. The level of TC and 
LDL were higher in DMTs-users but not significantly different.
48
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Table 2.3: Studies examining the lipid profile in people with multiple sclerosis 
Author  Study information Outcome measure of interest Main findings 
Guibilei and 
colleagues, (2002)88 
Case-control,18 MS 
cases & 18 controls 
Lipid profile differences between 
cases and controls & Correlation 
between lipid profile and CEL 
1. TC significantly higher in cases than controls 
2. LDL, Trig & ApoE higher in cases than controls but the difference not significant. 
3. TC and LDL correlated significantly with CEL number 
 
Salemi and colleagues, 
(2010)91 
Case-control, 40 MS 
cases & 80 controls 
Lipid profile differences between 
cases and controls 
1. HDL significantly higher in cases than controls 
2. TC & Trig higher in cases than controls but differences not significant 
 
 
Jamroz-Wisniewska 
and colleagues, 
(2009)89 
Case-control, 82 
RRMS, 55 
progressive MS & 40 
controls 
Lipid profile differences between 
cases and controls 
1. TC significantly higher in cases than controls. 
2. LDL significantly higher in RRMS in remission and progressive MS than controls 
3. HDL higher in cases than controls but difference not significant 
 
 
Sternberg and 
colleagues, (2013)8 
 
Case-control, 206 MS 
cases & 142 controls 
Lipid profile differences between 
cases and controls 
1. TC and HDL significantly higher in cases than non-MS patients used us controls. 
2. LDL & Trig higher in MS cases than controls but difference not significant 
Palavra and colleagues, 
(2013)90 
 
Case-control, 30 MS 
cases & 66 controls 
Lipid profile differences between 
cases and controls & Correlation 
between lipid profile and EDSS 
1. Trig, Ox-LDL & small HDL particles higher in MS cases than control 
2. LDL significantly lower in MS cases than controls 
3. TC, LDL & Ox-LDL significantly correlated positively with EDSS 
Çomoğlu and 
colleagues, (2004) 
 
Case-control, 22 MS 
cases & 16 healthy 
controls 
Lipid profile differences between 
cases and controls 
1. Trig & VLDL were significantly higher in MS cases than the healthy controls 
2. TC & LDL higher in cases than controls but difference not significant. 
3. LDL/HDL significantly higher in cases (male ) than the controls (males) 
Weinstock-Guttman 
and colleagues, 
(2011)34 
 
Cohort study, 178 
CDMS patients 
EDSS and MSSS 
 
1. EDSS associated with TC/HDL ratio 
2. No association between EDSS & MSSS and the other lipid variables 
Weinstock-Guttman Cohort study, 492 EDSS, MSSS CHEDSS, 1. Trend of association between lipid variables and EDSS, MSSS, CHEDSS and 
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and colleagues, 
(2011)92 
CDMS patients CHMSSS, and T1-LV, T2-LV 
lesions, CEL, CE-LV and BPF. 
CHMSSS 
3. Associations between lipids variables and CEL, CE-LV and BPF 
5. No association between lipid variables, BMI and T1-LV & T2-LV 
Weinstock-Guttman 
and colleagues, 
(2013)93  
Cohort study, 135 
CIS patients 
Relapse, MRI measures 1. TC & LDL associated with increased cumulative number of new T2 lesions. 
2. Trend of association of TC & LDL with lower baseline whole brain volume. 
3. Trend of association between TC and CEL. Other lipids were not associated with 
CEL 
Abbreviations:  
TC: Total cholesterol; LDL: Low density lipoprotein; Ox-LDL: Oxidised LDL; HDL; High density lipoprotein; Trig: Triglycerides; VLDL: Very low density lipoprotein; EDSS: Expanded disability status 
scale; CHEDSS: Change in EDSS; MSSS: Multiple sclerosis severity score; CHMSSS: Change in MSSS; CDMS: Clinically definite MS; CIS: Clinical isolated syndrome CEL: Contrast enhancing lesions; T1-
LV: T1 lesion volume; T2-LV: T2 lesion volume; BPF: Brain parenchyma fraction 
93 
 
93 
 
Further to this, contrasting results also exist showing that dyslipidaemia is more frequent in 
people with MS compared with healthy controls. Lavela and colleagues
52
 reported a 
significantly higher prevalence of dyslipidaemia in 1,142 male veterans with MS (48.5%) 
compared to 31,500 non-MS veterans (44.6%). Similarly Kang and colleagues
45
 reported 
significantly higher (p< 0.001) dyslipidaemia in 898 MS cases (14%) compared to 4490 
controls (6.9%).However, significantly (p<0.05) lower prevalence of dyslipidaemia was 
reported in 9,949 MS cases (3.0%) compared to 19,898 controls (5.1%) by Allen and 
colleagues.
19
  
The disparities in the lipid profile could stem from differences in the 
49
use of DMTs and other 
unrelated MS pharmacological agents which has been shown to modulate the lipid profiles.
48
 
The disparity in dyslipidaemia and lipid profile between the studies examined above could 
also be due to difference in what constitute a dyslipidaemia (cut off point), difference in 
population and age of MS patients recruited in the various studies. 
2.8.2 Lipids and MS disability 
A number of studies have been conducted to determine the impact of serum lipids on 
disability and disease progression. Using a time-to-event analysis model in the large 
NARCOMS registry, Marrie and colleagues reported that the presence of 
hypercholesterolemia (higher LDL and lower HDL) at any time during the disease course 
was associated with 35% increased risk of early gait disability (HR: 1.35; 95% CI: 1.26-
1.45), 33% increased risk of unilateral walking assistance (HR: 1.33; 95% CI: 1.23-1.44) and 
24% increased risk of bilateral walking assistance (HR: 1.24; 95% CI: 1.11-1.39).
6
 Similarly, 
hypercholesterolemia was associated with 83% (HR: 1.83 (1.67-2.01) increased risk of mild 
visual disability, 75% (HR: 1.75 (1.52-2.01) increased risk of moderate visual disability and 
59% increased risk of visual disability (HR: 1.59 (1.23-2.06).
49
 
94 
 
94 
 
 In a study by Palavra and colleagues,
90
 total cholesterol (r=0.40, p=0.027), LDL (r=0.37, 
p=0.05) and oxidised-LDL (r=0.46, p=0.01) were positively correlated with EDSS. In a 
study
34
 looking at the association between vitamin D and serum lipid profiles in a population 
of 178 MS patients, total cholesterol/HDL ratio was associated with higher EDSS (r=0.21, 
p=0.008). In our own work
29
, TC (p = 0.037), apolipoprotein B (ApoB) (p = 0.003), and the 
apolipoprotein B to apolipoprotein A-I ratio (ApoB/ApoA-I ratio) (p = 0.018) were 
independently associated with a higher EDSS. 
In terms of measuring progression of disability as an outcome, Weinstock-Guttman and 
colleagues
92
 assessed the associations of baseline lipid profile with subsequent disability 
progression. A cohort of 492 participants were followed for an average of 2.2 years and data 
on EDSS and serum lipids were collected at baseline and after a mean period of 2.2 ± 1.0 
years follow-up. They found that higher baseline total cholesterol (partial correlation 
coefficient (rp) =0.15, p=0.001), LDL (rp=0.13, p=0.006), triglycerides (rp=0.10, p=0.025), 
total cholesterol/HDL ratio (rp=0.091, p=0.005) were significantly associated with a greater 
increase in EDSS. We
29
 also investigated the relationship between the lipid profile and 
disability progression and reported that TC to HDL ratio (TC/HDL ratio) was prospectively 
associated with progression in clinical disability (p = 0.029) as measured by annual change in 
EDSS. 
 
Results from these studies suggest a possible relationship between adverse lipid profile, 
disability and disease progression. However, data on these relationships, particularly the 
prospective data, are limited and requires further investigation. 
2.8.3 Serum lipids and inflammatory activity in MS 
Studies have been conducted to determine whether any relationship exists between serum 
lipid profile and inflammatory activity as evidenced by MRI. Weinstock-Guttman and 
95 
 
95 
 
colleagues
92
 found that higher levels of HDL were associated with a reduced likelihood of 
having contrast-enhancing lesions (p=0.01) and with a reduced lesion volume when they did 
occur (p<0.001). Higher levels of triglyceride and total cholesterol/HDL ratio were associated 
with a greater likelihood of having contrast-enhancing lesions (p=0.038) and lesion volume 
(p=0.023). Giubilei and colleagues
88
 also reported that higher levels of total cholesterol 
(r=0.59, p=0.01) and LDL (r=0.54, p=0.02) were associated with a greater number of 
contrast-enhancing lesions. In a cohort of participants with clinically isolated syndromes, 
Weinstock-Guttman and colleagues
93
 also observed that higher LDL (p=0.006) and total 
cholesterol (p=0.001) levels were associated with increased cumulative number of new T2 
lesions over 2 years. From the MRI studies examined above, individuals with an adverse lipid 
profile had higher number of inflammatory lesions on MRI in clinically isolated syndromes 
or clinically definite MS. Since contrast-enhancing lesions represent recent inflammatory 
activity, their association with serum lipid profile in both early and established MS may be an 
indication of a causal relationship. However, whether maintaining the lipid profile within a 
normal range will modulate inflammatory activity is not clear and needs further investigation. 
2.8.4 Clinical trials of statins in MS 
Statins are a class of lipid-lowering drugs which inhibit the 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, the main rate-limiting enzyme in cholesterol 
biosynthesis. In addition to their lipid-lowering effects, statins have been found to have anti-
inflammatory and immunomodulatory properties.
94
 A number of small randomised controlled 
trials using statins have been conducted in MS patients, though with contradictory results. 
The first single-arm trial (simvastatin 80 mg/day) in 30 RRMS cases found a decrease in 
gadolinium-enhancing lesion number (44%) and volume (41%) compared to pre-treatment.
95
 
A recent double-blind placebo-controlled trial in secondary-progressive MS cases with 
simvastatin found that those on simvastatin had a 43% reduction in brain atrophy compared 
96 
 
96 
 
to the placebo group and a 40% reduction in the rate of disability progression between the 
active and control arms.
96
 The ACTIVE study
97
 and others
98, 99
 reported a protective effect of 
statin. 
However, others found no evidence of a protective effect of statin therapy. A post-hoc 
analysis of the SENTINEL trial in RRMS patients (natalizumab plus interferon-beta-1a 
(n=40) vs. placebo plus interferon-beta (n=542)) found no differences in relapse rate, 
disability progression or number of gadolinium-enhancing lesions between those using statins 
and those not.
100
 The SIMCOMBIN trial,
101
 STAyCIS study,
102
 and others
103, 104
 found no 
evidence of therapeutic effect of statin. 
The inconsistencies in the trial results calls for further research into the role of serum lipids in 
the pathogenesis of MS and obtaining a mechanistic understanding of cholesterol metabolism 
and the role of these pathways in MS. Understanding these mechanisms can inform as to the 
potential benefits of lipid-lowering drugs for MS in the future, which may be critical in 
designing future randomised controlled trials.  
2.8.5  Summary: lipid profile and MS 
Results from the case-control studies examined above were largely inconsistent but the best-
designed studies showed slightly elevated total cholesterol and HDL in MS cases compared 
to the controls. In the longitudinal and cross-sectional studies, higher levels of HDL were 
associated with lower acute inflammatory activity on MRI and lower MS disability, which is 
consistent with the antioxidant and anti-inflammatory properties of HDL. While MS cases 
may be expected to have lower levels of HDL than controls, the high concentrations observed 
may be due to their increased role in the antioxidant and anti-inflammatory activities and 
reverse cholesterol transfer in MS. This contradiction therefore calls for further investigation 
to provide a consistent body of knowledge on the relationship between serum lipids and MS 
in both longitudinal and case-control studies.  
97 
 
97 
 
On the whole, evidence from the studies examined above suggest a negative impact of high 
LDL and triglycerides on acute inflammatory activity and disease course in MS patients and a 
beneficial effect of higher HDL levels on MS. Holistically, the prevalence of dyslipidaemia 
and its association with disability may be an indication that the serum lipid profile could be a 
potential target for reducing or modulating the rate of disability progression. However, the 
results of the statin clinical trials on MS have been contradictory and needs further 
investigation to explore their potential benefits.  
2.9 Conclusions, implications and recommendations 
There is a growing body of evidence to indicate that MS is associated with vascular 
comorbidities such as obesity, type-2 diabetes, cardiovascular diseases and dyslipidaemia in a 
number of different ways. In relation to MS risk, there is evidence that high 
childhood/adolescent BMI, but not adult BMI is associated with MS, but it is unclear whether 
this is due to confounding by other factors like sun and/or vitamin D. The other factors show 
some indirect evidence of an association with MS, but the directionality of these associations, 
if any, is unclear. There is no data on whether type-2 diabetes, cardiovascular disease and 
dyslipidaemia are more common prior to the disease onset in people with MS compared to 
controls.   
Comparing people with established MS to healthy controls, there is insufficient evidence to 
suggest that the prevalence of obesity, hypertension or T2D is higher in people with MS, and 
there is inconsistent evidence around the association with lipids. However, people with MS 
appear to have a slightly increased risk of cardiovascular disease and they also die more often 
of cardiovascular disease. The question still remains whether this cardiovascular disease risk 
develops prior to the MS onset or after. Regardless, it is important from a clinical perspective, 
as the awareness by neurologists of this issue may assist with the prevention of 
cardiovascular disease or mortality in people with MS. At a patient level, the identification of 
98 
 
98 
 
personal risk factors of cardiovascular disease, including high BMI, dyslipidaemia, adverse 
diet, and low physical activity, can inform individual lifestyle modifications or drug 
treatments.   
The presence of vascular comorbidities could increase and complicate the MS disease 
burden. These comorbidities may be partly responsible for the highly variable inter and intra-
personal clinical course of MS. In relation to whether vascular comorbidities influence MS 
disability and the progression of disability or other aspects of the disease course, the key 
finding was that having a vascular comorbidity at diagnosis or at any point in the disease 
course may be associated with a worse progression in disability. In addition, a negative effect 
of high cholesterol and triglycerides and positive effect of higher HDL levels was observed 
on acute inflammatory activity, measured by MRI. Little data was available on BMI or T2D 
and progression. In general, it was clear from our review that prospective studies are sparse.  
There are important therapeutic opportunities for lipid lowering drugs. The use of these may 
be justified when the aim is to reduce a patient’s risk of cardiovascular disease. However, the 
use of these is not yet justified as an intervention in MS. Importantly, that statin trials have 
produced inconsistent evidence, including negative effects, is critical and may indicate that 
previous observational studies demonstrating associations may have been confounded. 
Adverse effects in people with MS are possibly explained by laboratory evidence showing 
negative impacts of statins on oligodendrocytes and myelin formation. Thus, care needs to be 
taken when considering the use of statins in the treatment of MS. 
We recommend that future studies of the prevalence and effects of vascular comorbidities on 
MS risk and disability progression should be prospective where relevant and using 
sufficiently validated means of assessing outcomes and vascular comorbidities, and where 
possible objectively assessed (e.g. BMI). Studies must separately investigate vascular 
comorbidities which occur before the onset of MS and those that occur during the course of 
99 
 
99 
 
MS in order to determine those that may be important in the onset or progression of MS and 
those that merely co-vary with age, decreased physical activity and subsequent increased 
BMI. This research will hopefully lead to potential interventions that may improve outcomes 
for persons with MS. 
2.10 Postscript 
This chapter has provided some key information on how vascular comorbidities may 
influence the onset and disease progression in MS. The next chapter is a review of the 
literature on the frequency of autoimmune comorbidities in MS and the contribution of 
immunomodulatory therapy to this frequency. 
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Chapter 3 Autoimmune comorbidities in MS 
3.1 Preface 
This chapter is made up of two manuscripts on the role of autoimmune comorbidities in MS. 
The first manuscript is on the frequency of autoimmune comorbidities in MS and the 
contribution of IFN-β therapy to this frequency. The second manuscript has been published. 
It describes the co-occurrence of multiple sclerosis and type 1 diabetes and the shared 
etiologic features and clinical implication for MS aetiology. The typeset version of the 
manuscript as it appeared in the journal is in Appendix 3A. In writing this review, relevant 
articles were retrieved by a variety of methods. Firstly, PubMed, Google Scholar and Web of 
Knowledge were comprehensively searched using the following terms: ‘‘multiple sclerosis’’ 
and ‘‘thyroid’’, ‘‘multiple sclerosis’’ and ‘‘rheumatoid’’, ‘‘multiple sclerosis’’ and ‘‘type 1 
diabetes’’, ‘‘multiple sclerosis’’ and ‘‘psoriasis’’, ‘‘multiple sclerosis’’ and ‘‘systemic lupus 
erythematosus’’, ‘‘multiple sclerosis’’ and ‘‘inflammatory bowel disease’’, ‘‘multiple 
sclerosis’’ and ‘‘Crohn’s’’, ‘‘multiple sclerosis’’ and ‘‘ulcerative colitis’’. In addition, a 
snowballing method was used by retrieving articles back in time by identifying new papers 
that the key articles cited. Lastly, citation tracking was used (reverse snowballing), where 
Web of Knowledge was used to retrieve articles forward in time by identifying new papers 
who cited the key articles. These autoimmune comorbidities were particularly examined 
based on their frequent report in people with MS.  
3.2 Frequency of autoimmune comorbidities in MS: the role of interferon-
beta therapy 
3.2.1 Introduction 
Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating disease of the 
central nervous system that is associated with progressive disability in young adults.
1
 Owing 
to the chronic and debilitating nature of the disease, MS patients may be at an increased risk 
of other autoimmune comorbid conditions. 
2, 3
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As a presumed autoimmune disease, MS has been associated with increased occurrence or 
coexistence with other autoimmune diseases and increased frequency of elevated 
autoantibodies; however, this has not been consistently shown.
2, 4, 5
 Evidence for association 
of MS with other autoimmune diseases such as type 1 diabetes, psoriasis, autoimmune 
thyroiditis, inflammatory bowel disease and rheumatoid arthritis
2, 3
 might indicate a shared 
susceptibility to autoimmunity and may support the hypothesis of an autoimmune 
pathogenesis for MS.
6, 7
  
Further, recent accumulating evidence indicates that chronic exposure to interferon-beta 
(IFN-β) therapy in MS patients is associated with the induction or exacerbation of thyroid 
disease, as either organ dysfunction or autoimmunity.
8-10
 IFN-β has been widely used to treat 
MS patients because of its capacity to reduce the frequency and severity of exacerbations and 
retard the progression of disability in secondary progressive MS.
8-11
 Since IFN-β modulates 
the immunoregulatory system, this cytokine may precipitate autoimmune disorders.
12, 13
 It is 
therefore important to know whether the frequency of autoimmune thyroid disease is 
increased in MS patients receiving interferon-beta therapy compared to those not receiving 
this therapy. 
Limited quality data exist on how immunomodulatory therapies may affect the frequency of 
other autoimmune diseases in MS patients. An increased understanding of factors that affect 
the frequency and severity of autoimmune comorbidities in MS may provide new insights 
and enhance MS management. In this review, we aimed to assess the frequency of commonly 
reported autoimmune comorbidities in MS and investigate the contribution of IFN-β to the 
frequency of autoimmune thyroid autoimmunity and dysfunction in MS patients. 
3.2.2 Thyroid autoimmunity and dysfunction  
The spectrum of thyroid autoimmunity and dysfunctions reported in MS includes 
hypothyroidism (Hashimoto’s thyroiditis), hyperthyroidism (Graves’ disease) and positive 
123 
123 
anti-thyroid antibodies without clinically significant thyroid disease.
8, 14
 Thyroid dysfunction
is defined as overt or subclinical hyperthyroidism or hypothyroidism, while thyroid 
autoimmunity is defined as the presence of anti-thyroid antibodies in serum.
15
 
16
3.2.2.1 Studies examining thyroid autoimmunity and dysfunction in IFN-β naïve MS 
patients 
Three studies compared the incidence of thyroid disease in the MS population to that in the 
general population.
17-19
 For instance, a 1990 epidemiological study by Wynn and colleagues
investigated the incidence of thyroid disease (Graves’ disease or Hashimoto’s thyroiditis) in 
137 female MS patients and found no significant difference in the incidence of thyroid 
disease between the MS patients and that of the general population (RR:1.33; 95% CI: 0.27-
3.87).
17
 Similarly, a study of 4,192 MS patients and 20,940 age, sex and geographically
matched controls did not find significant difference in the incidence of thyroid disease 
(Incidence Rate Ratio (IRR): 0.98; 95% CI 0.73–1.30).18 Furthermore, Nielsen and
colleagues
19
 reported an incidence of Hashimoto’s thyroiditis of 0% in a study of 10,596 MS
patients compared to age, gender, and period-specific national incidence rates from 1977 to 
2004. The estimated incidence of thyroid disease from these studies ranges from 0.15% to 
0.42%. Marrie and colleagues
3
 conducted a meta-analysis of the incidence of thyroid
dysfunction in MS patients and reported a summary incidence estimate of 0.17% (95% CI: 0–
0.40%). They also reported substantial heterogeneity among the three population-based 
studies included in the analysis (I
2
=89.9).
A substantial number of studies have been conducted evaluating the prevalence of thyroid 
diseases in MS patients, with some comparing it to a control or general population.
5, 7, 18, 20-27
Edwards and Constantinescu
5
 conducted a prospective study of 658 consecutive patients
diagnosed with MS between June 2002 and June 2003. Prevalence of autoimmune thyroid 
disease in these patients was compared with values from population studies. From the study, 
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the MS population had significantly increased rate of autoimmune thyroid disease compared 
to the general population (OR: 1.80; 95%CI 1.07–3.02). In a study using the National Health 
Insurance Research Dataset in Taiwan, Kang and colleagues reported that the prevalence of 
Hypothyroidism in a group of 898 MS patients was 1.7%, this was 3.2-times higher than that 
of the 4,490 randomly matched controls without MS (OR: 3.2; 95% CI: 1.7-6.1)
26
 
The association of MS with autoimmune thyroid disease (Graves' disease and Hashimoto's 
disease) was investigated in 491 MS patients and compared to 532 controls from the general 
population by Sloka and colleagues.
27
 There was a significantly higher prevalence of Graves' 
disease in MS (3.1%, p = 0.002) compared to the general population (0.4%). There was 
however no difference in the prevalence of Hashimoto's disease (p = 0.097). 
A number of studies investigated the sex difference in the frequency of autoimmune thyroid 
disease in MS. For example, Niederwieser and colleagues reported a significantly higher 
prevalence of autoimmune thyroiditis in male MS patients (9.4 %) than in male controls (1.9 
%; p = 0.03) while prevalence of autoimmune thyroiditis in female MS patients (8.7 %) did 
not differ from female controls (9.2 %).
24
 
Some studies did not report significant difference in the frequency of thyroid disease in MS 
compared to a general population. For instance, Marrie and colleagues
18
 reported a similar 
age-adjusted prevalence of thyroid disease in the MS population (PR: 9.51%; 95CI 8.46–
10.6) compared to the general population (PR: 8.56%; 95% CI 8.11–9.02). Likewise, Laroni 
and colleagues
23
 did not report significant difference in the prevalence of Graves’ disease and 
Hashimoto’s disease between MS patients (Graves’ disease: 2.04%; Hashimoto’s disease: 
1.63%) and general population (Graves’ disease: 1.22%; Hashimoto’s disease: 1.63%).  
125 
125 
Overall, the prevalence of thyroid disease in MS patients from these studies ranged from 
2.08% to 10%. Hashimoto’s thyroiditis ranged from 0% to16.1%, and Grave’s disease ranged 
from 0% to 2.56%.
3
Two studies conducted a meta-analysis of the prevalence of thyroid disease in MS patients. 
The meta-analysis by Marrie and colleagues in 2015 reported summary thyroid disease 
prevalence estimate of 6.44% (95% CI: 0.19–12.7%) with substantial heterogeneity 
(I
2
=95.4).
3
 The meta-analysis by Dobson and colleagues
2
 in 2013 investigated both thyroid
dysfunction and thyroid autoimmunity in MS patients. They included 14 studies and reported 
an overall increased risk of thyroid dysfunction in people with MS (OR: 1.66; 95% CI 1.35–
2.05) compared to healthy controls and without between-study heterogeneity (Cochran’s Q p 
= 0.16, I
2
 = 27 %). Nine studies were included in the thyroid autoantibodies analysis and
reported an overall increased risk of thyroid autoantibodies in patients with MS compared to 
healthy controls (OR: 2.36, 95% CI 1.32–4.20) but with significant heterogeneity (Cochran’s 
Q p = 0.0001, I
2
 = 74%).
3.2.2.2 Studies investigating IFN-β induced thyroid autoimmunity and dysfunction  
There is accumulating evidence showing that MS patients receiving IFN-β therapy are at 
increased risk of developing thyroid dysfunction and autoimmunity. Few studies on the 
incidence of IFN-β induced thyroid autoimmunity and dysfunction in MS patients have been 
conducted. In people with MS, a high incidence of IFN-β induced thyroid dysfunction has 
been reported by Caraccio and colleagues.
10
 In this study, 106 MS patients underwent IFN-β
therapy for up to 7 year and thyroid function and autoimmunity were assessed at baseline and 
every 3–6 months throughout the treatment course. Among these participants, thyroid 
dysfunction developed in 25 (hypothyroidism in 20 and hyperthyroidism in 5) of the 103 MS 
patients (24.3%) and thyroid autoimmunity developed in 22 of 97 patients (22.7%). The 
development of thyroid dysfunction and autoimmunity were mainly within the first year of 
126 
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treatment. On the whole, both baseline and incident autoimmunity was reported as significant 
risk factors for subsequent development of IFN-β induced thyroid dysfunction (p=0.001).  
The effect of one-year treatment with IFN-β on thyroid function and autoimmunity in 31 MS 
patients was evaluated by Monzani and colleagues.
12
 Systematic thyroid assessment was
performed at baseline and every 3 months during treatment. From the analysis, 16% of the 
patients had autoimmune thyroiditis (Hashimoto’s thyroiditis) before treatment. The overall 
incidence of thyroid dysfunction was 33% (8/26) over 1 year (10% hyperthyroidism, 23% 
hypothyroidism) and thyroid autoimmunity developed in 19%. In addition to autoantibody 
positivity at baseline, female gender and the presence of an ultrasound thyroid pattern 
suggestive of thyroiditis were identified as additional risk factors for the development of 
thyroid dysfunction.  
To evaluate the frequency of incident thyroid disease during longer term IFN-β therapy, 
Monzani and colleagues studied 31 MS patients and thyroid assessment was conducted every 
3 or 6 months during 3 years of IFN-β treatment.28 Among six MS patients who developed
incident subclinical hypothyroidism (19.4%) during the first year of treatment, thyroid 
dysfunction persisted in 2 with baseline autoimmune thyroiditis. Three patients developed 
incident transient hyperthyroidism (9.7%).  A positive thyroid autoantibody was continually 
detected in only two (6.5%) out of five patients without baseline autoimmunity. After the first 
year of IFN-β treatment, no further cases of thyroid disease were observed.  
Quite a substantial number of studies have investigated the prevalence of IFN-β induced 
thyroid autoimmunity and dysfunction in MS patients. Durelli and colleagues undertook a 
prospective two-year follow-up of autoimmune events in 40 consecutive IFN-β treated MS 
patients and in 21 untreated MS controls and monitored thyroid, liver function and serum 
levels of 12 autoantibodies.
16
 In contrast to the controls, thyroid dysfunction
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(hyperthyroidism=3, hypothyroidism=1) and anti-thyroid autoantibodies were detected in 4 
(10%) IFN-β treated MS patients with persistent autoimmune thyroid dysfunction occurring 
in 3 IFN-β treated patients with a family history of thyroid disease or anti-thyroid 
autoantibody positivity at baseline.  
Kreisler and colleagues investigated the frequency of clinical thyroid dysfunction in a group 
of 700 consecutive MS patients treated with IFN-b for at least 3 months, between 1996 and 
2000 and without past history or clinical signs of thyroid dysfunction before introduction of 
IFN-b.
13
 A total of eight patients (1.1%) developed clinical thyroid dysfunction. Among these 
participants, five developed hyperthyroidism (0.71%) and two developed hypothyroidism 
(0.29%). Out of these five hyperthyroidism cases, it was necessary to stop IFN-b treatment in 
three cases.  
In one of the long-term follow-up studies, a cohort of 787 MS patients was retrospectively 
followed for 8 years for IFN-β or glatiramer acetate (GA) induced thyroid dysfunction and 
thyroid autoimmunity at baseline and during treatment every 3–6 months.15 All patients 
received at least 2 years of IFN-β or GA treatment. The authors reported higher thyroid 
dysfunction (7% versus 13.2%; p < 0.02) and thyroid autoimmunity (3.5% versus 13.4%; p 
=0.01) during IFN-β treatment compared to baseline. On the contrary, there was no 
difference in thyroid dysfunction and autoimmunity before and after the beginning of GA 
treatment. The development of thyroid dysfunction and thyroid autoimmunity occurred 
mainly within the first year of treatment with IFN-β.  
Other authors conducted similar studies to investigate the occurrence of thyroid dysfunction 
and autoimmunity during IFN-β treatment.8, 9, 29 A number of case reports have also 
documented the effect of IFN- β on thyroid autoimmunity and dysfunction. 30-32 
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3.2.2.3 Summary and implications: Thyroid autoimmunity and dysfunction 
The induction or exacerbation of autoimmune diseases or autoantibodies is a well-known side 
effect of chronic type I IFN therapy. Long-term experience in chronic viral hepatitis 
treatment has documented the induction of reversible asymptomatic autoantibodies as well as 
the development of several autoimmune disorders such as thyroiditis, anaemia, hepatitis, 
diabetes, systemic lupus erythematosus or psoriasis during IFN-α or IFN-β treatment.16, 32
From the review of current available literature, a substantial number of epidemiological 
studies have documented the occurrence of thyroid dysfunction (hypothyroidism and 
hyperthyroidism) and autoimmunity (increased autoantibody levels) in both MS patients 
receiving IFN-β therapy and MS patients who are IFN-β naive. The frequency of IFN-β 
induced thyroid dysfunction has been estimated to ranges from 1–13% and that of thyroid 
autoimmunity ranges from 22–43% (13.4%).29 The frequency of thyroid dysfunction in MS
patients not receiving IFN-β have been estimated to ranges from 2–11%, and that of anti-
thyroid autoantibodies from 4–22% (26–31).29 It appears from the data available that IFN-β
therapy is associated with higher occurrence of thyroid autoimmunity and dysfunction in MS 
patients than those MS patients that are IFN-β naive. However this needs further 
investigation including meta-analysis to quantify the magnitude of effect exerted by the IFN-
β therapy. This is because only one study actually compared the risk of thyroid autoimmunity 
and dysfunction in MS patients on IFN-β therapy and those who are IFN-β naïve. 
The question remains as to whether there is a true link between IFN-β and the occurrence of 
thyroid disorder in MS patients. Probably, the short delay between introduction of IFN-β 
treatment and the onset of clinical symptoms of thyroid dysfunction argue in favour of a 
possible link. Furthermore, studies have demonstrated the occurrence of IFN-β induced 
thyroid autoimmunity and dysfunction in MS patients, when baseline analyses were normal 
in all patients.
13, 16
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The most common form of autoimmune IFN-β-induced thyroid disorder in MS is the 
presence of thyroid autoantibodies without thyroid dysfunction.
8, 31, 33
 Thyroid dysfunction 
was generally subclinical and mild in degree and is most often reversible.
10
 The occurrence of 
thyroid autoimmunity and dysfunction is particularly frequent within the first year of 
treatment
34
, although sporadic cases of late onset of dysfunction have been described.
13, 30
  
A number of risk factors have been suggested to be associated with the occurrence of thyroid 
autoimmunity and dysfunction in MS patients. The female gender has been associated with 
higher risk or susceptibility to IFN-β induced thyroid dysfunction than men, however in some 
studies, gender did not emerge as a significant risk factor
10
 or higher risk in the male 
gender.
10
 Also, the presence of elevated anti-thyroid antibodies prior to treatment with IFN-β 
or a family history of thyroid disease has been linked to the development of autoimmune 
dysfunction during treatment.
34
 In addition to pre-existing thyroiditis and female gender, 
hypoechoic thyroid pattern have been suggested as possible predictor of thyroid 
abnormalities.
12
  
The evidence provided by contemporary investigations show that IFN-β induced thyroid 
disorders are becoming a significant clinical problem for MS patients receiving IFN-β 
therapy. For instance, some cases of IFN-β induced thyroid dysfunction have been reported to 
result in dose reduction or discontinuation of interferon therapy which may compromise the 
therapeutic effect of the medication.
34
 There was no consensus on the recommendation for 
routine thyroid screening test or systematic assessment during IFN-β treatment. Some authors 
argue that the low frequency of clinical thyroid dysfunction does not warrant systematic 
thyroid investigation in MS patients receiving IFN-b therapy. However, they recommended 
that thyroid hormones should be tested as soon as any clinical signs suggestive of thyroid 
dysfunction are observed, because therapeutic changes may have to be quickly proposed.
13
 
When there is severe thyroid dysfunction, periodic withdrawal of treatment and evaluation of 
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thyroid function while off therapy is recommended to verify the possible recovery of thyroid 
function.
32
  
Although the mechanisms of IFN-β induced thyroid disorders are not clearly understood, the 
risk appears to be related to both immune stimulatory effects and direct effects on the 
thyroid.
8
 IFN-β has been suggested to induce thyroid dysfunction by stimulating the 
production of thyroid-inhibitory cytokines and/or activation of cytotoxic lymphocytes in the 
thyroid.
12
 In those patients who develop hypothyroidism without autoantibody production, a 
direct inhibitory effect on iodine organification may be postulated.
15
 
3.2.3 Rheumatoid arthritis 
The incidence of rheumatoid arthritis in MS patients has been investigated by few studies. A 
1990 epidemiological study by Wynn and colleagues investigated the incidence of 
rheumatoid arthritis in 137 female MS patients and found higher incidence of rheumatoid 
arthritis in people with MS compared to  the general population of Rochester but this was not 
statistically significant, probably due to small sample size (RR: 1.58; 0.43-4.04).
17
 Also, 
Nielsen and colleagues
19
 investigated the incidence of rheumatoid arthritis in a study of 
10,596 MS patients compared to age, gender, and period-specific national incidence rates 
from 1977 to 2004. They reported a significant decreased risk of rheumatoid arthritis in 
patients with MS (RR: 0.5; 95% CI: 0.4–0.8). From the systematic  review of the literature, 
Marrie and colleagues reported the incidence of rheumatoid arthritis to range from 0.14–
1.28% and a meta-analysis of the incidence of rheumatoid arthritis in individuals with MS 
was summarized as 0.21% (95% CI: 0.087–0.33%).3   
Findings from studies investigating the prevalence of rheumatoid arthritis in MS patients 
have been inconsistent, with some reporting higher, similar or lower prevalence of the disease 
in MS patients compared to a comparator population.
5, 7, 20, 23, 25, 26, 35-37
 Kang and colleagues 
investigated the prevalence of rheumatoid arthritis in a group of 898 MS patients and 
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compared it to a 4,490 randomly matched controls without MS using the National Health 
Insurance Research Dataset in Taiwan. From the study, they reported a higher odds of 
rheumatoid arthritis compared to the matched control group (OR: 4.8; 95% CI: 2.9-8.1)
26
 
Ramagopalan and colleagues
25
 used data from a national, multicentre, population-based 
sample to investigate the rate of autoimmune disease in 5031 MS patients, 30 259 of their 
first-degree relatives, and 2707 spousal controls. From the analysis, there was a higher 
prevalence of rheumatoid arthritis in MS patients (153/5031 = 3.04%) compared to their 
spousal controls (Spouses: 66/2,707= 2.44%) or first degree relatives (529/ 30,259 = 1.75%). 
Edwards and Constantinescu
5
 conducted a prospective study of 658 consecutive patients 
diagnosed with MS between June 2002 and June 2003. From the analysis, there was no 
significant difference in the prevalence of rheumatoid arthritis in MS patients compared with 
the general population (OR: 0.93; 0.23-3.74). 
From the systematic review of seventeen studies, Marrie and colleagues reported the 
prevalence of rheumatoid arthritis to range from 0.30–3.64%. Meta-analysis of prevalence 
estimates from two population-based studies was 2.92% (95% CI: 1.8–4.0%).3 From the 
meta-analysis of eleven studies examining the risk of rheumatoid arthritis in MS, there was 
no significant difference in the prevalence of rheumatoid arthritis in MS patients compared to 
a comparator group (OR 1.15, 95 % CI 0.77–1.73, p = 0.49). There was significant 
heterogeneity between studies.
2
 
3.2.4 Systemic lupus erythematosus 
A study on the incidence of systemic lupus erythematosus (SLE) in MS patients was 
conducted by Nielsen and colleagues. The incidence of SLE in 10,596 MS patients was not 
statistically different when compared to age, gender, and period-specific national incidence 
rates from 1977 to 2004 (RR: 0.5; 95% CI: 0.1-2.0). From a systematic review of the 
literature, Marrie and colleagues reported the incidence of SLE to range from 0.02–0.35%. 
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However, the methods used in the two incidence studies differed substantially.
19, 38
 The study 
by Nielsen and colleagues with the lower estimate used population-based administrative 
data
19
, while the study by Marrie and colleagues with higher estimate used a volunteer 
sample reporting diagnoses using a validated self-report questionnaire.
38
 
Mixed findings have been reported from studies investigating the prevalence of SLE in MS 
patients.
7, 25, 26, 35, 36
 For instance, Kang and colleagues using the National Health Insurance 
Research Dataset in Taiwan, reported significantly higher prevalence of SLE in a group of 
898 MS patients when compared to 4,490 randomly matched controls without MS (OR: 26.9; 
95% CI: 10.3-70.3)
26
 However, in a population-based case–control study of MS patients 
enrolled in the Northern California Kaiser Permanente Medical Care Program, the prevalence 
of SLE in MS patients was not significantly different from that of the matched control (OR: 
1.1; 95% CI: 0.8–1.4).36  
Marrie and colleagues
3
 conducted a systematic review of nine studies and reported 
prevalence of SLE to range from 0.14–2.90%. Dobson and colleagues2 conducted a meta-
analysis of five studies on the prevalence of SLE in MS. There was an increased risk of SLE 
in MS but this was not significant (OR: 2.80, 95% CI: 0.76–10.25). This may be due to the 
substantial heterogeneity among the studies included (Cochran’s Q p<0.00001, I2 = 88 %).  
3.2.5 Type 1 Diabetes 
Currently, there are no studies on the incidence of type I diabetes (T1D) in MS patients. 
However, a study investigated the incidence of MS in T1D patients and reported that the 
incidence rate for MS in patients with T1D was more than three-fold when compared to the 
general population (relative risk (RR: 3.26; 95% CI: 1.80-5.88).
39
 
A number of epidemiological studies on the occurrence of T1D in MS patients have reported 
similar, lower or higher prevalence of T1D in MS patients compared to that in the general 
population or other comparator population.
5, 7, 20, 25, 26, 36, 37, 40, 41
 These studies have been 
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assessed in two systematic reviews and meta-analyses.
2, 3
 Marrie and colleagues
3
 reviewed 
eighteen studies and reported the prevalence of T1D to range from 0–9.4%. Meta-analysis of 
the prevalence of T1D was estimated as 0.016% (95% CI: 0.01–0.21%). Heterogeneity of the 
estimates was however substantial (I
2
=95.3).  
In the meta-analysis by Dobson and colleagues
2
, 16 studies examining prevalence of T1D in 
MS were included in the analysis. Overall, there was an increased risk of T1D in people with 
MS compared to a comparator population (OR: 2.02; 95% CI: 1.22–3.40). However, there 
was a significant heterogeneity between the studies included in the analysis (Cochran’s Q 
p<0.00001, I
2
 = 91%). 
Detailed literature review on the co-occurrence of T1D and MS, shared etiological and 
pathologic mechanisms have been conducted and presented in next section of this chapter. 
3.2.6 Inflammatory bowel disease 
Studies on the incidence of inflammatory bowel disease (IBD: ulcerative colitis & Crohn’s 
disease) in people with MS are limited. The incidence of IBD in MS patients have been 
investigated by Nielsen and colleagues.
19
 They reported higher incidence of ulcerative colitis 
(RR = 2.0; 95% CI: 1.4–2.8) in a study of 10,596 MS patients compared to age, gender, and 
period-specific national incidence rates from 1977 to 2004. There was also significant 
difference in the incidence of Crohn’s disease (RR: 0.7; 95% CI: 0.3–1.5) when compared to 
the general population. A systematic review of two studies on the incidence of IBD in MS 
patients range from 0.33–1.0%.3    
Findings regarding the prevalence of IBD in MS patients were inconsistent, but most studies 
reported that the prevalence of IBD were higher in the MS population than in the general 
population.
5, 7, 19, 25, 36, 42
 A prospective study of 658 consecutive MS patients reported 
increased risk of Ulcerative colitis (OR: 3.15; 95% CI: 1.30-7.64) and Crohn’s disease (OR: 
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3.17; 95% CI: 1.01-9.95) in the MS patients compared to the general population. The overall 
IBD prevalence was higher in MS patients (OR: 3.17: 95% CI: 1.57-6.40). 
5
 
A study was conducted to determine the frequency of IBD prior to the diagnosis of MS. 
Using the Northern California Kaiser Permanente Medical Care Program, Langer-Gould and 
colleagues conducted case–control study of 5,296 MS patients and 26,478 matched controls 
and reported an increased prevalence of IBD prior to the diagnosis of MS compared to the 
controls (OR: 1.7; 95% CI: 1.2–2.5).36  
Ramagopalan and colleagues
25
 used data from a national, multicentre, population-based 
sample to investigate the rate of autoimmune disease in 5031 MS patients, 30 259 of their 
first-degree relatives, and 2707 spousal controls. From the analysis, there was no significant 
difference in the prevalence of ulcerative colitis (0·2%) when compared to the spousal 
controls (0·2%) or first-degree relatives (0·3%). Similarly there was no significant difference 
in the prevalence of Crohn’s disease (0.2%) when compared to the spousal controls (0.2%) or 
first-degree relatives (0.2%). Systematic review of twelve studies estimated the prevalence of 
IBD to range from 0.36–4.66%.3 
Dobson and colleagues
2
 conducted a meta-analysis of the prevalence of IBD in MS patients 
compared to a comparator population. In the meta-analysis of six studies, they reported an 
increased risk of ulcerative colitis in people with MS (OR: 2.26: 95% CI: 1.23–4.14), but 
with significant heterogeneity (Cochran’s Q p = 0.003, I2 = 72 %). Similarly, in a meta-
analysis of four studies, they reported increased risk of Crohn’s disease in people with MS 
(OR: 1.37; 95% CI: 1.12–1.69) and without significant heterogeneity. Overall, there was an 
increased risk of IBD in MS patients compared to a comparator group when six studies were 
meta-analysed. 
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3.2.7 Psoriasis 
Fewer studies investigated the incidence of psoriasis in MS patients. Using the Danish 
Multiple Sclerosis Register, the Danish Hospital Discharge Register, and the Danish Civil 
Registration System, Nielsen and colleagues reported a higher incidence of psoriasis in the 
MS population than expected for the Danish general population but this was not statistically 
significant (RR: 1.5; 95% CI 0.95-2.4).
19
 The incidence of psoriasis in two European
populations was estimated to range from 0.17–1.63%.3
Studies also compared the prevalence of psoriasis in the MS population with a general 
population.
4, 5, 7, 23, 25, 36, 37
 In a prospective study of 658 consecutive outpatients attending a
MS clinic, Edwards and Constantinescu reported increased risk of psoriasis in the MS cohort 
as compared to published data for the general population (OR: 2.11; 95% CI 1.13-3.94).
5
Midgard and colleagues
37
 conducted a hospital-based case-control study of 155 MS patients
and 200 controls to investigate the possible association between MS and autoimmune 
diseases. They reported increased more than two-fold increased risk of psoriasis in MS 
patients compared to hospital-based controls without a history of MS (OR: 2.18; 95% CI 
0.72-6.70), but this was not statistically significant. 
Using the Swedish register, Roshanisefat and colleagues investigated immune-mediated 
disease risk among 11284 fathers and 12006 mothers of MS patients, compared with 123,158 
fathers and 129,409 mothers of index subjects without MS. Similar analyses were conducted 
among 20,276 index subjects with MS and 203,951 without. From the analysis, index 
subjects with MS had a consistently increased risk of psoriasis compared with the control 
population (HR: 2.27; 95% CI 1.81–2.84).4 There was however no significant increased risk
of psoriasis among parents with offspring who have MS, compared with parents of children 
without MS. 
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From a systematic review of the literature, the prevalence of psoriasis was estimated to range 
from 0.39–7.74%.3Dobson and colleagues2 conducted a meta-analysis to assess the risk of 
psoriasis in MS patients. Eight studies were included in the analysis and they reported a 
significant increased risk of psoriasis in people with MS compared to a control group (OR: 
1.31; 95% CI 1.09–1.57). There was no significant between-study heterogeneity (Cochran’s 
Q p = 0.16, I
2
 = 34%). 
3.2.8 Discussion 
The literature was reviewed on the incidence and prevalence of common autoimmune 
diseases associated with MS including comparison with their respective general population 
estimates. While there is a substantial amount of data on the prevalence of autoimmune 
comorbidities in MS, incidence studies are uncommon. 
Based on the review of the literature and meta-analyses, the most prevalent comorbid 
autoimmune diseases were psoriasis and thyroid disease. The studies reviewed demonstrated 
a consistent increase in the risk of clinical thyroid disorders, IBD and psoriasis among people 
with MS compared to a general or comparator population. The prevalence of RA and SLE in 
MS patients was however not significantly different from that of the comparator populations. 
The interpretation of these results is complicated by the significant heterogeneity between 
studies included in the meta-analysis. 
The prevalence of T1D was significantly higher in MS patients when compared to the general 
population but this was characterised by substantial between study heterogeneity which limits 
the interpretation of the result. This heterogeneity may be due to differences in study designs 
used in the various investigations. The mode or source of data used could also account or 
explain part of this heterogeneity. For instance some studies used a questionnaire-based 
studies while other used large administrative or research databases. Questionnaire-based 
study is subject to high misclassification or mismatching of diseases since these autoimmune 
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diseases are self-reported by participants. This was evident from a study which compared 
self-reports to diagnoses verified by general practitioners. They reported that the positive 
predictive value of a patient-reported condition varied from 32 % for RA to 85 % for thyroid 
disease.
43
 Moreover, while some studies used population-based samples, others used hospital-
based samples.  
There was also disparity in the type of comparator populations used in the various studies. 
While some used population-based controls, others used spousal controls or first-degree 
relatives, potentially leading to overmatching. Moreover, among the studies that evaluated the 
frequency of autoimmune disease in MS and a comparator population, fewer studies used 
concurrent controls that were clearly drawn from the same underlying source population.  
Additionally, some authors
2
 reported that publication bias clearly affected the results of some 
of the autoimmune diseases meta-analysed. From their investigation, studies using large 
databases did not show publication bias or heterogeneity, unlike the smaller-scale studies in 
which there was evidence of persisting bias.  
In summary, current studies available have demonstrated that certain comorbidities may be 
more prevalent in MS patients than in the general population. Incidence studies were however 
uncommon. The quality of studies also needs to be improved. A limited number of quality 
studies using population-based design hamper the ability to calculate good estimates of the 
incidence or prevalence of autoimmune comorbidities in MS and identify temporal trends in 
the risk of autoimmune disease in MS patients. We therefore recommend that future studies 
should have a population-based design with large dataset and a concurrent control to 
minimize heterogeneity due to differences in study design. 
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3.3 The co-occurrence of multiple sclerosis and type 1 diabetes: shared 
etiologic features and clinical implication for MS aetiology 
 
3.3.1 Abstract 
We reviewed the evidence for the co-occurrence of type 1 diabetes mellitus (T1D) and 
multiple sclerosis (MS), and assessed the clinical significance of this association and the 
shared aetiological features of the two diseases. T1D and MS contribute considerably to the 
burden of autoimmune diseases in young adults. The co-occurrence of MS and T1D has been 
reported by a number of studies, suggesting the two conditions share one or more aetiological 
components. Both conditions have been associated with distinct human leukocyte antigen 
(HLA) haplotypes but share a number of similarities in clinical, epidemiological and 
immunological features, leading to suggestions of possible common mechanisms of 
development. While underlying genetic factors may be important for the co-occurrence of 
both conditions, some evidence suggests that environmental factors such as vitamin D 
deficiency may also modulate an individual’s risk for the development of both conditions. 
Evidence on whether the co-occurrence of the two autoimmune conditions will affect the 
disease course and severity of MS is merely absent. Further studies need to be conducted to 
ascertain whether the neuropathology associated with T1D might influence the disease course 
and contribute to the severity of MS.  
3.3.2 Introduction  
Multiple sclerosis (MS) and type 1 diabetes mellitus (T1D) represent significant public health 
problems worldwide, because of their considerable contribution to medical and social 
management cost and eventual disability of affected individuals.
44-46
 MS and T1D via 
diabetic neuropathy and accelerated cerebrovascular disease contribute substantially to the 
burden of neurologic disability
47, 48
 in young adults and significantly affect quality of life.  
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MS and T1D are considered to be organ-specific autoimmune disorders with an inflammatory 
component, but with marked differences in their pathogenesis and clinical manifestations.
49
 
While MS is predominantly associated with neurological and physical disability and loss of 
function resulting from inflammatory demyelination and neurodegeneration of the central 
nervous system (CNS),
50
 the chronic hyperglycaemic condition characteristic of T1D results 
from the selective inflammatory autoimmune destruction of the pancreatic Islets of 
Langerhans responsible for insulin production.
51
 Despite the organ specificity of these two 
disorders, a possible aetiologic and pathologic relationship between the two diseases has been 
suggested.
39, 52
 The framework behind the co-occurrence is unclear. While genetic 
predisposition appear to be involved in each of these autoimmune conditions, the low 
concordance among identical twins for MS and T1D and trends of increasing incidence for 
both diseases over time suggest that environmental factors are also important diseases 
determinants in the occurrence of the two diseases.
53
  
In this review, we assessed the available data on the co-occurrence of MS and T1D, the 
clinical significance of T1D in patients with MS and the aetiologic similarities between these 
two autoimmune disorders. Understanding the similarities in aetiology and pathophysiology 
may help clarify causality and help in the management of both conditions. 
3.3.3 Studies investigating the co-occurrence of MS and T1D 
3.3.3.1 Incidence studies on the co-occurrence of MS and T1D 
Table 3.1 summarises studies that have examined the risk of the co-occurrence of MS and 
T1D. A Danish population-based cohort study
39
 assessed the risk of MS in individuals with 
T1D and the risk for T1D in first-degree relatives of MS patients. Data from the Danish 
Hospital Discharge Register, Danish MS Register and Danish Civil Registration System were 
used to identify patients with T1D (n=6,078), MS (n=11,862) and first-degree relatives of MS 
patients (n=14,771) respectively. Patients with T1D and first-degree relatives of MS patients 
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were followed up for the occurrence of MS and T1D respectively. This work found that the 
expected incidence rate for MS in patients with T1D was more than three-fold higher than 
what was expected based on available incidence rate data in Denmark (relative risk (RR): 
3.26, 95% CI: 1.80-5.88). The observed incidence rate for T1D was also higher in first-
degree relatives of MS patients (RR: 1.44, 95% CI: 1.11-1.88). 
In summary, this study has demonstrated a higher risk of developing MS in people with T1D 
compared to the general population. Further to this, data on the risk of T1D in first-degree 
relatives of MS patients suggest an increased risk of T1D in people at higher risk of MS 
compared to the general population. Since there is only one study using incidence data, 
further studies are required to strengthen the evidence of this relationship. 
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Table  3.1: Studies investigating the co-occurrence of MS and T1D 
Author  Study information Outcome measure of interest Main findings 
Nielsen & 
colleagues (2006)
39
  
Cohort study: 11 862 
MS cases, 6078 T1D 
cases & 1
st
-degree 
relatives: 4771 
1. RR of MS in T1D patients - 
Observed incidence rate for MS 
in patients with T1D compared 
to the expected incidence rate 
(based on available incidence 
rate data from Denmark)  
2.  RR of T1D in 1st degree 
relatives of MS patients - 
Observed incidence rate of T1D 
in 1
st
-degree relatives of MS 
patients MS compared to the 
expected incidence rate (based 
on available incidence rate data 
from Denmark  
1. RR for MS in T1D patients: 3.26 (95%CI: 1.80-5.88). 
2. RR forT1D in 1
st
-degree relatives of MS patients:  1.63 (95% 
CI: 1.26-2.12). 
Bechtold & 
colleagues (2013)
52
  
Cohort study: 19 MS 
cases & 56,653 T1D 
cases  
1.  RR of MS in T1D patients - 
Observed prevalence rate for 
MS in a paediatric & adolescent 
T1D population compared to the 
expected prevalence rate (based 
1. RR of MS: 3.35 (95% CI: 1.56 -7.21) to 4.79 (2.01-11.39) 
for an observed prevalence of 7 to 10 patients per 100,000   
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on available prevalence data in 
Germany & Austria ) 
Marrosu &  
colleagues (2002)
54
  
Cohort study: 1090 MS 
cases, 2180 parents & 
3300 siblings 
1. Prevalence of T1D in MS 
patients compared to healthy 
siblings of MS patients and the 
general population;  
2. Adjusted odds ratio for risk of 
T1D in  people with MS & in 
their healthy siblings  
1. Prevalence of T1D in MS patients (2.6%) was about 3-fold 
that in healthy siblings of MS patients (1.0%) (p=0.001) & 5-
fold that in the general population (0.4%) (p<0.001).  
2. MS patients with relatives with MS versus healthy siblings of 
MS patients without other relatives with the disease; OR: 6.03 
(2.50–14.54). 
3. Sibling with other relatives with MS versus sibling without 
other relatives with MS; OR: 3.41 (1.57-7.37). 
Dorman &  
colleagues (2003)
55, 
56
 
Case-control: 143 T1D 
female cases,  186 
sisters & 160 controls
*
  
1. Prevalence of MS in women 
with T1D compared to the 
general population 
 
1. 20-fold increase in the prevalence of MS in T1D women 
(2%) compared female general population (~0.1% on average, 
p=0.003 for difference). 
2. 5-fold increase in prevalence of MS in non-diabetic sisters 
(0.5%) compared with the general population (non-significant). 
Wertman & 
colleagues (1992)
41
 
Cross-sectional: 334 
MS cases & T1D in 
general population in 
1950 
1. Prevalence of T1D in  people 
with MS under the age of 30 
years compared to that of the 
general population  
1. PR of T1D: 94.53; p<0.001 
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Hussein & Reddy 
(2006)
57
 
Cross-sectional: 1,206 
MS  cases & T1D in 
general population 
1. Prevalence of T1D in  people 
with MS compared to that of the 
general population 
1. Prevalence of T1D: 0.92% (95% CI: 0.38–1.46); p= 0.15 for 
difference with general population) 
2. 36% family history of diabetes among MS patients with T1D 
 
RR: Relative risk; OR: Odds ratio; PR: Prevalence ratio; T1D: Type 1 diabetes; MS: Multiple sclerosis 
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3.3.3.2 Prevalence studies on the co-occurrence of MS and T1D 
A number of epidemiological studies of MS and T1D co-occurrence have reported either 
similar or higher prevalence of T1D and MS compared to that in the general population or 
other comparison group. Table 3.1 summarises studies that have examined the prevalence of 
MS and T1D. 
Bechtold and colleagues
52
 investigated the co-occurrence of T1D and MS by estimating the 
relative risk for MS in a paediatric and adolescent diabetes population. Data on 56,653 
patients with T1D in the Diabetes Patienten Verlaufsdokumentation (DPV) database were 
collected in 248 centres in Germany and Austria and published data on German and Mid-
European MS prevalence were used for comparison. The relative risk for MS in the diabetes 
population was 3.35 (95% CI: 1.56 to 7.21) to 4.79 (95% CI: 2.01 to 11.39) based on the 
observed prevalence compared to the expected prevalence of 7 to 10 per 100,000 population. 
Similarly, a Sardinian cohort study by Marrosu and colleagues
54
 assessed the prevalence of 
T1D in 1,090 individuals with MS and their parents (n=2,180) and siblings (n=3,300) to 
ascertain the risk of T1D in this cohort of MS patients. The population prevalence of T1D in 
the province of Oristano
58
 was also used as a comparator. The prevalence of T1D in 
participants with MS was nearly three-fold greater than their healthy siblings (3.0 vs. 1.0%, 
p=0.001) and five-times greater than that of the general population (3.0 vs. 0.5%); however, 
there was no difference in the T1D prevalence between MS cases and their parents (2.0 vs. 
3.0%, p=0.23). In multivariable analysis, the risk of T1D was six-fold higher in MS patients 
who had relatives with MS than in healthy siblings of MS patients without other relatives 
with MS (odds ratio (OR): 6.03, 95% CI: 2.50-14.54, p>0.001). The presence of other 
relatives with MS also conferred a more than three-fold increased risk of T1D to healthy 
siblings of individuals with MS (OR: 3.41, 95% CI: 1.57-7.37, p=0.002) 
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In the Familial Autoimmune and Diabetes Study by Dorman and colleagues
55
, a significantly 
increased prevalence of MS in adults with T1D and their first-degree relatives was observed. 
Data on the clustering of autoimmune thyroid disease, rheumatoid arthritis and T1D were 
collected in a cohort of adult T1D subjects, as well as self-reported data on other autoimmune 
disorders. 94 non-diabetic control families were also recruited for comparison; however, no 
members of these families had any cases of MS. Compared with the average prevalence of 
MS in the female population of the USA (calculated by the authors as approximately 0.1%), 
the 2.0% prevalence of MS in this sample constituted a 20-fold increase in the prevalence of 
MS in the women with T1D (p=0.003). In parallel with this, the 0.5% prevalence of MS in 
the sisters of T1D women constituted a five-fold higher prevalence of MS compared with the 
general population, though this did not reach statistical significance. As no MS cases were 
observed in any male cases or male siblings, these could not be assessed.  
In another study by Wertman and colleagues, the prevalence of T1D in 334 MS patients 
under the age of 30 years was found to be 94.5 times higher than that in the Israeli population 
of the same age (8.98/1000 vs. 0.095/1000, p<0.001).
41
 This finding of a nearly hundred-fold 
increase in T1D prevalence may be due to chance as a result of low numbers of T1D cases in 
the study population. In a larger study of 1,206 MS cases drawn from an MS database by 
Hussein and Reddy
57
, the prevalence of T1D in MS patients (0.92% (95% CI: 0.38–1.46)) 
was similar to that in the general population (p= 0.15). They also reported that, 36% of the 
patients with the co-occurrence of MS and T1D have a positive family history of diabetes.    
In summary, apart from one study which showed a similar prevalence of T1D in people with 
MS compared to the general population, the prevalence of T1D was higher in people with MS 
compared to the general population. Studies have also presented data indicating higher 
prevalence of MS in people with T1D compared to the general population. In addition, the 
prevalence of T1D in first-degree relatives of MS patients was higher compared to the 
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general population or the comparison group, and vice versa, the prevalence of MS in first-
degree relatives of T1D patients was higher compared to the general population. The 
individual frequency and familial clustering of MS and T1D may be an indication that both 
genetic and environmental factors may modulate the risk for the co-occurrence of both 
diseases. 
Furthermore, the occurrence or clustering of autoimmune conditions in MS patients and their 
families is not limited to MS and T1D. For instance, a recent meta-analysis demonstrated a 
consistent increase in the risk of autoimmune disorders, such as autoimmune thyroid disease, 
inflammatory bowel disease as well as T1D amongst people with MS and their first-degree 
relatives.
2
 Studies have also reported that the total combined risk of a number of autoimmune 
diseases was higher in people with MS and their first-degree relatives than controls. 
7, 59
  
The co-occurrence of additional autoimmune disease in MS patients suggests the existence of 
similar genetic, epidemiological and immunological features with a central role in general 
autoimmunity.
7, 59
 Because of the phenomenon of common susceptibility to multiple 
autoimmune diseases in patients and families, individuals with T1D or MS and their relatives 
may not only be at increased risk of MS or T1D compared to the general population, but may 
also be at greater risk of other autoimmune diseases.  
3.3.4  Studies investigating the effect of T1D on clinical disability in MS 
To the best of our knowledge, there is currently no data on the effect of T1D on clinical 
disability in MS. There is, however, a study available which examined the combined effect of 
having T1D or T2D. In this study,
60
 diabetes was associated with a more rapid progression of 
ambulatory disability in a population of 8,983 MS patients enrolled in the North American 
Research Committee on MS (NARCOMS) Registry While having any vascular condition, 
including diabetes, hypertension, heart disease, peripheral vascular disease and/or 
hypercholesterolemia, either at MS diagnosis or developing after MS diagnosis, were 
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strongly predictive of subsequent disability progression and an earlier occurrence thereof, 
evaluating these conditions individually found diabetes among the strongest conditions 
predictive of subsequent disability. Compared with MS patients who did not report diabetes, 
individuals with MS who developed diabetes at any point during their disease course had a 
29% increased risk of early gait disability [EDSS: 4.0] (HR: 1.29; 95% CI: 1.13-1.48), 28% 
increased risk of requiring unilateral assistance [EDSS: 6.0] (HR: 1.28; 95% CI: 1.11-1.49) 
and a 56% increased risk of requiring bilateral assistance [EDSS: 6.5] (HR: 1.56; 95% CI: 
1.30-1.88), persisting after adjustment for sex, year of symptom onset, age at symptom onset, 
income, health insurance status, race, and region of residence. It is unclear how the results 
extrapolate to T1D only given that the prevalence of T1D is roughly ten-fold lower than T2D. 
In summary, there is no data specifically on the effect of T1D diabetes on clinical disability 
in people with MS, but for the combined effect of T1D and T2D there is evidence that this is 
associated with a worse progression in disability compared to MS patients without T1D or 
T2D diabetes. Associations were also found for other comorbidities such as dyslipidaemia, 
heart disease and hypertension. Research specifically on T1D is required to provide high 
quality evidence on its association with disability.   
3.3.5 Shared aetiologic features of MS and T1D  
3.3.5.1 Increasing incidence of MS and T1D 
Accumulating epidemiological studies on MS and T1D suggest a trend of increasing 
incidence over the last few decades and the rapid rate of increase in children is of particular 
concern.
61, 62
 In the case of MS, the incidence rate in Canada has increased from 5.2 to 22.3 
per 100 000 between 1985–1989 and 1990–2004.63 In the Sassari province of Sardinia, 
incidence has increased from 1.1 to 5.8 between 1965–1969 and 1995–1999.64 Increasing 
incidence rates have also been reported in France
65
, Netherlands
66
, Australia,
67
 Japan,
68
 
Finland,
69
 Norway
70, 71
 and Italy.
72
 Interestingly, an increase in female-to-male ratio of MS 
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incidence has also been observed, with a systematic review and meta-analysis estimating a 
ratio increase from 1.4 in 1955 to 2.3 in 2000 in incident cases, when incidence studies were 
repeated after some years or decades in the same population.
73
 
A rapid increase in the incidence of T1D has also been reported in many countries. For 
instance, in Europe the pooled annual rate of increase in incidence was 3.4% (95% CI: 2.5–
4.4%).
74
 Among T1D patients in Taiwan, the biannual incidence of T1D increased from 2.63 
per 100,000 in 1999–2000 to 3.22 per 100,000 in 2009–2010.75 A substantial increase in the 
incidence of T1D among children has been documented as well. For example, in Finland, the 
incidence of T1D among children diagnosed before the age of 15 years increased from 31.4 
per 100,000 per year in 1980 to 64.2 per 100,000 per year in 2005.
76
 In the US state of 
Colorado, the incidence of T1D among  youth  (0 to 17 year-old) increased by 2.3% (95% CI: 
1.6–3.1) per year from 1978 to 2004.77 In France, the incidence rate increased from 8.86 per 
100,000 per year (95% CI: 6.27-11.45) in 1988 to 13.47 per 100,000 per year (95% CI: 
10.29-16.65) in 2004, indicating an annual increase in incidence of 3.34% (95% CI: 3.33-
3.34) in children aged less than 15 years.
78
 In the DIAMOND project, 114 populations in 112 
centres in 57 countries were analysed, and an average annual increase in incidence of 2.8% 
(95% CI: 2.4-3.2%) was calculated among children under 14 years old from 103 centres.
62
 
There seem to be no clear sex ratio in the incidence of T1D as observed in MS. A study 
reported that overall sex ratio is almost equal in children diagnosed under the age of 15, while 
male preponderance was observed in populations with high incidence. Similarly, 
approximately 3:2 male: female ratio was reported in populations of European origin aged 
15-40 years.
79
 A study in Sweden has reported that there was no sex difference in the 
incidence rate of T1D in children aged 0-14 years but male preponderance of about twofold 
was found in subjects aged 15-39 years.
80
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The observed increase in incidence of MS and T1D cannot be restricted to consequences of 
changes in diagnostic methods, access to care and ascertainment and enhanced genetic 
susceptibility alone but may mostly be due to changes in lifestyle and environmental factors 
because of the marked increase over these few decades.  For instance in Northern Japan, the 
accuracy of diagnostic procedures has not  changed since 2000 and therefore the trend of 
increased incidence observed after this period strongly suggests a  real increased risk of 
MS.
68
 In Sardinia, where the population is genetically homogeneous and stable, repeated 
surveys showed increasing disease incidence. The time scale of these changes tends to 
suggest changes in environmental factors.
64
 
In summary, evidence from available data, documents an increased incidence of MS and T1D 
over the last few decades. Understanding why these changes occurred could shed light on the 
causes of MS and T1D.  
3.3.5.2 Genetic and immunologic features 
The association of one autoimmune disease with another in the same patient is a well-known 
phenomenon.
7, 23, 81, 82
 The pathophysiological mechanism behind the co-occurrence of MS 
and T1D is not yet clear but may involve both genetic and environmental causes. The 
observed familial aggregation and higher susceptivity to both diseases in first-degree relatives 
than the general population supports a genetic predisposition to both diseases. Due to what 
seems to be mutually exclusive, predisposing HLA haplotypes in patients with T1D and MS, 
the co-occurrence of MS and T1D has been considered unlikely
83
, given that the HLA 
haplotype DRB1*1501-DQA1*0102-B1*0602 bestows susceptibility for MS while protecting 
against T1D.
83, 84
 However, with the rapid identification of novel susceptibility loci in both 
diseases in recent years, it is likely that more overlap will be identified. Indeed, a review from 
2009 showed that out of seven single nucleotide polymorphisms (SNPs) shown to be 
unequivocally associated with T1D, two – rs12708716 from the CLEC16A gene (OR=1.18 
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(95% CI: 1.08–1.29, p=1.6×10-16)  and rs763361 from the CD226 gene (OR= 1.11 (95% CI: 
1.02–1.21, p=5.4×10-8) – also demonstrated evidence for associations with MS.85  There are 
other non-HLA genes associated with the risk of MS and T1D which include IL2RA and 
IL7RA. For instance interleukin-2 receptor α gene (IL2RA; SNP: rs2104286) and interleukin-
7 receptor α gene (IL7RA; SNP: rs6897932) were associated with 33% (OR=1.33 (95% lower 
bound: 1.17, p<0.001)) and 15% (OR=1.15 (95% lower bound: 1.01, p=0.035)) increased risk 
of MS, respectively.
86
 Similarly, in T1D, IL2RA (SNP: rs3118470) has been associated with a 
28% increased risk of T1D (OR=1.28 (95% CI: 1.10–1.47)).87 
MS and T1D are thought to share several similarities in immunological and epidemiological 
features which lend support to possible common mechanisms in the development of both 
diseases. Immunologically, both diseases are considered T-cell-mediated diseases
49
 
characterised by auto-antigen-specific T-helper (Th)1 cell responses
88
, decreased T-cell 
suppressor activity
41, 89
 and the presence of various autoantibodies, some which could operate 
in both diseases.
49, 90, 91
 In people with MS, serum pro-inflammatory cytokines such as TNF-α 
and IFN-γ which are elevated before clinical exacerbations of MS can activate  cerebral 
endothelial cells (CECs) and alter their anatomic structure and function, leading to the 
disruption of the blood-brain barrier (BBB) as evidenced by a decrease expression of 
endothelial tight junction proteins of the CECs. Dysfunction of the CECs and permeability of 
the BBB causes adherence and trans-endothelial migration of T-lymphocytes and monocytes 
to the CNS, with destructive and often neurodegenerative consequences.
92, 93
 T1D is 
associated with a shift in Th cell differentiation in favour of a pathogenic Th1 pathway and 
against an immunoregulatory Th2 subset of T-cells. This allows Th1 cytokines, including 
interleukin-2, interferon-γ and tumour necrosis factor β (TNF-β) -to induce a cascade of 
immune/inflammatory processes in the islet of Langerhans, culminating in the destruction of 
the beta-cells of the Islets of Langerhans. Th1 cytokines activate cytotoxic T-cells that 
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interact specifically with beta-cells of the Islets of Langerhans and destroy them. They also 
activate macrophages to produce proinflammatory cytokines and oxygen and nitrogen free 
radicals that are highly toxic to the beta-cells of the Islets of Langerhans.
94, 95
  
Additionally, a study by Winer and colleagues demonstrated that auto-reactive T-cells were 
capable of targeting both pancreatic Islet of Langerhans and CNS auto-antigens in individuals 
with MS and people with T1D, including relatives of patients with T1D.
49
 However, a 
polymorphism in the T-cell receptor did not influence the susceptibility to T1D and MS in a 
Sardinian population.
96
 IL-2 receptor polymorphisms have been proposed to reflect the 
existence of a heterogeneous association between T1D and MS, suggesting different 
immunopathological mechanisms of IL2RA in the two diseases.  
In summary, shared genetic and immunological predisposition to both diseases may play a 
role in the co-occurrence of MS and T1D.  
3.3.5.3 Latitudinal gradient, ultraviolet radiation (UVR) and vitamin D 
In MS, a latitudinal gradient in MS prevalence and incidence has been reported in North 
America, Europe and Australasia.
97
 The persistence of a positive gradient in Europe after 
adjustment for HLA-DRB1 allele frequencies strongly supports a role for environmental 
factors which may vary with latitude.
97
 Similarly a positive association of T1D prevalence 
has been demonstrated, with increasing southern latitude of residence in Australia.
98
 In 
Europe, incidence of T1D has also been associated with increasing northern latitude.
74
 With 
respect to MS, persons migrating from lower to higher latitude after the age of puberty are 
thought to carry their former high risk with them, while those that migrate prior to puberty 
seem to have the risk associated with the new area to which they migrated.
99
 In the case of 
T1D, migration studies have reported that the incidence of T1D is similarly increased in 
population groups who have moved from a low-incidence to a high-incidence region.
100
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One explanation proposed for the observed association of MS and T1D with latitude is that 
exposure to sunlight may be protective, either because of an effect of ultraviolet radiation 
(UVR) directly or via UVR-induced production of vitamin D.
101
 The protective effect of 
UVR-induced immunosuppression on MS and T1D is a plausible explanation of the gradient 
as ambient UVR levels decrease with increasing latitude.
53
 In line with this hypothesis, a 
number of studies have found an inverse relationship between sun exposure, ultraviolet 
radiation exposure, or serum levels of vitamin D and the risk or prevalence of MS and T1D.
98, 
102-105
 For instance, Staples and colleagues
98
 reported that the latitudinal gradient for T1D 
prevalence in adults reflects a strong negative correlation between ambient UVR and the 
prevalence of T1D. Similarly, in a study of 51 regions around the world, Mohr and 
colleagues
106
 found that areas with lower levels of UVR had a higher incidence of T1D. In 
MS, higher sun exposure during childhood and adolescence was associated with a decreased 
risk of MS
102, 107
 and regional UVB radiation was predictive of corresponding MS prevalence 
rates, supporting the hypothesis that sunlight exposure influences MS risk.
103, 108
 Lower UV 
exposure therefore may predict a higher autoimmune disease susceptibility explaining the co-
occurrence of several autoimmune diseases in one person.
53, 109
 
In MS, studies have also shown that low vitamin D, which is predominantly UVR derived, is 
prospectively associated with the risk and clinical course of MS.
104, 110, 111
 Consistent with 
this evidence, a prospective cohort study using the Nurses' Health Study (NHS; 92,253 
women followed from 1980 to 2000) and Nurses' Health Study II (NHS II; 95,310 women 
followed from 1991 to 2001) reported that the risk of developing MS was significantly 
reduced for women taking ≥400 international units/day of vitamin D.112 Randomised clinical 
trials on the efficacy of vitamin D supplementation in MS patients were conflicting, 
however.
113-115
 In T1D, a retrospective birth-cohort study was conducted by Hypponen and 
colleagues in Oulu and Lapland, northern Finland which followed 10,821 children up at age 
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one year and assessed the prevention of T1D by vitamin D supplementation during the first 
one year of life. Data was retrospectively collected on frequency and dose of vitamin D 
during the first year follow-up period. This study showed a large decrease in the risk of T1D 
later in life among the children who regularly received vitamin D supplementation compared 
to those who did not( RR= 0.12, 95% CI 0.03–0.51).116 In confirmation, a recent meta-
analysis by Zipitis and Akobeng reported that T1D risk was significantly reduced in infants 
who received supplemental vitamin D as compared with those who did not (pooled odds 
ratio: 0.71, (95% CI: 0.60–0.84).105 Since there were no randomised controlled trials, studies 
included in the meta-analysis were observational in design.   
In summary, there is some evidence to suggest a possible influence of latitudinal gradient, 
UVR and vitamin D on the risk of MS and T1D. Randomised controlled trials on the efficacy 
of vitamin D to modulate the risk and progression of MS are inconsistent, however. Unlike 
MS, there were no randomised controlled trials found for the effect of vitamin D on the risk 
of developing T1D to strengthen the current available evidence. That said, the observational 
studies that have been done, particularly the birth cohort study by Hypponen and colleagues, 
are of high methodological rigour and, while not as robust as randomised controlled trials, are 
potentially supportive of some treatment impact on T1D risk. For this reason, current data 
suggesting that supplementation with vitamin D in early life might be important in conferring 
protection against the risk of developing T1D later in life must be interpreted with caution. 
Even though vitamin D supplementation appears to be a promising treatment worthy of 
further exploration in both diseases, the paucity of randomised controlled trials and use of 
different doses in studies is as yet incomplete evidence to recommend supplementation in the 
prevention of either condition. 
Among the other known risk factors for MS, smoking has been associated with the risk of 
MS and known to increase the progression in disability.
117, 118
 In T1D smoking has not been 
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directly associated with the risk of the disease but  with increased risk for diabetic 
nephropathy, retinopathy, and neuropathy.
119
 Other risk factors that have been associated 
with MS and T1D are viral infection and exposure to cow-milk protein. Evidence for a link 
between viral infection and the autoimmune process has been repeatedly shown in T1D and 
MS.
120, 121
 The risk of MS has been consistently associated with Epstein Barr virus 
infection
121, 122
 while T1D has been associated with different viruses including enteroviruses, 
rubella and rotaviruses.
120, 123
 Exposure to cow-milk protein, for example, have been 
tentatively associated with increased risk of development of MS
124
 and T1D.
125
  
3.3.6 Clinical implication of T1D in people with MS 
From the studies examined above, T1D was both a consistent risk factor and a significant 
comorbidity in MS and their first-degree relatives. Consistent with this background, people 
with T1D have an increased risk of developing MS. Evidence on whether the co-occurrence 
of the two autoimmune conditions will affect the disease course and progression of disability 
in MS is absent. However, available data shows that individuals who developed T1D or T2D 
diabetes or other cardiovascular risk factors or disease at any point during MS disease course 
may have more rapid progression in ambulatory disability.
60
  
The consistent association between MS and T1D calls for a critical assessment of the clinical 
impact of T1D in patients with MS. The impact of T1D on the risk of MS and possibly 
disability progression can be hypothesised to be occurring by both direct and indirect 
mechanisms. Considered an autoimmune disease, T1D may directly worsen the autoimmune 
dysfunction in MS. Up to 50% of people with T1D are eventually affected by diabetic 
neuropathy, which is a major cause of morbidity and increased mortality and reduced quality 
of life.
48
 In diabetic neuropathy, damage to the peripheral nervous system is characterised by 
symptoms such as paraesthesia, sensory loss, neuropathic pain, numbness, tingling, muscle 
weakness and significant autonomic dysfunction
48
 which may mimic and exacerbate MS 
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symptoms. In T1D, chronic hyperglycaemia and the consequent occurrence of 
cerebrovascular complications, as well as recurrent episodes of severe hypoglycaemia have 
been associated with accelerated CNS white matter ischaemic disease leading to cognitive 
dysfunction, impairment of coordination and other neurological dysfunction that may 
significantly add to the disease burden of MS.
126-128
  
3.3.7 Conclusions 
We have reviewed current data on the concurrence of MS and T1D that has shown that the 
co-occurrence of the two diseases is not uncommon. The shared similarities in their aetiologic 
features, including low sun exposure/UVR or vitamin D deficiency, may partly explain the 
co-occurrence of the two conditions in genetically susceptible individuals. The mechanism by 
which T1D may impact the clinical course of MS in largely undetermined, as studies in this 
area are lacking. We have therefore hypothesised that the presence of T1D in patients with 
MS may potentially increase the rate of disability progression in MS and could worsen 
cognitive impairment observed in people with MS. Further studies on the co-occurrence of 
the two diseases are desirable to provide the needed evidence on how T1D might influence 
progression in clinical disability or determine the clinical course of MS. 
3.4 Postscript 
This chapter has provided some key information on the frequency of autoimmune 
comorbidities and contribution of IFN-β to this frequency and their influence on disease 
progression in MS. The next chapter investigates the role of serum lipids on the disability and 
progression in disability in people with MS. 
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Chapter 4 : An adverse lipid profile is associated with disability and 
progression in disability in people with MS 
4.1 Preface 
The manuscript presented in this chapter has been published. The typeset version of the 
manuscript as it appeared in the journal is in Appendix 4A. The text of this chapter is the 
same as the published version. This investigation describes the relationship between an 
adverse lipid profile and disability and progression in disability in people with MS. 
4.2 Abstract 
Background: There is accumulating data suggesting an association between serum lipids, 
apolipoproteins and disability in MS. 
Objective: To investigate the associations between serum lipids, apolipoproteins and 
disability in MS. 
Methods: A cohort of 178 participants with clinically definite MS in southern Tasmania 
were prospectively followed from 2002-2005 and serum samples were obtained at study entry 
and at each biannual review and to measure lipid profile and apolipoprotein levels. 
Associations with disability and annual change in disability were evaluated using linear 
regression and multilevel mixed-effects linear regression. 
Results: In the unadjusted analyses, nearly all lipid-related variables were positively 
associated with Expanded Disability Status Scale (EDSS). After adjustment for confounders, 
total cholesterol (TC) (p=0.037), apolipoprotein B (ApoB) (p=0.003), and apolipoprotein B to 
apolipoprotein A-I ratio (ApoB/ApoA-I ratio) (p=0.018) were independently associated with 
a higher EDSS. Higher BMI was also independently associated with higher EDSS (p=0.013). 
With the progression analysis, total cholesterol to HDL ratio (TC/HDL ratio) (p=0.029) was 
prospectively associated with subsequent change in EDSS.  
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Conclusion: In this prospective population-based cohort study, an adverse lipid profile was 
associated with high MS disability and disease progression. Improving serum lipids may be 
beneficial for MS patients to potentially improve clinical outcomes and vascular 
comorbidities. 
4.3 Introduction 
Multiple sclerosis (MS) is an inflammatory, demyelinating condition of the central nervous 
system (CNS). It has a highly variable inter- and intra-personal clinical course, suggesting 
multiple contributory factors
1
 but there is still little data on factors that modify the disease
course. 
Lipids play important roles in the CNS and transport through the blood-brain barrier (BBB) 
has been demonstrated.
2, 3
 Lipids are involved in the regulation of neural functions, cell
signalling, and in tissue structure and apolipoproteins are key players in the metabolism, 
transport and delivery of lipids.
4, 5
 Oxidative stress and consequent lipid peroxidation may
play a role in the inflammatory processes and pathogenesis of MS.
6, 7
 Oxidative modifications
of low density lipoprotein (LDL), the major carrier of plasma cholesterol, have been 
established in the parenchyma of MS plaques.
3
 Lipid peroxidation and oxidised LDL uptake
by activated microglia and infiltrating macrophages in the early stages of MS plaque 
development, are thought to play crucial roles in demyelination.
3
  HDL on the other hand
may have protective effects due to its antioxidant properties and role in reverse cholesterol 
transport.
2
There is little epidemiological evidence on lipids and MS. High rates of obesity and 
overweight have been reported in MS,
8, 9
 and vascular comorbidities seem to be more
common in MS than the general population.
10 A high body mass index (BMI) during
adolescence has been associated with an increased MS risk.
11, 12
 Strong associations were
found between total cholesterol (TC), LDL and the number of gadolinium-enhancing lesions 
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on magnetic resonance imaging (MRI).
13
 Lipoproteins and apolipoproteins were associated
with new MRI lesions and grey matter atrophy in clinically isolated syndrome
14, 15
 and high
cholesterol level was associated with low retinal nerve fibre layer thickness in MS patients 
with optic neuritis.
16
 A prospective study found that higher baseline total cholesterol (TC),
LDL, triglycerides and lower high density lipoprotein (HDL) were associated with 
subsequent worsening clinical disability,
17
 but this study did not take confounding factors
into account.  
In this prospective clinical cohort of people with MS with repeated lipid measures, we 
examined the association between lipid-related measures (BMI, serum lipid and 
apolipoprotein levels) and disability and progression in disability.  
4.4 Methods 
4.4.1 Study design 
The Southern Tasmanian Multiple Sclerosis Longitudinal (MSL) Study is a prospective 
population-based study, which followed a cohort of 203 persons with clinically definite MS
18
living in southern Tasmania, Australia from 2002–2005. An estimated 78% (203/259) of 
eligible cases were included. The study retention rate was 90% (183/203), with 4% (8/203) 
withdrawing early and 6% (12/203) lost because they moved interstate or died. One person 
only participated in a pilot before Wave 1, and four participants were excluded because they 
did not meet the criteria for definite MS after neurological review at the end of the study 
(with all available data). For this analysis, the sample was limited to those with BMI data 
(n=178), excluding 20 people whose weight and height could not be assessed because of their 
high disability. 
The study methodology has been previously described.
19 
At each biannual review participants
were asked about their lifestyle, including physical activity, smoking, vitamin D supplement 
use and dosage, statin and other medication use. Height and weight was measured at baseline. 
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The Expanded Disability Status Scale (EDSS) was assessed each winter by a single 
physician. The Multiple Sclerosis Severity Score (MSSS) was calculated from the EDSS and 
disease duration by comparing it to the global MSSS reference dataset.
20
 Ethics approval was
obtained from the Southern Tasmania Human Research Ethics Committee and all participants 
provided informed consent. 
4.4.2 Biological samples and measurements 
Non-fasting serum samples were collected at study entry and at each biannual review and 
stored at −80°C until use. Traditionally triglycerides were measured in a fasting state; 
however there has been a shift to non-fasting samples as post-prandial non-fasting values are 
more representative of the usual metabolic state.
21
 Total cholesterol and triglycerides were
measured using enzymatic colorimetry (Wako Chemicals USA, Inc., Richmond, VA). HDL-
cholesterol levels were measured using precipitation and enzymatic assay (Wako Chemicals 
USA, Inc., Richmond, VA). LDL-cholesterol was estimated using Friedewald equation
22
except when triglyceride levels were above 5.1mmol/L (n=9), then it was measured by direct 
assay (Wako). Non-HDL-cholesterol levels were computed by subtracting HDL-cholesterol 
from total cholesterol.  
The apolipoproteins, ApoA-I and ApoB were measured as they are the main proteins 
components of HDL, and LDL/VLDL, respectively. Lipoprotein(a) (Lp(a)) is the complex of 
LDL-cholesterol and apolipoprotein (a). ApoB, ApoE and ApoA-1 levels were measured by 
turbidimetric immunoassay using goat anti-human ApoB or ApoA-I (Wako Chemicals USA, 
Inc., Richmond, VA) and Lp(a) measured by a sandwich DELFIA (LKB-Pharmacia). Serum 
levels of highly sensitive C-reactive protein (hs-CRP) were measured with an hs-CRP ELISA 
Kit (Alpha Diagnostic Int., San Antonio, Texas, USA) according to the manufacturer’s 
instructions (detection limit 0.35 ng/ml). Samples were diluted 1:100 and studied in duplets 
and re-measurement with a dilution of 1:200 was performed for samples out of range.   
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Serum 25-OH-D levels were measured with a commercially available radioimmunoassay 
(DiaSorin, Stillwater, MN). Inter-batch reproducibility was 4.6% at 32nmol/l and 6.4% at 
125nmol/l. 
4.4.3 Statistical Analysis 
Total cholesterol to HDL ratio (TC/HDL ratio), LDL to HDL ratio (LDL/HDL ratio), ApoB 
to ApoA-I ratio (ApoB/ApoA-I ratio) were calculated as they are validated predictors of 
cardiovascular disease risk.
23
 We used established cut-points of the American Heart
Association for high and normal lipid levels.
24
Associations with lipid-related variables and disability as outcome variables were assessed by 
linear regression (cross-sectional analyses). Associations with annual change in disability 
were assessed by multilevel mixed-effects linear regression to account for intra-individual 
course over time (prospective analyses).  
Associations with disability were adjusted for relevant confounders including relapse at the 
time of disability assessment (no, yes), age at study entry, sex, smoking (no, yes) and statin 
use (no, yes), BMI (kg/m
2
), physical activity (Mets) and 25(OH)D (nmol/L). Associations
with annual change in EDSS were also adjusted for a categorical term for baseline EDSS (0-
3, 3.5-5.5, 6-7, 7.5), because the progression of disability depends on baseline disability, 
and for change in relapse at the time of disability assessment. Transformation was applied as 
required to satisfy homoscedasticity; however, all coefficients are reported on the scale of the 
original disability measure. All analyses were done using STATA/IC for Windows (Version 
12.1; StataCorp LP College Station USA). 
Our standard analysis evaluated the prospective associations of the lipid-related variables at a 
winter review with the subsequent annual change in EDSS from that winter to the next winter 
as the outcome variable. In order to evaluate causality, we used a time lag analysis, where we 
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shifted the lipid-related variables six and twelve months before or after the outcome variable. 
If the observed associations were due to reverse causality one would expect the magnitude of 
effects to become stronger when associations are modelled 6 or 12 months after the outcome 
variable. 
4.5 Results 
4.5.1 Participant characteristics 
Table 4.1 shows the characteristics of the cohort at study entry. The cohort was followed for 
an average of 2.2 (SD 0.5) years, 62.9% were overweight or obese (25 kg/m2), and only 
5.6% (n=11) were treated with statins during the study. Using the established lipid cut-
points
24
, 51% of the participants had TC above 5.2 mmol/L, 24% had HDL below 1 mmol/L, 
67% had LDL above 2.6 mmol/L and 39% had triglyceride above 1.7 mmol/L. 
4.5.2 Determinants of serum lipids and apolipoproteins 
Supplementary Table 4.1 shows the correlation between the lipid variables and 
supplementary Text shows details on the determinants of serum lipids and apolipoproteins.  
In summary, strong correlations were observed between a number of lipid measures, for 
example between TC, LDL, nonHDL and ApoB (r>0.87). A higher age was associated with 
many of the lipid and apolipoprotein measures. Importantly, BMI was a significant 
independent predictor of lipid and apolipoprotein levels, taking into account factors such as 
age, sex, smoking, physical activity and statin use, and some associations were also seen for 
physical activity and smoking.  
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Table 4.1: Demographic and clinical characteristics of the MS cohort at study entry 
Characteristics n/N (%) 
Total 178/178 (100) 
Female sex 128/178 (72) 
MS Course at study entry 
   Relapsing-Remitting MS 149/178 (83) 
   Secondary Progressive MS 20/178 (11) 
   Primary Progressive MS  9/178 (5) 
Used Immunomodulatory therapy during study? 132/178 (74) 
Smoker during study 48/178 (27) 
Body Mass Index (Kg/m
2
)
   Normal 66/178 (37.1) 
   Overweight 74/178 (41.6) 
   Obese 38/178 (21.3) 
Mean (SD; Range) 
Age 47.4 (11.4; 21-77) 
Median (IQR) 
MS duration from diagnosis (years) 6.0 (2.0,12.0) 
EDSS at study entry 3.5 (2.0, 5.0) 
MSSS at study entry 4.0 (2.3, 6.2) 
Physical activity (Met) 17.6 (3.3, 40.0) 
Body Mass Index (Kg/m
2
) 26.31( 23.4, 28.8) 
TC (mmol/L) 5.2 (4.5, 6.1) 
LDL (mmol/L) 3.4 (2.3, 3.6) 
ApoB (g/L) 0.97 (0.82, 1.2) 
nonHDL (mmol/L) 3.7 (3.0, 4.6) 
Trig (mmol/L) 1.5 (1.1, 2.2) 
HDL (mmol/L) 1.4 (1.1, 1.7) 
ApoA-I (g/L) 1.6 (1.3, 1.8) 
ApoE (mg/L) 52.0 (41.0, 64.0) 
Lp(a) (µmol/L) 0.5 (0.2, 1.4) 
hs-CRP (mg/L) 16.5 (8.0, 36.0) 
TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apoprotein B; NonHDL: Non 
high density lipoprotein; Trig: Triglycerides; HDL: High density lipoprotein; ApoA-I: 
Apoprotein A-I; ApoE: Apoprotein E; Lp(a): Lipoprotein a; Hs-CRP: High sensitive C-
reactive protein 
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4.5.3 Association between lipid-related variables and clinical disability 
In the basic analyses, nearly all lipid-related variables, including BMI, were associated with 
clinical disability as measured by EDSS (Table 4.2) and MSSS (data not shown), such that 
higher total cholesterol, LDL, and triglycerides, as well as ApoE, ApoB, and Lp(a) were 
associated with higher disability. Age and sex explained part of the associations, as 
adjustment for age and sex attenuated the associations; additional adjustment for smoking and 
statin use did not affect the associations. Neither HDL nor its associated apolipoprotein Apo-
A-I were associated with disability in any analysis.
In clinical terms, adjusted for age and sex, those who had a 2 mmol/L higher TC, LDL and 
nonHDL, had on average a 0.61 (p=0.006), 0.54 (p=0.037), and 0.59 (p=0.003) higher current 
EDSS level, respectively. From the regression lines (adjusted for age and sex), we estimated 
that those at the cut-point of high TC, HDL, and LDL had a mean EDSS of 3.9, 4.2 and 4.5, 
respectively. In relation to BMI, those who had a 5 kg/m
2 
higher BMI score had on average a
0.38 higher EDSS level.   
The cross-sectional associations above could reflect reverse causality, where increased 
disability acts via an increased BMI and reduced physical activity to yield an adverse lipid 
profile. To account for reverse causality, we further adjusted for BMI and self-reported 
physical activity in the period prior to lipid measurement. In general, adjustment for BMI and 
physical activity reduced the magnitude of the coefficients (Table 4.2), with most of it driven 
by BMI rather than physical activity, even though there was some association between 
physical activity and EDSS (basic model (-0.012(-0.018, -0.005) p<0.001); adjusted model 2 
(-0.005(-0.010, 0.0003) p=0.06). Importantly, total cholesterol, ApoB, ApoB/ApoA-I ratio 
remained significantly associated, even after taking BMI, physical activity and other 
confounders into account. In addition, there was an independent effect of BMI on disability. 
Adjustment for comorbid hypertension status did not affect the magnitude of the associations.  
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Similar associations were observed with MSSS. In the unadjusted analyses, higher TC, LDL, 
nonHDL and LDL/HDL ratio were significantly associated with higher MSSS. Again, 
adjusting for variables such as age, sex, BMI and physical activity explained part of the 
association, but independent associations were observed for TC (0.51 (0.18, 0.85) p=0.003), 
LDL (0.68 (0.29, 1.08) p=0.001), nonHDL (0.48 (0.16, 0.79) p=0.003), LDL/HDL ratio (0.43 
Table 4.2: Associations between lipid-related variables and EDSS 
Basic model Adjusted model 1 Adjusted model 2 
Coefficient p-value Coefficient p-value Coefficient p-value
BMI (kg/m2) 0.08(0.03, 0.14) 0.002 0.07 (0.02, 0.11) 0.004 0.06 (0.01, 0.10)* 0.013 
TC(mmol/L) 0.44 (0.20, 0.68) <0.001 0.30 (0.09, 0.52) 0.006 0.23 (0.01, 0.44) 0.037 
LDL(mmol/L) 0.40 ( 0.11, 0.69) 0.007 0.27 (0.01, 0.53) 0.039 0.14 (-0.11, 0.40) 0.26 
ApoB(g/L) 2.06 ( 0.98, 3.14) <0.001 1.53 (0.61, 2.45) 0.001 1.01 (0.09, 1.93) 0.003 
NonHDL(mmol/L) 0.40 (0.18, 0.62) 0.001 029 (0.10, 0.49) 0.004 0.18 (-0.02, 0.38) 0.08 
Trig(mmol/L) 0.26 (0.07, 0.45) 0.009 0.17(0.01, 0.34) 0.038 0.11 (-0.05, 0.27) 0.19 
HDL(mmol/L) -0.10 (-0.72, 0.51) 0.74 -0.31 (-.86, 0.23) 0.26 0.01 (-0.56, 0.59) 0.96 
ApoA-I(g/L) 0.18 (-0.53, 0.89) 0.62 -0.12 (-0.77, 0.53) 0.73 0.28 (-0.39, 0.95) 0.41 
ApoE(mg/L) 0.02 ( 0.01, 0.03) 0.005 0.01 (-0.0001, 0.02) 0.052 0.01 (-0.001, 0.02)  0.26 
Lp(a) (µmol/L) 0.20 (0.05, 0.35) 0.011 0.08 (-0.05, 0.21) 0.22 0.08 (-0.04, 0.21) 0.20 
Hs-CRP (mg/L) 0.01 (0.001, 0.01) 0.010 0.005 (0.001, 0.01) 0.014 0.003 (-0.001,0.007) 0.54 
TC/HDL ratio 0.18 (0.02, 0.34) 0.024  0.14 (-0.001, 0.28) 0.052 0.05 (-0.10, 0.19) 0.52 
LDL/HDL ratio 0.28 (0.03, 0.48) 0.09 0.22 (-0.01, 0.45) 0.058 0.06 (-0.17, 0.29) 0.63 
ApoB/ApoA-I ratio 1.42 (0.18, 2.66) 0.004 1.41 (.30, 2.51) 0.013 0.68 (-0.41, 1.77) 0.018 
Basic Model: Adjusted for relapse at the time of review 
Adjusted model 1: Further adjusted for age at study entry, sex, smoking and statin use. 
Adjusted model 2: Further adjusted for BMI and physical activity 
*Also adjusted for Total cholesterol and triglycerides
TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apoprotein B; NonHDL: Non high density
lipoprotein; Trig: Triglycerides; HDL: High density lipoprotein; ApoA-I: Apoprotein A-I; ApoE: Apoprotein E;
Lipo(a): Lipoprotein a; Hs-CRP: High sensitive C-reactive protein
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(0.07, 0.79) P=0.019), ApoB (2.40 (0.85, 3.95) p=0.003) and ApoB/ApoA-I ratio (2.26 (0.40, 
4.13) p=0.018). Again, no associations were seen with HDL (p=0.12) and ApoA-I (p=0.12). 
For BMI, those who had a 5 kg/m
2
 higher BMI score had on average a 0.63 higher MSSS
level independent of other confounding factors.  
4.5.4 Associations between lipid-related variables and change in clinical disability 
We next sought to evaluate the relationship between lipid levels and subsequent change in 
disability. The prospective model (Table 4.3) is the preferred model where the lipid values 
are measured at the beginning of the interval of measuring change in disability. Only 
TC/HDL ratio was significantly associated with annual change in EDSS and this association 
remained in the fully adjusted model. Examining different lags for this association 
(Supplementary Table 4.2) did not indicate that the effect was due to reverse causality, as the 
association was weaker when TC/HDL ratio was measured in the middle, end or after the 
interval over which change in EDSS was measured.  
Stronger associations were observed in the basic model when lipids were measured in the 
middle of the outcome interval (defined as cross-sectional model), but only HDL was 
significant in the fully adjusted model. From the findings on HDL using other lags for HDL, 
we could not determine whether or not this association was due to reverse causality.  
BMI (at baseline) was not associated with change in disability (basic model, coefficient 
+0.003 (-0.011, 0.02) p=0.64; adjusted model 1, coefficient +0.005 (-0.01, 0.02) p=0.53;
adjusted model 2, coefficient -0.002 (-0.02, 0.01) p=0.82). No associations were observed for 
any of the models for triglycerides, Lp(a), Hs-CRP and ApoE, nor for physical activity (data 
not shown).  
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Table 4.3: Prospective association between lipid-related variables and annual change in EDSS 
Basic Model 
TC LDL ApoB nonHDL HDL ApoA-I TC/HDL LDL/HDL ApoB/ApoA-I 
Basic Model 
0.02 (-0.05, 
0.09) 
p=0.50 
0.04 
(-0.04, 0.13) 
p=0.32 
0.22 
(-0.09, 0.52) 
p=0.16 
0.04 
(-0.02, 0.11) 
p=0.20 
-0.11
(-0.28, 0.06) 
p=0.19 
-0.05
(-0.24, 0.14) 
p=0.62 
0.05 
(0.00, 0.09) 
p=0.045 
+0.06
(-0.03, 0.15) 
p=0.17 
0.26 
(-0.12, 0.63) 
p=0.18 
Adjusted model 
1 
0.03 
(-0.05, 0.10) 
p=0.47 
0.05 
(-0.04, 0.13) 
p=0.29 
0.21 
(-0.10, 0.51) 
p=0.18 
0.04 
(-0.03, 0.11) 
p=0.23 
-0.10
(-0.27, 0.08) 
p=0.28 
-0.01
(-0.21, 0.19) 
p=0.91 
0.04 
(0.003,0.09) 
p=0.07 
0.05 
(-0.03, 0.14) 
p=0.23 
0.24 
(-0.13, 0.61) 
p=0.21 
Adjusted model 
2 
0.04 
(-0.04, 0.11) 
p=0.33 
0.05 
(-0.03, 0.14) 
p=0.22 
0.26 
(-0.05, 0.57) 
p=0.10 
0.05 
(-0.02, 0.11) 
p=0.14 
-0.10
(-0.28, 0.08) 
p=0.29 
-0.005
(-0.21, 0.20) 
p=0.96 
0.05 
(0.01, 0.10) 
p=0.029 
0.06 
( -0.03,0.16)
p=0.16
0.28 
(-0.11, 0.66) 
p=0.16 
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4.6 Discussion 
Using a prospective cohort design in people with MS, we have found that higher TC, ApoB 
and ApoB/ApoA-I ratio were associated with a higher disability and that a higher TC/HDL 
ratio was associated with a faster accrual of disability, suggesting that lipid lowering 
interventions may be of benefit for people with MS. 
We observed that those with an adverse lipid profile (elevated TC, LDL, nonHDL, 
triglyceride, ApoB, ApoB/ApoA-I ratio) had higher levels of clinical disability. Part of the 
effect was explained by age and sex. However as we examined these associations cross-
sectionally, this raises the question of reverse causality, i.e. whether an increased BMI and 
adverse lipid profile results in  higher disability, or whether  increased disability results in a 
higher BMI and more adverse lipid profile. We know that a higher BMI results in a more 
adverse lipid profile.
25-27
 Indeed, adjustment for BMI and physical activity reduced the
magnitude of the associations, but independent associations were still observed for TC, ApoB 
and ApoB/ApoA-I ratio. In addition, we observed an effect of BMI on disability that was 
independent of the effect of lipids. Our findings agree with studies that have found 
associations between LDL,
10, 28
 TC,
10
 TC/HDL ratio,
17
 BMI
29
 and disability.
We also examined whether lipid-related measures influenced clinical course by examining 
the association with annual change in disability. It has previously been reported that higher 
baseline LDL, TC and triglycerides were associated with a worsening in EDSS and MSSS 
over 2.2 years, but this study did not adjust for potential confounders apart from age and 
sex.
17
 We found in our prospective analysis that the TC/HDL ratio was associated with a
higher annual change in EDSS. Examining different lags for this association did not indicate 
that the effect was due to reverse causality. Our findings are in line with a recent placebo-
controlled trial in people with MS, which found that those using lipid lowering statins had a 
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lower change in EDSS after two years.
30
 Baseline BMI was not associated with change in
disability. 
Although comparable to that of the general population,
31
 our MS population had on average
high total cholesterol (5.36 mmol/L (SD1.14)) and LDL levels (3.12 mmol/L (SD 0.97)). The 
level of dyslipidaemia (TC>5.5mmol/L) was also high with 35% of participants classified as 
being dyslipidemic. In analyses adjusted for age and sex, for each 2 mmol/L increase in TC, 
LDL and nonHDL, EDSS was 0.6 higher, and for each 5 kg/m
2 
higher BMI, EDSS was 0.4
higher. Those with a lipid profile reaching the established cut-points for high lipid levels
45
had on average an EDSS score of 3.6 to 4.8, depending on the lipid type measured. 
Considering that a 0.03 mmol/L increase in LDL cholesterol confers a >1% increase in 
cardiovascular disease risk
32
 and that vascular comorbidities are common in MS,
10
 these
levels will be associated with a significantly increased cardiovascular disease burden. 
Clinicians should therefore monitor lipid levels in people with MS and treat adverse levels as 
early as possible. 
We found stronger associations for ApoB than for LDL in relation to EDSS and change in 
EDSS, which is in line with data demonstrating that ApoB is a better measure of the relative 
number of circulating LDL particles and a better indicator of heart disease risk than total 
cholesterol or LDL.
33
7-dehydrocholesterol is required as a substrate for the endogenous production of 25(OH)D in
the skin, and previously, significant positive associations have been found between 25(OH)D 
and HDL
34
 and negative associations with triglycerides.
34
 We observed an independent
association between higher 25(OH)D and higher HDL, ApoA-I, ApoE , lower LDL/HDL 
ratio and lower TC/HDL ratio.  
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Our study has significant strengths, including being a prospective population-based cohort 
study with the capability to adjust for relevant confounders and examine mediation pathways. 
The study had some limitations. A two year change in clinical disability measured is limited, 
and a longer follow-up is preferable when measuring change in disability. We examined 
reverse causality, but this cannot be fully ruled out in observational studies. We used non-
fasting serum samples, which may have influenced the levels of triglycerides,
35
 and this could
have contributed to observing non-significant associations with triglycerides. Some 
associations have been observed with MRI markers,
13-15
 but we could not examine that in this
study.  
Clinicians should be aware of the associations between lipids, BMI and disability in MS and 
monitor and treat adverse lipid profiles as early as possible, preferably in a clinical trial 
setting. Our findings that adverse lipid levels were associated with disability as well as 
disability progression, suggests that reducing lipids, decreasing BMI into the healthy range 
and increasing physical activity may significantly reduce disability accumulation. Early 
interventions in the disease course are likely to be more successful, and our findings provide 
support for studies of lipid reducing interventions in early MS before sustained disability 
should occurred.  
4.7 Postscript 
This chapter has provided some evidence on the relationship between an adverse lipid profile 
and disability and progression in disability in people with MS. The next chapter investigates 
the association between serum lipids and the hazard of relapse in people with MS. 
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Supplementary table 4.1: Correlation of serum lipid-related variables 
TC HDL LDL Triglycerides   nonHDL 
TC 
HDL  0.07 
p=0.04 
LDL 0.91 
p<0.001 
-0.17
p=0.001 
Trig 0.43 
p<0.001 
-0.44
p<0.001 
0.25 
p<0.001 
nonHDL 0.92 
p=0.001 
-0.32
p=0.001 
0.94 
p<0.001 
0.58 
p<0.001 
ApoE 0.48 
p<0.001 
0.06    
p=0.09 
0.30 
p<0.001 
0.52 
p<0.001 
0.44 
p<0.001 
ApoB 0.87 
p<0.001 
-0.32
p=0.001 
0.88 
p>0.001
0.56 
p<0.001 
0.95 
p<0.001 
ApoA-I 0.18 
p<0.001 
0.86 
p<0.001 
-0.10
p=0.002 
-0.20
p<0.001 
-0.16
p<0.001 
Lipo(a) 0.23 
p<0.001 
0.003 
p=0.93 
0.23 
p<0.001 
0.09 
p=0.007 
0.22 
p<0.001 
hs-CRP 0.06 
p=0.07 
-0.10
p=0.003 
0.05 
p=0.19 
0.11 
p<0.001 
0.10 
p=0.004 
TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apoprotein B; NonHDL: Non 
high density lipoprotein; Trig: Triglycerides; HDL: High density lipoprotein; ApoA-I: 
Apoprotein A-I; ApoE: Apoprotein E; Lipo(a): Lipoprotein a; Hs-CRP: High sensitive C-
reactive protein 
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4.9 Supplementary Text: Determinants of serum lipids and 
apolipoproteins 
Correlation between lipid-related variables – Supplementary Table 4.1 shows the 
correlations between the serum lipids and apolipoproteins. Strong correlations were observed 
between TC, LDL, nonHDL and ApoB (r0.87). ApoA-I was only strongly correlated with 
HDL (r=0.86). Triglycerides were moderately correlated with TC, ApoB and ApoE 
(0.43r0.56) and inversely with HDL (r=-0.44). Correlations with Lp(a) and Hs-CRP were 
all lower (r0.25). 
Age and sex – Age at study entry was strongly associated with higher TC (p=0.001), HDL 
(p=0.023), LDL (p=0.013), nonHDL (p=0.015), ApoE (p=0.038), ApoB (p=0.008), ApoA-I 
(p=0.002) and Lp(a) (p=0.003). Females have significantly higher HDL (p<0.001), ApoA-I 
(p<0.001), lower LDL/HDL ratio (p<0.001), TC/HDL ratio (p<0.001), and ApoB/ApoA-I 
ratio (p<0.001) than males. The other lipids and apolipoproteins variables did not show 
evidence of variation with age and sex. 
BMI – BMI was a significant independent predictor of serum lipid levels and apolipoproteins. 
After adjustment for age, sex, smoking, physical activity and statin use, higher BMI was 
significantly associated with lower HDL level (p<0.001) and higher TC (p=0.032), LDL 
(p=0.007), nonHDL (p<0.001), triglycerides (p=0.003), TC/HDL ratio (p<0.001), LDL/HDL 
ratio (p<0.001). Likewise after adjustment for confounders, higher BMI was associated with 
lower ApoA-I (p=0.002), higher ApoB (p<0.001), hs-CRP (p<0.001) and ApoB/ApoA-I ratio 
(p<0.001). 
25(OH)D – Significant associations were observed between 25(OH)D and serum lipids and 
apolipoproteins. After adjustment for age at study entry and sex, higher 25(OH)D was 
associated with higher HDL (p<0.001), ApoA-I (p=0.003), ApoE (p=0.16), lower LDL 
(p=0.034), triglyceride (p=0.017), nonHDL (p=0.012), TC/HDL ratio (p<0.001), LDL/HDL 
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ratio (p<0.001), ApoB (p=0.027), ApoB/ApoA-I (p=0.002) and hs-CRP (p=0.017). After 
further adjustment for BMI, physical activity, smoking and statin use, each 10 nmol/L 
increase in 25(OH)D was  associated with higher HDL level (coefficient 0.04 (0.01, 0.07), 
p=0.004), higher ApoA-I (coefficient 0.03, (0.004, 0.06) p=0.025), higher ApoE (coefficient 
1.49, (0.03, 2.94) p=0.045), lower LDL/HDL ratio (coefficient -0.10, (-0.17, -0.03) p=0.004) 
and lower TC/HDL ratio (coefficient -0.12, (-0.21, -0.03) p=0.01). 
Physical activity, smoking, statin use and dietary saturated fat – Physical activity was 
associated with lower triglycerides (p=0.004), nonHDL (p=0.005), TC/HDL ratio (p=0.012), 
LDL/HDL ratio (p=0.038), ApoB (p=0.004), and ApoB/ApoA-I ratio (p=0.030). Smoking 
was associated with lower ApoA-I (p=0.048) and statin use was associated with lower TC 
(p<0.001), LDL (p=0.001) and nonHDL (p=0.019). Dietary saturated fat was not a significant 
determinant of serum lipid or apolipoprotein levels. 
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Supplementary table 4.2: Association between lipid-related variables and annual change in EDSS 
Basic Model 
TC LDL ApoB nonHDL HDL ApoA-I TC/HDL LDL/HDL ApoB/ApoA-I 
Pre-interval  
(Summer values) 
0.01 
(-0.12, 0.13) 
p=0.93 
-0.01
(-0.16, 0.13) 
p=0.86 
+0.26
(-0.33, 0.86) 
p=0.39 
+0.04
(-0.09, 0.17) 
p=0.52 
-0.21
(-0.48, 0.06) 
p=0.13 
-0.21
(-0.53, 0.10) 
p=0.19 
+0.06
(-0.03, 0.15) 
p=0.18 
+0.05
(-0.07, 0.16) 
p=0.46 
+0.46
(-0.08, 1.01) 
p=0.094 
Prospective 
(Winter values) 
0.02 (-0.05, 
0.09) 
p=0.50 
+0.04
(-0.04, 0.13) 
p=0.32 
+0.22
(-0.09, 0.52) 
p=0.16 
+0.04
(-0.02, 0.11) 
p=0.20 
-0.11
(-0.28, 0.06) 
p=0.19 
-0.05
(-0.24, 0.14) 
p=0.62 
+0.05
(0.00, 0.09) 
p=0.045 
+0.06
(-0.03, 0.15) 
p=0.17 
+0.26
(-0.12, 0.63) 
p=0.18 
Cross-sectional  
(Summer values) 
0.04 
(-0.02, 0.11) 
P=0.21 
+0.10
(0.01, 0.19) 
p=0.034 
+0.25
(-0.05, 0.55) 
p=0.098 
+0.07
(0.00, 0.14) 
p=0.041 
-0.19
(-0.36, -0.02) 
p=0.025 
-0.27
(-0.53, -0.02) 
p=0.034 
+0.05
(-0.01, 0.11) 
p=0.075 
+0.11
(0.01, 0.20) 
p=0.024 
+0.49
(0.10, 0.88) 
p=0.013 
Retrospective  
(Winter values) 
0.02 
(-0.06, 0.09) 
p=0.69 
+0.04
(-0.06, 0.14) 
p=0.46 
+0.12
(-0.19, 0.42) 
p=0.45 
+0.04
(-0.04, 0.12) 
p=0.34 
-0.14
(-0.27, -0.01) 
p=0.041 
-0.27
(-0.48, -0.06) 
p=0.013 
+0.04
(-0.02, 0.10) 
p=0.16 
+0.05
(-0.05, 0.14) 
p=0.33 
+0.21
(-0.12, 0.55) 
p=0.21 
Post-interval  
(Summer values) 
-0.002
(-0.06, 0.06) 
P=0.95 
+0.01
(-0.08, 0.10) 
p=0.88 
+0.03
(-0.21, 0.28) 
p=0.80 
+0.02
(-0.05, 0.08) 
p=0.61 
-0.13
(-0.27, 0.01) 
p=0.078 
-0.20
(-0.39, -0.01) 
p=0.042 
+0.03
(-0.01, 0.07) 
p=0.18 
+0.03
(-0.04, 0.10) 
p=0.39 
+0.15
(-0.15, 0.45) 
p=0.32 
Adjusted model 1 
TC LDL ApoB nonHDL HDL ApoA-I TC/HDL LDL/HDL ApoB/ApoA-I 
Pre-interval  
(Summer values) 
-0.01
(-0.13, 0.11) 
p=0.90 
-0.03
(-0.16, 0.11) 
p=0.69 
0.23 
(-0.33, 0.80) 
p=0.72 
0.03 
(-0.09, 0.16) 
p=0.58 
-0.23
(-0.51, 0.04) 
p=0.10 
-0.26
(-0.60 , 0.08) 
p=0.13 
0.07 
(-0.02, 0.15) 
p=0.13 
0.04 
(-0.07, 0.16) 
p=0.45 
0.54 
(-0.01, 1.08) 
p=0.06 
Prospective 
(Winter values) 
0.03 
(-0.05, 0.10) 
p=0.47 
0.05 
(-0.04, 0.13) 
p=0.29 
0.21 
(-0.10, 0.51) 
p=0.18 
0.04 
(-0.03, 0.11) 
p=0.23 
-0.10
(-0.27, 0.08) 
p=0.28 
-0.01
(-0.21, 0.19) 
p=0.91 
0.04 
(-0.003,0.09) 
p=0.07 
0.05 
(-0.03, 0.14) 
p=0.23 
0.24 
(-0.13, 0.61) 
p=0.21 
Cross-sectional +0.03 0.08 (-0.01, 0.19 0.05 -0.17 -0.24 0.04 (-0.02, 0.08 (-0.01, 0.31 
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(Summer values) (-0.04, 0.10) 
p=0.36 
0.16) 
p=0.09 
(-0.08, 0.47) 
p=0.17 
(-0.01, 0.12) 
p=0.09 
(-0.34, 0.002) 
p=0.047 
(-0.51, 0.03) 
p=0.08 
0.09) 
p=0.20 
0.16) 
p=0.08 
(0.02, 0.77) 
p=0.039 
Retrospective  
(Winter values) 
0.002 
(-0.07, 0.07) 
p=0.95 
0.02 
(-0.07, 0.11) 
p=0.68 
0.09 
(-0.18, 0.37) 
p=0.51 
0.04 
(-0.05, 0.10) 
p=0.48 
-0.14
(-0.28,-0.003) 
p=0.045 
-0.28
(-0.50, -0.07) 
p=0.01 
0.03 
(-0.02, 0.09) 
p=0.22 
0.03 
(-0.06, 0.12) 
p=0.50 
0.21 
(-0.12, 0.54) 
p=0.22 
Post-interval  
(Summer values) 
-0.01
(-0.08, 0.05) 
p=0.71 
-0.01
(-0.09, 0.07) 
p=0.75 
0.003 
(-0.23, 0.23) 
p=0.98 
0.01 
(-0.05, 0.07) 
p=0.84 
-0.12
(-0.27, 0.03) 
p=0.18 
-0.21
(-0.41, 0.004) 
p=0.045 
0.02 
(-0.02, 0.06) 
p=0.27 
0.02 
(-0.05, 0.08) 
P=0.60 
0.11 
(-0.16, 0.39) 
p=0.42 
Adjusted model 2 
TC LDL ApoB nonHDL HDL ApoA-I TC/HDL LDL/HDL ApoB/ApoA-I 
Pre-interval  
(Summer values) 
0.01 
(-0.11, 0.13) 
p=0.85 
-0.01
(-0.15, 0.13) 
P=0.92 
0.39 
(-0.22, 1.0) 
P=0.21 
0.06 
(-0.07, 0.19) 
P=0.34 
-0.29
(-0.58, -0.01) 
P=0.045 
-0.31
(-0.65, 0.02) 
P=0.07 
0.09 
(0.001, 
0.19) 
P=0.047 
0.07 
(-0.05, 0.20) 
P=0.26 
0.74 
(0.18, 1.31) 
P=0.01 
Prospective 
(Winter values) 
0.04 
(-0.04, 0.11) 
p=0.33 
0.05 
(-0.03, 0.14 ) 
p=0.22 
0.26 
(-0.05, 0.57) 
p=0.10 
0.05 
(-0.02, 0.11) 
p=0.14 
-0.10
(-0.28, 0.08) 
p=0.29 
-0.005
(-0.21, 0.20) 
p=0.96 
0.05 
(0.01, 0.10) 
p=0.029 
0.06 
( -0.03,0.16)
p=0.16
0.28 
(-0.11, 0.66) 
p=0.16 
Cross-sectional  
(Summer values) 
+0.03
(-0.04, 0.10) 
p=0.38 
0.07 (-0.01, 
0.16) 
p=0.10 
0.20 
(-0.09, 0.48) 
p=0.18 
0.06 
(-0.01, 0.12) 
p=0.10 
-0.18
(-0.35, -0.002) 
p=0.047 
-0.24
(-0.52, 0.04) 
p=0.09 
0.04 
(-0.02, 0.09) 
p=0.19 
0.08 
(-0.01, 0.17) 
p=0.08 
0.42 
(0.03, 0.81) 
p=0.036 
Retrospective  
(Winter values) 
-0.01
(-0.08, 0.07) 
p=0.89 
0.01 
(-0.09, 0.11) 
p=0.85 
0.05 
(-.24, 0.34) 
p=0.74 
0.02  
(-0.06, 0.09 ) 
p=0.68 
-0.12
(-0.26, 0 .01) 
p=0.08 
-0.26
(-0.48, -0.05) 
p=0.015 
0.03 
(-0.03, 0.09) 
p=0.39 
0.03 
( -0.03,0.0)
p=0.34
0.17 
(-0.18, 0.52) 
p=0.35 
Post-interval  
(Summer values) 
-0.02
(-0.08, 0.05) 
p=0.60 
-0.02
(-0.10, 0.06) 
p=0.61 
-0.03
(-0.26, 0.21) 
p=0.82 
0.02  
(-0.06, 0.09 ) 
p=0.68 
-0.12
(-0.27, 0.04) 
p=0.14 
-0.02
(-.41, 0.001) 
p=0.051 
0.02 
(-0.02, 0.06) 
p=0.33 
0.01 
(-0.06, 0.08) 
p=0.74 
0.09 
(-0.19, 0.36) 
p=0.54 
Basic Model: Adjusted for change in relapse, EDSS at baseline 
Adjusted model 1: Further adjusted for age at study entry, sex, MS duration, smoking and statin use. 
Adjusted model 2: Further adjusted for BMI and physical activity 
TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apoprotein B; NonHDL: None high density lipoprotein; HDL: High density lipoprotein; 
ApoA-I: Apoprotein A-I  
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Chapter 5 : Adverse lipid profile is not associated with relapse risk in 
MS: Results from an observational cohort study 
5.1 Preface 
The manuscript presented in this chapter has been published. The typeset version of the 
manuscript as it appeared in the journal is in Appendix 5A. The text of this chapter is the 
same as the published version. This investigation describes the association between an 
adverse lipid profile and the risk of relapse in people with MS. 
5.2 Abstract 
Background: There is increasing evidence that serum lipids and apolipoproteins may be 
associated with multiple sclerosis (MS) clinical course. 
Objective: To investigate the associations between serum lipids, apolipoproteins, body mass 
index and relapse in MS. 
Methods: A prospective cohort of 141 participants with relapsing-remitting MS was 
followed from 2002 to 2005. Serum lipid and apolipoprotein levels were measured 
biannually, and body mass index at baseline. The association with hazard of relapse was 
assessed using survival analysis. 
Results: Neither body mass index nor any of the lipid-related measures were associated with 
the hazard of relapse. 
Conclusion: Serum lipid profile and body mass index are not associated with the hazard of 
relapse in MS.  
5.3 Introduction 
The peroxidation of lipoproteins and their associated serum lipids have been implicated as 
potential agents involved in demyelination and axonal injury in multiple sclerosis (MS) (1). 
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There is now emerging evidence suggesting that dyslipidaemia as comorbidity in MS is 
linked with a more rapid progression in disability (2). Recent evidence suggests a role for an 
adverse lipid profile (low HDL, increased LDL and triglycerides) in MS clinical course with 
some evidence of an association with both disability and progression in disability (3). 
Associations have also been found between serum lipids and number of gadolinium-
enhancing lesions on magnetic resonance imaging in a small sample of people with first 
demyelinating events (4). A modification of serum lipids has been reported also in clinically 
stable MS (5). Only one study has evaluated the association between serum lipid profile and 
relapse, prospectively following a cohort with a clinically isolated syndrome (CIS)  treated 
with interferon-β and finding no association between lipid profile and relapse risk (6). To 
date, however, no studies have examined the association between serum lipids and 
apolipoproteins and the subsequent risk of relapse in people with clinically definite MS. 
Here we examine whether an adverse lipid profile is associated with a higher risk of relapse 
in people with clinically definite relapsing-remitting MS (RRMS) using a prospective cohort 
study design. 
5.4 Methodology 
5.4.1 Study design 
The Southern Tasmanian Multiple Sclerosis Longitudinal (MSL) Study prospectively 
followed a cohort of 203 persons with clinically definite MS (using 2001 McDonald criteria) 
living in southern Tasmania, Australia, between 2002 and 2005. An estimated 78% (203/259) 
of eligible cases were included and data from 198 participants were obtained. A total of 141 
participants had a relapsing-remitting (RRMS) course. When participants discontinued 
participation (4%) or were lost to follow-up (6%), they were censored as of the date of study 
exit or last attended review. 
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The study methodology has been previously described (7). At each biannual review 
participants were asked about their lifestyle, including physical activity, smoking, and 
medication use. Clinical disability (Expanded Disability Status Scale (EDSS)) was measured 
annually by a single physician. Body mass index (BMI) was measured at baseline (weight 
divided by height squared). Ethics approval was obtained from the Southern Tasmania 
Human Research Ethics Committee; all participants provided informed consent. 
5.4.2 Measurement of relapses 
Relapses were reported in real time by phone to the study clinician or subsequently at 
biannual review, and all relapse reports were validated by the study physician and 
neurologist. Using a real-time relapse notification system, participants telephoned the study 
centre if they thought they were experiencing a relapse. Additionally, at each biannual 
review, participants were queried about the occurrence of a relapse in the preceding 6 
months. To ensure each relapse was a true relapse, the study nurse or physician administered 
a relapse questionnaire detailing relapse symptoms, medical practitioner review, treatment, 
and co-occurrence of infection or fever. For quality control, the study physician also 
performed a physical examination for those reporting a relapse by telephone. Throughout the 
study, each relapse was reviewed rigorously by the study physician and further by the study 
neurologist.  
5.4.3 Biological samples and measurement  
Serum samples were collected at study entry and at each biannual review and stored at -80°C 
until measurement. Triglyceride (trig) was measured using non-fasting samples because post-
prandial non-fasting values are more representative of the usual metabolic state (8). Total 
cholesterol (TC) and trig were measured using enzymatic colorimetry and high density 
lipoprotein cholesterol (HDL) levels were measured using precipitation and enzymatic assay 
(Wako Chemicals USA, Inc., Richmond, VA). Low density lipoprotein cholesterol (LDL) 
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was estimated using the Friedewald equation except for trig levels above 5.1mmol/L (n=5) 
measured by direct assay (Wako Chemicals USA, Inc., Richmond, VA).  
Apolipoprotein A-I (ApoA-I), apolipoprotein E (ApoE) and apolipoprotein B (ApoB) were 
measured because they are the main proteins components of HDL, and LDL/VLDL (very 
LDL). Lipoprotein(a) (Lp(a)) is the complex of LDL-cholesterol and apolipoprotein(a). 
ApoB, ApoE and ApoA-I levels were measured by turbidimetric immunoassay using goat 
anti-human ApoB or ApoA-I (Wako Chemicals USA, Inc., Richmond, VA) and Lp(a) 
measured by a sandwich DELFIA (LKB-Pharmacia). Serum levels of highly sensitive C-
reactive protein (hs-CRP) were measured with an hs-CRP ELISA Kit (Alpha Diagnostic Int., 
San Antonio, Texas, USA) according to the manufacturer’s instructions (detection limit 0.35 
ng/ml). 25(OH)D levels were measured with a commercially available radioimmunoassay 
(DiaSorin, Stillwater, MN), which has a detection range of 12.5 to 250nmol/l (inter-batch 
reproducibility was 4.6% at 32nmol/l and 6.4% at 125nmol/l).  
5.4.4 Data analysis 
For relapse analyses, covariates measured at each review were carried forward to the time of 
relapse, such that all parameters were as measured within six months prior to the occurrence 
of relapse. 
The effect of serum lipid variables and other covariates on time-to-relapse was calculated 
using Cox proportional hazards models for repeated events, whereby multiple relapses by the 
same persons are treated as independent observations but accounted for at the intra-individual 
level, and the time until a prior event does not influence the composition of the risk set for a 
subsequent event. 
All covariates satisfied the proportional hazards assumption with the exception of the binary 
variable for sex and the categorical variable for baseline EDSS (0–<3, 3–<5.5, 5.5–<7.5, 7.5–
205 
9). For this reason, all models were stratified to allow the baseline hazards to differ by sex 
and baseline EDSS category. 
TC to HDL ratio (TC/HDL ratio), LDL to HDL ratio (LDL/HDL ratio), ApoB to ApoA-I 
ratio (ApoB/ApoA-I ratio) and nonHDL were created because they are predictors of 
cardiovascular disease risk, and vascular comorbidity is common in MS (9).  
All analyses were done using STATA/IC for Windows (Version 12.1; StataCorp LP College 
Station USA). 
5.5 Results 
5.5.1 Participant characteristics and correlations between lipid measures 
The prospective cohort of 141 participants with RRMS was followed for an average of 2.3 
(SD 0.5) years. During the study, a total of 122 confirmed relapses (99 with lipid data) 
occurred in 70 participants. The cohort was majority female, of overweight BMI (median 
BMI: 26.1), and of low disability (median EDSS: 3.5) (Table 5.1). Strong correlations were 
observed between TC, LDL, nonHDL and trig (0.43r0.94). HDL was negatively correlated 
with trig, LDL, nonHDL, TC/HDL ratio and LDL/HDL ratio (-0.33r-0.75). ApoB was 
strongly correlated with LDL, TC, nonHDL, trig, TC/HDL ratio and LDL/HDL ratio 
(0.56r0.94). ApoA-I was only positively correlated with HDL (r=0.83). ApoE was also 
positively correlated with trig, TC, and nonHDL (0.43r0.54).
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Table 5.1: Demographic  and clinical characteristics of the MS cohort at study entry 
Characteristics                                                                  n/N (%) 
Total                              141/141 (100) 
sex (Females)  105/141 (74.5) 
Relapse during study? 70/141 (49.6) 
Any Immunomodulatory therapy during study? 119/141 (84.4) 
Any Statin during study? 9/141 (6.4) 
Smoker during study 39/141 (27.7) 
Body Mass Index (Kg/m
2
)  
  Normal 55/141 (39.0) 
  Overweight 55/141 (39.0) 
  Obese 31/141 (22.0) 
 
                                                                                           Mean (SD; Range) 
Age at study entry (years) 44.8 (10.8; 21, 76) 
  
 Median (IQR) 
MS duration from diagnosis (years) 6.0 (2.0,12.0) 
EDSS at study entry 3.5 (2.0, 5.0) 
MSSS at study entry 4.0 (2.3, 6.2) 
Physical activity (Met) 17.6 (3.3, 40.0) 
TC (mmol/L) 5.2 (4.5, 6.2) 
LDL (mmol/L) 3.4 (2.7, 4.4) 
ApoB (g/L) 0.97 (0.82, 1.2) 
nonHDL (mmol/L) 3.7 (3.1, 4.9) 
Trig (mmol/L) 1.4 (1.0, 1.9) 
HDL (mmol/L) 1.4 (1.1, 1.6) 
ApoA-I (g/L) 1.5 (1.4, 1.8) 
ApoE (mg/L) 52.0 (40.0, 58.0) 
Lp(a) (µmol/L) 0.5 (0.2, 1.1) 
hs-CRP (mg/L) 21.0 (10.0, 47.0) 
TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apolipoprotein B; NonHDL: non-high density 
lipoprotein; Trig: Triglycerides; HDL: High density lipoprotein; ApoA-I: Apolipoprotein A-I; ApoE: 
Apolipoprotein E; Lp(a): Lipoprotein (a); hs-CRP: highly sensitive C-reactive protein 
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5.5.2 Associations between lipid-related variables and hazard of relapse 
We examined whether lipid-related variables were associated with the hazard of relapse 
(Table 5.2). We found that none of the lipid-related measures were associated with the hazard 
of relapse. Adjustment for age at study entry, BMI, 25(OH)D, physical activity, 
immunomodulatory therapy use during the study, season, smoking, physical activity and 
statin use during the study did not influence the magnitude of effect. We also found no 
association between baseline BMI (Table 5.2) or physical activity (data not shown) and 
hazard of relapse.  
 
Table 5.2: Association between serum lipid-related variables and hazard of relapse 
 Unadjusted   Adjusted*  
 Hazard Ratio (95%CI) p-value  Hazard Ratio (95%CI) p-value 
BMI 1.02 (0.98, 1.07) 0.29  1.00 (0.95, 1.05)** 0.84 
TC (mmol/L) 0.98 (0.79, 1.20) 0.82  0.99 (0.80, 1.23) 0.94 
LDL (mol/L) 1.02 (0.82, 1.27) 0.87  0.99 (0.79, 1.24) 0.95 
ApoB (g/L) 1.17 (0.48, 2.83) 0.73  1.15 (0.46, 2.92) 0.76 
nonHDL (mmol/L) 1.01 (0.82, 1.23) 0.94  0.99 (0.80, 1.22) 0.90 
Trig (mmol/L) 0.96 (0.76, 1.21) 0.73  0.96 (0.73, 1.26) 0.79 
HDL(mmol/L) 0.81 (0.50, 1.31) 0.39  1.05 ( 0.58, 1.89) 0.87 
ApoA-I (g/L) 0.76 (0.40, 1.44) 0.40  1.08 (0.53, 2.20) 0.84 
ApoE (mg/L) 1.00 (0.99, 1.02) 0.57  1.00 (0.99, 1.02) 0.63 
Lp(a) (µmol/L) 1.06 (0.94, 1.21) 0.35  1.14 (0.99, 1.32) 0.07 
hs-CRP (mg/L) 1.00 (1.00 1.00) 0.14  1.00 (1.00, 1.01) 0.19 
TC/HDL ratio 1.04 (0.88, 1.23) 0.67  0.98 (0.81, 1.19) 0.86 
LDL/HDL ratio 1.05 (0.87, 1.27) 0.59  0.99 (0.80, 1.22) 0.91 
ApoB/ApoA-I ratio 1.59 (0.56, 4.51) 0.38  1.18 (0.38, 3.68) 0.78 
*Adjusted for age at study entry, baseline BMI, 25(OH)D (nmol/L), physical activity (METs), smoking during the 
study (no, yes), statin use during the study (no, yes), season and Immunomodulatory therapy use during the study 
(no, yes). 
** Further adjusted for TC and Trig 
TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apolipoprotein B; NonHDL: Non high density 
lipoprotein; Trig: Triglycerides; HDL: High density lipoprotein; ApoA-I: Apolipoprotein A-I; ApoE: Apolipoprotein 
E; Lp(a): Lipoprotein a; Hs-CRP: Highly sensitive C-reactive protein 
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5.6 Discussion 
We have evaluated the association between serum lipids and apolipoproteins and the 
subsequent hazard of relapse in MS patients using a prospective cohort study design, finding 
none of the lipids, apolipoproteins or baseline BMI were significant predictors of relapse. 
These findings are in agreement with work by Weinstock-Guttman and colleagues(6) who 
showed no associations between HDL, LDL and total cholesterol and either time to first 
relapse or number of relapses in an interferon-β-treated CIS cohort. This is to our knowledge 
the first study to evaluate the associations between serum lipids and apolipoproteins and 
relapse in people with established MS.  
Dysfunction of the metabolism and oxidation of lipids have been implicated in the 
pathogenesis of MS(10) and there is evidence of early involvement of serum lipids in the 
development of MS lesions as oxidized LDL was detected in the parenchyma of MS plaques 
(11). This is in line with MRI data in CIS cases, where those with higher total cholesterol and 
LDL had a higher number of gadolinium-enhancing lesions(4) and a higher risk of 
developing new and newly enlarging T2 lesions over two years (6).  
In a study by Palavra and colleagues (12), TC, LDL and oxidised-LDL were positively 
correlated with MS disability (EDSS). Similarly, Weinstock-Guttman and colleagues found 
positive associations between MS disability, progression of disability and TC, LDL and trig 
(3). 
The fact that lipid profile may be associated with MS disability, progression of disability and 
disease activity on MRI, but not with relapses may provide some insights as to how an 
adverse lipid profile and/or oxidised lipids may exert their effect. Others have found 
associations with MRI activity among persons with CIS, since the pathologies shown on MRI 
can correlate with relapse activity (4, 6). However that these results were found in persons 
with CIS and not clinically definite MS may account for this disparity. Indeed, the differences 
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between inflammatory attacks and the mechanisms driving disability accumulation and 
conversion to secondary progressive MS have been a point of considerable interest in the MS 
literature(13). Indirect evidence from statin trials provides support for this construction since, 
while a therapeutic effect of simvastatin in reducing brain atrophy by 43% and significantly 
decreasing progression in EDSS has been recently shown(14), therapeutic effects of statins in 
relapse reduction have been inconsistent(15-17), as have been studies evaluating the effects 
of statin treatment on MS disability(15-17). These inconsistencies call for further research 
into the role of serum lipids in the pathogenesis of MS and the potential therapeutic benefits 
of statins in MS. 
In conclusion, the results of our investigation indicate that serum lipid levels are not 
associated with the hazard of relapse in established RRMS.  
5.7 Postscript 
This chapter has provided some evidence on the relationship between an adverse lipid profile 
and the risk pf relapse in people with MS. The next chapter describes the associations 
between lipid-related variables and conversion to clinically definite MS, time to relapse and 
progression in disability. 
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Chapter 6 An adverse lipid profile and increased body mass index 
significantly predicts clinical course after a first demyelinating 
event. 
 
6.1 Preface 
This investigation examines whether there are relationships between lipid-related variables 
and conversion to clinically definite MS, time to relapse and progression in disability in a 
cohort for people with a first clinical diagnosis of CNS demyelination. 
6.2 Abstract 
Data on whether the accumulation of disability and relapse may be influenced by serum lipid 
levels and body mass index (BMI) in patients with a first clinical diagnosis of demyelination 
is limited. We aimed to investigate whether there were any associations between lipid-related 
variables at study entry and conversion to clinically definite MS (CDMS), time to subsequent 
relapse and progression in disability.  
Methods: A cohort of 279 patients with a first clinical diagnosis of demyelination in the 
Ausimmune Longitudinal (AusLong) Study was prospectively followed, the present analysis 
including follow-up to 5-year review. Height and weight were assessed and serum samples 
obtained to measure serum lipid and apolipoprotein levels. Associations with conversion to 
CDMS and hazard of relapse were assessed using survival analysis, and associations with 
annualised change in disability were evaluated using linear regression. 
Results: Higher BMI (Adjusted hazard ratio (AHR): 1.04 (95% CI 1.01, 1.08) p=0.014) and 
triglyceride levels (AHR: 1.20 (95% CI 1.03, 1.40) p=0.021) at study entry were associated 
with increased risk of subsequent relapse while lipid-related measures were not significantly 
associated with conversion to CDMS. In addition, higher BMI (β: 0.01 (95% CI 0.001, 0.13) 
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p=0.010) and TC/HDL ratio (β: 0.05 (95% CI 0.001, 0.10) p=0.044) at study entry were 
associated with a higher subsequent annual change in disability. 
Conclusions: In this prospective study, we found no significant association with CDMS risk 
after adjustment. However, we found that higher BMI and triglycerides were associated with 
relapse, and a higher BMI and TC/HDL ratio were associated with a higher rate in disability 
progression. These results suggest that improving lipid profile and losing weight into the 
healthy range may improve the disease course of MS, even early in the course of disease.  
6.3 Introduction 
Multiple sclerosis (MS) is an inflammatory, demyelinating, neurodegenerative disease of the 
central nervous system (CNS).
1
 Clinical isolated syndrome (CIS) or first demyelinating event 
(FDE) represents the earliest clinical stage in the development of MS.
2, 3
 Following the 
CIS/FDE, the diagnosis of MS can be made based on the development of a second clinical 
episode or paraclinical evidence that meet diagnostic criteria.
4
 A better understanding of the 
factors involved in the risk of FDE could help identify biomarkers that predict conversion to 
clinically definite MS, disability progression, and other elements of clinical course and 
quality of life, which could lead to interventions tatgets.
5, 6
 
There is now emerging evidence suggesting that dyslipidaemia as a comorbidity in people 
with MS is linked with a more rapid progression in disability.
7
 Similarly, recent evidence 
suggests a potential role for an adverse lipid profile (low HDL, increased LDL and 
triglycerides) in MS clinical course with some evidence of an association with both disability 
and progression in disability.
8, 9
 Studies have also shown an association between serum lipid 
variables and disease activity on magnetic resonance imaging (MRI).
5, 10
 
In relation to relapse in MS, Weinstock-Guttman and colleagues evaluated the association 
between the serum lipid profile and conversion to clinically definite MS (CDMS) and 
subsequent risk of relapse in a prospective cohort of patients with a CIS treated with 
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interferon-β in a clinical trial. From the analysis, none of the lipid profile variables (total 
cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and 
triglycerides) were associated with conversion to CDMS or subsequent risk of relapse.
5
 We 
verified the outcome of this study, by conducting a study examining whether serum lipids and 
apolipoproteins predicted subsequent risk of relapse in clinically definite MS patients with 
average disease duration of 12 years and on immunomodulatory therapy. Like Weinstock-
Guttman, we found that none of the lipid-related variables were associated with the risk of 
relapse.
11
  
Studies have also been conducted examining how BMI may influence the disease course of 
MS. Accumulating evidence suggests an increased risk of MS in people with a high BMI 
during childhood or adolescence but not adulthood.
12-15
 In relation to the question whether 
high BMI is associated with disability or a change in disability, studies in this area are scarce 
and results have been inconsistent
8, 16, 17
 and therefore further investigations are needed. 
Whether an adverse lipid profile and increased BMI drive subsequent clinical course is often 
hard to disentangle from the reverse association where those who are more disabled are 
becoming more sedentary, overweight and developing an adverse lipid profile. A prospective 
study design where the lipid profile is measured right at the start of the disease process, when 
no disability has accumulated yet, is therefore an ideal observational design to answer this 
research question. This present research therefore investigates the association between lipid-
related variables and conversion to clinically definite MS (CDMS), time to subsequent 
relapse and progression in disability in a prospective cohort of patients with a first clinical 
diagnosis of demyelination. 
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6.4 Methodology 
6.4.1 Study design 
The Ausimmune Longitudinal (AusLong) Study, which built upon the original Ausimmune 
case-control study, seeks to elucidate environmental, genetic and lifestyle risk factors for the 
onset and early progression of MS. The Ausimmune Study recruited 282 participants with a 
first clinical diagnosis of CNS demyelination, including 169cases who had their initial onset 
event just prior to the initial participation in the Ausimmune Study referred to here as “classic 
FDE” between 1 Nov 2003 and 31 Dec 2006.18 At the 5-year follow-up, 3 participants had 
now been diagnosed with a none-MS disease (a case of Susac’s Syndrome, neuromyelitis 
optica and pineal germinoma). Within the remaining 279 cases, 258 were now considered to 
have had bout-onset disease (169 of whom had “classic FDE”), and 69 who had had the 
initial event in the more distant past). Twenty-one participants were now considered to have 
had progressive-onset disease. Since 2009, the AusLong Study has followed case participants 
in the Ausimmune Study (retention rate 84.6%); many participants have now been followed 
for over nine years since their initial participation in the study. The present analysis is for the 
period from first recorded symptom onset, to the 5-year review, as this is the most recent 
face-to-face review which all currently enrolled participants have completed.  
The Ausimmune and AusLong Study were approved by nine regional Human Research 
Ethics Committees. All participants provided written informed consent. 
6.4.2 Measurement of CDMS and relapse and disability  
For the purposes of the present investigation, a number of clinical outcomes were evaluated, 
including conversion to clinically definite MS (CDMS), occurrence of relapses, and 
annualised disability progression from FDE to five-year review. 
Conversion to CDMS was defined primarily as the occurrence of two or more clinical 
demyelinating episodes, thus satisfying the diagnostic requirements of dissemination in space 
and time, or a single episode plus paraclinical evidence, as per the 2005 McDonald criteria
19
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(a minority of cases were diagnosed following MRI based on this latter criterion (n=20)). 
Conversion to CDMS was reported at annual review and cross-checked with neurological 
records. A relapse was defined according to the 2001 McDonald Criteria
20
 as the acute or 
subacute appearance or reappearance of a neurological abnormality (lasting at least 24 hours), 
immediately preceded by a stable, improving, or slowly progressive neurological state for 30 
days, in the absence of fever, known infection, concurrent steroid withdrawal, or externally 
derived increases in body temperature. Relapses were reported at annual review or derived 
from medical records, and only relapses which were diagnosed and verified by a neurologist 
were included in this analysis. Disability was assessed by the Kurtzke Expanded Disability 
Status Scale (EDSS)
21
 at the 5-year review; the EDSS on the day before FDE was assumed to 
be 0. The Multiple Sclerosis Severity Score (MSSS) was calculated from the EDSS and 
disease duration, by comparing it to the global MSSS reference dataset.
22
 
Clinical history was derived from medical records at initial presentation, describing the 
nature of the episode/symptoms which brought the participant into the Ausimmune Study, as 
well as historical symptoms prior to presentation. In the event that a person had no history 
preceding their referral symptoms, the referral symptom onset date was taken to be their 
symptom onset. Where a person had a bout-onset presentation and had symptoms some time 
previous to the referral episode, this was validated to the extent possible from available 
clinical notes contemporaneous with the historical episode or taken as valid if judged to be so 
by the attending neurologist at the referral episode. Finally, where a person was progressive 
from onset, symptom onset was defined as either the earliest onset of symptoms identified by 
the attending neurologist at the referral episode, or one year preceding the referral clinic date, 
whichever was first.  
MRI scans were performed as part of the study. The study MRI protocol included a sagittal 
FLAIR (fluid attenuated inversion recovery) sequence selected for its high contrast sensitivity 
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for perivascular and callosal demyelinating lesions. MRI scans (Corpus callosum area) were 
measured at baseline and at five-year review. 
6.4.3 Biological samples and measurements 
Non-fasting serum samples were collected at three time points (cohort entry, 2/3-year and 5-
year reviews), and stored at -80°C until use. Traditionally, triglycerides were measured in a 
fasting state; however, there has been a shift to non-fasting samples, as post-prandial non-
fasting values are more representative of the usual metabolic state.
23
 Total cholesterol and 
triglycerides were measured using enzymatic colorimetry (Wako Chemicals, Richmond, VA, 
USA). HDL-cholesterol levels were measured using precipitation and enzymatic assay 
(Wako Chemicals, Richmond, VA, USA). LDL-cholesterol was measured by direct assay 
using enzymatic colorimetry (Wako Chemicals, Richmond, VA, USA). Non-HDL-
cholesterol levels were computed by subtracting HDL-cholesterol from total cholesterol.  
The apolipoproteins, ApoA-I and ApoB, were measured as they are the main protein 
components of HDL and LDL/VLDL, respectively. Lipoprotein (a) (Lp (a)) is the complex of 
LDL-cholesterol and ApoA. ApoB and ApoA-I levels were measured by turbidimetric 
immunoassay, using goat anti-human ApoB or ApoA-I (Wako Chemicals, Richmond, VA, 
USA). Lp(a) was measured by a sandwich dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA) (LKB-Pharmacia, Stockholm, Sweden).  
Serum 25-OH-D levels were measured with liquid chromatography/tandem mass 
spectrometry and deseasonalised 25(OH)D levels were estimated by sinusoidal regression 
functions for each of the four study sites, given the widely disparate levels of ambient UV 
and the strong seasonal variation of 25(OH)D.
30, 31
  25(OH)D values were  desesonalised to 
reduce the effect of the time of year that the serum samples was taken. This produced values 
that were more like those that would have obtained if all participants were measured at the 
same time of year.
30, 31
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6.5  Data analysis  
The effect of serum lipid variables and other covariates on conversion to CDMS (single 
event) and subsequent relapses (repeated events) were evaluated by Cox proportional hazards 
regression models. CDMS was evaluated by simple single-failure Cox regression, while 
relapse was evaluated  using the gap-time model by Prentice and colleagues, where multiple 
relapses by the same persons are treated as independent observations, and the time until a 
prior event does not influence the composition of the risk set for a subsequent event.
24
 BMI 
was also rendered into categories as normal (18.5 to 25 Kg/m2), overweight (>25 to 30 
Kg/m2) and obese (>30 Kg/m2) and its relationship with conversion to CDMS and hazard of 
relapse evaluated. All covariates satisfied the proportional hazard assumption, except where 
otherwise stated. Because the association between continuous serum lipid variables and 
conversion to CDMS violates the proportional hazard assumption, the serum lipid variables 
were rendered into quartile categorical variables which satisfied the proportional hazard 
assumption.   
Annualised change in EDSS was calculated by taking the five-year review EDSS and 
dividing by the duration between the day before FDE and the five-year review, this 
proportion then being expressed as an annualised value. The relationships between the lipid-
related variables at study entry and annualized change in EDSS were evaluated by linear 
regression, adjusted for whether persons were having a relapse at the time of 5-year disability 
measure (n=22). Baseline disability was not included as a covariate as all persons were 
assumed to be zero EDSS the day before FDE. Because the annualised change in disability 
was highly skewed, a log-transformation was applied to satisfy linear regression assumptions 
of minimal heteroskedasticity. All means and coefficients, however, were back-transformed 
and presented on the original scale of both cross-sectional and change in EDSS at the mean of 
model covariates. Log binomial regression analysis was also used to compare the relationship 
the lipid-related variables and annualised change in disability. 
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All statistical analyses were conducted in Stata/IC 12.1 (StataCorp LP, College Station, 
Texas, USA). 
6.6 Results 
6.6.1 Participant characteristics 
Table 6.1 shows the characteristics of the study participants. Of the 279 participants, 214 
(77%) were female and the mean age at study entry was 38.8 years (SD 9.7), more than half 
of the cohort (64.6%) were overweight or obese (≥25 kg/m2), and only 6.1% (n=17) were 
treated with statins during the study. By the five-year review, 72.0% (201/279) had converted 
to CDMS and had 446 relapses. The median EDSS at the five-year review was 1.5 (IQR: 1.0, 
2.5). Using the established lipid cut-off points, we found that 50.4% of the participants had 
TC level above 5.2mmol/L, 61% had LDL above 2.6mmol/L and 39% had triglyceride above 
1.7mmol/L. 
When restricted to the “classic FDE” (n=169), 78% were female and the mean age at study 
entry was 37.7 (SD 9.7). By five-year review, 56.2% (95/169) had converted to CDMS and 
had 222 relapses. The median EDSS at the five-year review was 1.0 (IQR: 0.5, 2.0) 
6.6.2 Association between lipid-related variables and hazard of relapse 
Table 6.2 summarises the association between the serum lipid variables and hazard of 
relapse. The association between all the continuous serum lipid variables and hazard of 
relapse satisfied the proportional hazard assumption. The univariable association between 
BMI and hazard of relapse showed some evidence of positive association but this was not 
significant (p=0.14). However, upon adjustment for sex and age at study entry, BMI became 
significantly associated with higher hazard of relapse (HR: 1.04; 95% CI: 1.01, 1.08; 
p=0.014). Each 5 kg/m
2 
increase in BMI, was associated with a 22% increased risk of relapse 
(HR: 1.22; 95% CI: 1.04, 1.44; p=0.014). Compared to normal weight, overweight and obese 
BMI were significantly associated with increased risk of relapse after adjustment for age at 
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study entry, sex and study site (p-trend=0.021). Figure 1 shows the Kaplan-Meier survival 
plots by category of BMI demonstrating that those with higher BMI levels experienced more 
relapses compared to those with lower BMI. The results were similar when we included BMI 
levels at 2/3-year review.  
 
The relationship between triglycerides and the hazard of relapse showed some evidence of 
positive association but this was not significant in the univariable analysis (p=0.31). 
However, upon adjustment for age at study entry and sex, the association was enhanced and 
triglycerides became significantly associated with a 23% increased hazard of relapse (HR: 
1.23; 95% CI: 1.06, 1.42; p=0.006). The association was independent of BMI as it was robust 
to further adjustment for BMI (HR: 1.20; 95% CI: 1.03, 1.40; p=0.022). Triglyceride levels 
was then dichotomised into categories of <2.30 mmol/L and 2.30 mmol/L (considered as 
clinically high risk for cardiovascular disease) and it association with hazard of relapse 
assessed. Those with 2.30 mmol/L levels of triglycerides had a relapse risk that was 2.18 
times (p=0.022) higher than those with lower levels after adjustment for age at study entry, 
sex, BMI and study site. The results were similar when we included the lipid levels at 2/3-
year review.  
6.6.2.1 Other predictors of hazard of relapse 
Age at study entry was significantly associated with hazard of relapse (HR: 0.97; 95% CI: 
0.95, 0.98; p<0.001). Female sex was also a significant predictor of relapse (HR: 2.25; 95% 
CI: 1.27, 3.97; p=0.005). Compared to New South Wales, Tasmanian participants (HR: 0.57; 
95% CI: 0.35, 0.93; p=0.025) had a decreased hazard of relapse, but no difference was seen 
for Queensland (p=0.67) or Victoria (p=0.52). In addition, neither smoking status (p=0.26), 
physical activity (p=0.24), 25(OH)D (p=0.34) nor statin use (p=0.30) were significant 
predictors of relapse. 
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Table 6.1: Demographic and clinical characteristics of the MS cohort at study entry 
                                                                          All persons (279) Classic FDE (169) 
Characteristics                                                      n/N (%) n/N (%) 
sex (Females)  214/279 (77.0) 131/169 (78) 
Relapse during study? 170/279 (60.9) 85/169 (50.3) 
 Immunomodulatory therapy use during 
study? 
146/279 (52.3) 78/169 (46.2) 
Any Statin during study? 17/279 (6.1) 11/169 (6.5) 
Smoke ever? 174/279 (62.4) 104/169 (61.5) 
Body Mass Index (Kg/m
2
)   
 Normal 122/277 (44.0) 76/167 (45.5) 
 Overweight 80/277 (28.9) 48/167 (28.7) 
 Obese 75/277 (27.1) 43/167 (25.7) 
 
                                                                                        Mean (SD; Range) 
Age at study entry (years) 38.8 (9.7; 18, 58) 37.7 (9.7; 18, 58) 
   
                                                                                            Median (IQR) 
MS duration from symptom onset 
(years) 
6.3 (5.7, 7.4) 5.8 (5.3, 6.2) 
Annualised change in EDSS 0.3 (0.2, 0.4) 0.3 (0.2, 0.4) 
EDSS score 1.5 (1.0, 2.5) 1.5 (0.5, 2.0) 
MSSS score 2.6 (1.3, 4.5) 2.3 (0.3, 3.9) 
Physical activity (Met) 8.0 (0.0, 24.0) 8.0 (0.0, 24.0) 
TC (mmol/L) 5.4 (4.7, 6.2) 5.5 (4.7, 6.4) 
LDL (mmol/L) 3.2 (2.7, 3.8) 3.2 (2.7, 3.9) 
ApoB (g/L) 0.8 (0.7, 1.0) 0.8 (0.7, 1.0) 
nonHDL (mmol/L) 4.0 (3.2, 4.7) 40 (3.3, 4.9) 
Trig (mmol/L) 1.5 (1.1, 2.2) 1.5 (1.1, 2.2) 
HDL (mmol/L) 1.4 (1.1, 1.6) 1.3 (1.1, 1.7) 
ApoA-I (g/L) 1.5 (1.4, 1.8) 1.5 (1.4, 1.8) 
Lp(a) (µmol/L) 0.4 (0.2, 1.3) 0.4 (0.2, 1.2) 
TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apolipoprotein B; NonHDL: 
non-high density lipoprotein; Trig: Triglycerides; HDL: High density lipoprotein; ApoA-I: 
Apolipoprotein A-I; Lp(a): Lipoprotein (a)  
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Table 6.2: Association between lipid-related variables at study entry and hazard of relapse 
 Unadjusted   Adjusted*  
 Hazard Ratio (95%CI) p-value  Hazard Ratio (95%CI) p-value 
BMI 1.03 (0.99, 1.06) 0.14  1.04 (1.01, 1.08) 0.014 
  Normal 1.00 [Reference]   1.00 [Reference]  
  Overweight 1.08 (0.69, 1.71) 0.73  1.44 (0.96, 2.16) 0.08 
  Obese 1.34 (0.78, 2.30) 0.29  1.78 (1.07, 2.96) 0.027 
   Trend  0.30   0.022 
TC (mmol/L) 1.03 (0.81, 1.31) 0.80  1.16 (0.89, 1.53) 0.27 
LDL (mol/L) 0.93 (0.70, 1.25) 0.64  1.05 (0.77, 1.44) 0.74 
ApoB (g/L) 1.49 (0.38, 5.80) 0.57  2.75 (0.61, 12.39) 0.19 
nonHDL (mmol/L) 1.02 (0.81, 1.28) 0.88  1.17 (0.90, 1.53) 0.23 
Trig (mmol/L) 1.07 (0.94, 1.23) 0.31  1.20 (1.03, 1.40) 0.021 
   <2.30  1.00 [Reference]   1.00 [Reference]  
   >=2.30  1.31 (0.69, 2.47) 0.41  2.18 (1.12, 4.25) 0.022 
HDL(mmol/L) 1.12 (0.57, 2.22) 0.75  0.93 (0.44, 1.94) 0.84 
ApoA-I (g/L) 1.63 (0.66, 4.05) 0.29  1.36 (0.56, 3.31) 0.49 
Lp(a) (µmol/L) 1.02 (0.69, 1.50) 0.94  0.94 (0.563 1.42) 0.78 
TC/HDL ratio 0.99 (0.78, 1.25) 0.92  1.16 (0.88, 1.52) 0.29 
LDL/HDL ratio 0.86 (0.61, 1.21) 0.38  1.03 (0.73, 1.46) 0.87 
ApoB/ApoA-I ratio 0.68 (0.14, 3.24) 0.63  1.49 (0.24, 9.38) 0.67 
*Adjusted for sex, age at study entry, BMI & study site 
 
BMI: Body mass index; TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apolipoprotein B; 
NonHDL: Non high density lipoprotein;  
Trig: Triglycerides; HDL: High density lipoprotein; ApoA-I: Apolipoprotein A-I; Lp(a): Lipoprotein a 
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6.6.3 Association between lipid-related variables and conversion to CDMS 
Table 6.3 summarises the association between the serum lipid-related variables at study entry 
and conversion to CDMS. In the univariable analysis, HDL was significantly associated with 
conversion to CDMS (p-trend=0.042).  Although the magnitude of effect remained robust, 
this became non-significant on adjustment for age at study entry, sex and study site (p-
trend=0.14). Similarly, LDL/HDL ratio showed an inverse association with CDMS, but the 
association became non-significant upon adjustment (p-trend=0.15). Similar associations 
were observed for the corresponding ApoA-I and ApoB/ApoA-I ratio. From the analysis, TC, 
LDL, triglycerides, ApoB, BMI or any other serum lipid-related variable was not significant 
predictor of conversion to clinical definite MS. The results were similar when we included 
the lipid levels at 2/3-year review to allow for possible changes over time.  
6.6.3.1 Other predictors of conversion to clinically definite MS  
Age at study entry was significantly associated with conversion to CDMS (HR: 0.97; 95% 
CI: 0.95, 0.99; p=0.008). Similarly, sex was a significant predictor of conversion to CDMS 
(HR: 1.94; 95% CI: 1.27, 3.97; p=0.012). Compared to New South Wales, Tasmania (HR: 
0.51; 95% CI: 0.28, 0.95; p=0.033) as a study site was associated with a lower risk of 
conversion to CDMS, though the other sites did not materially differ. Neither smoking status 
(p=0.58), physical activity (p=0.25), 25(OH)D (p=0.94) nor statin medication use (p=0.45) 
was a significant predictor of conversion to CDMS. 
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Table 6.3: Association between lipid-related variables at study entry and conversion to CDMS 
 Failure/person-
years (rate) 
Unadjusted   Adjusted*  
 Hazard Ratio (95%CI) p-value  Hazard Ratio (95%CI) p-value 
BMI (Kg/m
2
)       
  Normal 26/191.34 (0.14) 1.00 [Reference]   1.00 [Reference]  
  Overweight 20/158.52 (0.13) 0.93 (0.51, 1.71) 0.82  1.20 (0.60, 2.39) 0.62 
  Obese 13/143.47 (0.09) 0.68 (0.37, 1.26) 0.22  0.96 (0.48, 1.93) 0.92 
   Trend   0.24   0.99 
TC (mmol/L)       
3.0-4.7 9/48.60 (0.19) 1.00 [Reference]   1.00 [Reference]  
>4.7-5.3 8/43.79 (0.18) 1.16 (0.44, 3.11) 0.76  1.49 (0.52, 4.30) 0.46 
>5.3-6.1 8/52.23 (0.15) 0.98 (0.37, 2.58) 0.79  1.40 (0.53, 3.67) 0.50 
>6.1-10.4 10/62.08 (0.16) 1.12 (0.46, 2.76) 0.80  2.37 (0.82, 6.837) 0.11 
Trend   0.89   0.13 
LDL (mol/L)       
1.3-2.5 11/51.00 (0.22) 1.00 [Reference]   1.00 [Reference]  
>2.5-2.9 8/ 36.57 (0.22) 0.98 (0.39, 2.46) 0.97  0.88 (0.35, 2.19) 0.78 
>2.9-3.5 7/50.42 (0.14) 0.87 (0.33, 2.30) 0.78  0.99 (0.34, 2.88) 0.98 
>3.5-7.4 6/58.36 (0.10) 0.62 (0.23, 1.67) 0.34  0.77 (0.25, 2.35) 0.65 
Trend   0.33   0.71 
nonHDL (mmol/L)       
1.9-3.1 9/42.28 (0.21) 1.00 [Reference]   1.00 [Reference]  
>3.1-3.7 11/44.21 (0.25) 1.15 (0.46, 2.88) 0.77  1.54 (0.58, 4.12) 0.39 
>3.7-4.6 7/53.88 (0.13) 0.70 (0.25, 1.98) 0.51  0.95 (0.30, 3.00) 0.94 
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>4.6-9.2 8/66.30 (0.12) 0.73 (0.28, 1.88) 0.52  1.27 (0.40, 3.97) 0.69 
Trend   0.34   0.93 
Trig (mmol/L)       
0.5-1.1  11/42.57 (0.26) 1.00 [Reference]   1.00 [Reference]  
>1.1-1.5 6/44.40 (0.014) 0.52 (0.19, 1.45) 0.21  0.86 (1.12, 4.24) 0.78 
>1.5-2.2 14/91.01 (0.15) 0.61 (0.27, 1.38) 0.24  0.69 (0.28, 1.68) 0.41 
>2.2-10.9 4/28.69 (0.14) 0.67 (0.24, 1.90) 0.46  1.74 (0.51, 5.89) 0.37 
Trend   0.37   0.81 
HDL(mmol/L)       
0.8-1.3 4/63.15 (0.06) 1.00 [Reference]   1.00 [Reference]  
>1.3-1.5 7/43.51 (0.16) 1.86 (0.59, 5.83) 0.29  1.12 (0.34, 3.70) 0.85   
>1.5-1.8 11/45.49 (0.24) 2.66 (0.90, 7.84) 0.08  2.19 (0.77, 6.28) 0.14 
>1.8-2.8 13/54.52 (0.24) 2.82 (0.98, 8.11 0.054  2.05 (0.70, 5.98) 0.19 
Trend   0.042   0.14 
ApoA-I (g/L)       
0.9-1.3 5/62.07 (0.08) 1.00 [Reference]   1.00 [Reference]  
>1.3-1.5 11/41.70 (0.26) 3.04 ( 1.09, 8.43) 0.033  2.41 (0.83, 7.05) 0.11 
>1.5-1.7 8/53.59 (0.15) 1.80 (0.60, 5.37) 0.29  1.67 (0.54, 5.20) 0.38 
>1.7-2.6 11/49.32 (0.22) 2.65 (0.92, 7.58) 0.07  2.16 (0.70, 6.59) 0.18 
Trend   0.16   0.33 
Lp(a) (µmol/L)       
0.05-0.2 5/46.08 (0.11) 1.00 [Reference]   1.00 [Reference]  
>0.2-0.4 10/62.06 (0.16) 1.35 (0.48, 3.82) 0.57  1.91 (0.55, 6.70) 0.31 
>0.4-1.1 2/54.59 (0.04) 0.45 (0.09, 2.23) 0.33  0.44 (0.11, 1.87) 0.27 
>1.1-3.3 7/44.46 (0.16) 1.32 (0.43, 4.02) 0.63  1.51 (0.46, 4.99) 0.50 
Trend   0.95   0.91 
TC/HDL ratio       
2.0-2.9 12/53.06 (0.23) 1.00 [Reference]   1.00 [Reference]  
>2.9-3.5 11/31.83 (0.35) 1.52 (0.64, 3.60) 0.34  1.78 (0.74, 4.26) 0.20 
>3.5-4.3 6/54.28 (0.11) 0.54 (0.19, 1.49) 0.23  0.77 (.24, 2.46) 0.66 
>4.3-8.9 6/67.48 (0.09) 0.57 (0.23, 1.44) 0.24  0.84 (0.30, 2.37) 0.74 
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Trend   0.09   0.54 
LDL/HDL ratio       
0.8-1.5 13/51.28 (0.25) 1.00 [Reference]   1.00 [Reference]  
>1.5-2.0 10/34.23 (0.29) 1.14 (0.49, 2.64) 0.77  1.22 (0.50, 3.01) 0.66 
2.0-2.5 5/48.04 (0.10) 0.43 (0.15, 1.27) 0.13  0.60 (0.17, 2.06) 0.42 
2.5-6.6 4/62.81 (0.06) 0.34 (0.11, 1.01) 0.053  0.47 (0.15, 1.49) 0.20 
Trend   0.016   0.15 
ApoB/ApoA-I ratio       
0.2-0.4 9/46.38 (0.19) 1.00 [Reference]   1.00 [Reference]  
>0.4-0.5 12/38.70 (0.31) 1.41 (0.56, 3.53) 0.46  1.69 (0.62, 4.61) 0.31 
>0.5-0.7 7/49.17 (0.14) 0.90 (0.33, 2.48) 0.84  1.27 (0.46, 3.52) 0.65 
>0.7-1.22 7/72.42 (0.10) 0.54 (0.20, 1.43) 0.21  0.74 (0.25, 2.21) 0.59 
Trend       
*Adjusted for sex, age at study entry, & study site 
 
BMI: Body mass index; TC: Total cholesterol; LDL: Low density lipoprotein; ApoB: Apolipoprotein B; NonHDL: Non 
high density lipoprotein;  
Trig: Triglycerides; HDL: High density lipoprotein; ApoA-I: Apolipoprotein A-I; Lp(a): Lipoprotein a 
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6.6.4 Associations between lipid-related variables and disability progression 
We next sought to evaluate the relationship between lipid-related variables at study entry and 
the subsequent change in disability (Table 6.4). BMI at study entry was a significant predictor 
of subsequent annualised change in EDSS (β: 0.01; 95% CI: 0.003, 0.02; p=0.005).This 
association was robust to adjustment for age at study entry and sex (β: 0.01; 95% CI: 0.001, 
0.013; p=0.01). Using log binomial regression, participants with BMI level in the overweight 
and obese category (BMI ≥25) had 60% increased risk of experiencing a change in EDSS 
greater than 0.5 after adjustment for confounders (RR: 1.60; 95% CI: 1.05, 2.45; p=0.029). 
When we examined a related outcome variable, MSSS, we also observed a significant 
association between MSSS and BMI after adjusting for confounders (β: 0.09; 95% CI: 0.02, 
0.15; p=0.008). 
In relation to the lipids, in the basic model, TC (p=0.019), ApoB (p=0.028), nonHDL 
(p=0.009), triglycerides (0.016), TC/HDL ratio (0.013) and ApoB/ApoA-I ratio (0.047) were 
significantly associated with greater five-year change in EDSS. Upon further adjustment for 
age at study entry and sex, the association with TC (β: 0.04; 95% CI: 0.03, 0.07; p=0.032), 
ApoB (β: 0.26; 95% CI: 0.01, 0.52; p=0.042) nonHDL (β: 0.04; 95% CI: 0.01, 0.08; 
p=0.018), triglycerides (β: 0.04; 95% CI: 0.005, 0.07; p=0.026) and TC/HDL ratio (β: 0.06; 
95% CI: 0.01, 0.10; p=0.019) remained significant. When these associations were further 
adjusted for BMI, only the association with TC/HDL ratio remained independently associated 
(p=0.044). There was no significant interaction between sex and TC/HDL ratio (p=0.40) and 
between TC/HDL ratio and age at study entry and between BMI and TC/HDL ratio (p=0.11).  
Using log binomial regression, participants with TC/HDL ratio level greater than 4.0 have a 
more than doubled risk of experiencing an annualised change in EDSS greater than 0.5 points 
compared to participants with TC/HDL ratio level of ≤4.0 after adjustment for confounders 
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(RR: 2.07; 95% CI: 1.40, 3.06; p<0.001). A TC/HDL ratio of 4 is considered a clinically high 
level for the risk of cardiovascular disease.  
The direction of effect for TC/HDL was similar when we examined MSSS as an outcome 
(adjusted analysis β: 0.49 (-0.07, 1.04) p=0.09). With MSSS, significant associations were 
observed for nonHDL (β: 0.45; 95% CI: 0.01, 0.88; p=0.045) and a trend with TC (0.36 (-
0.03, 0.76), p = 0.07), ApoB (2.68 (-0.01, 5.37), p = 0.051) and ApoB/ApoA-I ratio (3.36 (-
0.56, 7.29), p = 0.09) after adjustment for confounding factors. 
6.6.4.1 Other predictors of change in EDSS 
Neither age at study entry (p=0.19), sex (p=0.74), smoking status (p=0.38), physical activity 
(p=0.90), 25(OH)D levels (p=0.26) nor statin use (p=0.07) were significantly associated with 
change in EDSS. Compared to New South Wales, there was no difference in the change in 
EDSS among participants from Tasmanian (p=0.92), Queensland (p=0.33) or Victoria 
(p=0.30). 
Table 6.4: Association between lipid-related variables at study entry and annualised 
change in EDSS 
 Basic model#   Adjusted*  
 β (95%CI) p-value  β (95%CI) p-value 
BMI 0.01 (0.003, 0.02) 0.005  0.01 (0.001, 0.13) 0.01 
TC (mmol/L) 0.04 (0.01, 0.07) 0.019  0.03 (-0.01, 0.07) 0.09 
LDL (mol/L) 0.02 (-0.02, 0.06) 0.38  0.01 (-0.03, 0.05) 0.68 
ApoB (g/L) 0.28 (0.03, 0.52) 0.028  0.22 (-0.03, 0.48) 0.09 
nonHDL 
(mmol/L) 
0.04 (0.01, 0.08) 0.009  0.04 (-0.0002  0.08) 0.051 
Trig (mmol/L) 0.04 (0.01, 0.07) 0.016  0.03 (-0.003, 0.07) 0.07 
HDL(mmol/L) -0.03 (-0.12, 0.07) 0.58  -0.03 (-0.14, 0.07) 0.55 
ApoA-I (g/L) 0.003 (-0.12, 0.12) 0.96  -0.01 (-0.26, 0.18) 0.90 
Lp(a) (µmol/L) -0.01 (-0.05, 0.03) 0.64  -0.01 (-0.05, 0.04) 0.78 
TC/HDL ratio 0.05 (0.01, 0.09) 0.013  0.05 (0.001, 0.10) 0.044 
LDL/HDL ratio 0.04 (-0.01, 0.09) 0.15  0.03 (-0.03, 0.09) 0.32 
ApoB/ApoA-I 
ratio 
0.40 (0.01, 0.80) 0.047  0.39 (-0.06, 0.84) 0.09 
# Adjusted for relapse at the time of review 
*Adjusted for sex, age at study entry, study site and BMI 
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Figure 6.1: Kaplan-Meier survival plots by category of BMI at study entry.  The plots 
show the proportion of subjects relapse-free each day since study entry.  
 
6.7 Discussion 
Using a prospective cohort design in people with a first clinical diagnosis of CNS 
demyelinating disease, we found that a higher BMI and TC/HDL ratio at study entry was 
associated with a higher annual change in clinical disability, and higher BMI and 
triglycerides were associated with increased risk of subsequent relapse but not conversion to 
CDMS, suggesting that improving lipid profile and losing weight into the healthy range may 
improve the disease course of MS.  
We found that higher BMI and TC/HDL ratio were independently associated with a higher 
annual change in EDSS. Similar findings were seen with MSSS. Overweight and obese 
people had a 60% increased risk of experiencing an annualised change in EDSS greater than 
0.5 and those with a TC/HDL ratio level greater than 4.0 had a doubling in risk of 
  
  
0
.0
0
 
  
  
0
.2
5
 
  
  
0
.5
0
 
  
  
0
.7
5
 
  
  
1
.0
0
 
0 1000 2000 3000 
Analysis time 
BMI = Normal BMI = Overweight 
BMI = Obese 
S
u
rv
iv
a
l 
p
ro
p
o
rt
io
n
 
233 
 
233 
 
experiencing an annualised change in EDSS greater than 0.5 points. The same was found in 
our previous study in people with established MS, with the same magnitude of effect.
8
 It is 
also in agreement with previous work by Weinstock-Guttman and colleagues who showed 
that higher baseline LDL, TC and triglycerides were associated with a worsening in EDSS 
and MSSS over 2.2 years after adjustment for age and sex.
9
 The association between BMI 
and annual change in EDSS was not observed in our previous study.
8
  
In the relapse analysis, we found that being obese was associated with a 1.78 fold higher risk 
of relapse compared to those of normal weight (HR: 1.78; 95% CI: 1.07, 2.96; p=0.027). In 
addition, an independent effect was observed for those with high triglycerides, where those 
with clinically high levels (2.30 mmol/L) having a 2.18 fold risk of relapse compared to 
those with lower levels (HR: 2.18; 95% CI: 1.12, 4.25; p=0.022). These findings do not align 
with two earlier studies from our group
11
 and Weinstock-Guttman and colleagues.
5
 The 
reason for this disparity may be due to the fact that participants of the current study were at a 
much earlier disease state (FDE/CIS) compared to the participants of the Tasmanian MS 
Longitudinal study (MSL study)
11
 who were prevalent cases of CDMS with longer disease 
duration (median: 12 years) and largely on treatment, thus significantly reducing the relapse 
rate in that group. In the current study treatment was not as widely applied and not instituted 
after CIS in the vast majority of cases (slow uptake of immunomodulatory therapy after 
conversion of CDMS with 52% of participants on therapy at the five year review). Further, 
the study by Weinstock-Guttman and colleagues was an RCT while ours was a population-
based cohort study.  
The lack of significant association between serum lipid-related variables and conversion to 
clinically definite MS in our study is in line with the findings of from Weinstock-Guttman 
and colleagues.
5
 The study by these authors prospectively followed a cohort of participants 
with a clinically isolated syndrome (CIS) treated with interferon-β and reported finding no 
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significant association between serum lipid-related variables and conversion to CDMS.
5
 
While this finding needs further investigation, it is suggesting that serum lipid-related 
variables may not be as strongly associated with the pathophysiological mechanisms that are 
involved in susceptibility to MS but rather with the clinical course of the disease. 
The findings that BMI and adverse lipid levels are associated with disease course raises the 
crucial question whether interventions aimed at lowering adverse serum lipid levels into 
healthy ranges may reduce the accumulation of disability in people with MS. This question 
was partly answered by a recent phase II placebo-controlled trial conducted by Chataway and 
colleagues.
25
 In that trial, MS patients using high dose simvastatin had a lower change in 
EDSS after two years compared to the placebo arm (difference -0.254; 95% CI: -0.464 to -
0.069).
25
 Similarly, a trial by Togha and colleagues demonstrated a lower EDSS score in MS 
patient on both simvastatin and interferon beta-1a compared to those on only interferon beta-
1a.
26
 However, a trial conducted to determine the efficacy of a combined therapy of low-dose 
atorvastatin plus high-dose interferon beta-1a showed that, adding low-dose atorvastatin was 
not beneficial in terms of reducing the progression of disability.
27
 This disparity in outcome 
may stem from the type of statin used, dosing of statin and whether the statin is combined 
with immunomodulatory therapy or not. On the other hand, due to the pleomorphic 
therapeutic effect of statins, the benefit of reducing the rate of relapse and disability 
progression in MS may not be directly related to its effect on lipid levels but rather it may be 
due to the anti-inflammatory and immunomodulatory properties of statin. Further studies 
unravelling these properties will open-up therapeutic opportunities for people with MS. 
The mechanisms by which BMI and serum lipid-related variables may influence MS 
disability and risk of relapse are not yet established. However, serum lipid-related variables 
may act through the lipid pathway where adverse serum lipid levels may directly influence 
disability levels or lead to increased weight and reduced physical activity, which may also 
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lead to increased disability in MS patients. Alternatively, there may be shared pathway 
between vitamin D and lipids where adverse lipid levels may lead to increased weight and 
reduced physical activity, which may also lead to reduced vitamin D to yield increased 
disability. 
Our study has significant strengths, including being a prospective population-based cohort 
study with the capability to adjust for relevant confounders. This study has a longer follow-up 
period (5 years) which improves upon our previous study with only 2.3-year average follow-
up period. This is important because a longer follow-up is preferable when measuring change 
in disability. Also, lipids and BMI at study entry were measured prior to the accrual of 
disability and associated with subsequent change over five years, therefore limiting the 
potential for reverse causality. The study had some limitations. Some associations have been 
observed with MRI markers,
5, 10, 28
 but we could not examine that in this study. We used non-
fasting serum samples, which may have influenced the levels of triglycerides but this is 
becoming more accepted as a better measure of overall lipid and metabolic status.
29
 
In conclusion, we have demonstrated that higher BMI and TC/HDL ratio were associated 
with a higher rate of disability progression, and higher BMI and triglycerides were associated 
with relapse but not conclusively with conversion to CDMS, suggesting that improving lipid 
profile and losing weight into the healthy range may reduce the accumulation of disability. It 
is now important to test this in trials.  
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6.8 Postscript 
This chapter has provided some evidence on how lipid-related variables may influence MS 
relapse and disability progression. The next chapter describes the frequency of comorbidities 
and their association with clinical disability and relapse in people with MS. 
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Chapter 7 Frequency of comorbidities and their association with 
clinical disability and relapse in multiple sclerosis 
 
7.1 Preface 
The manuscript presented in this chapter has been published. The typeset version of the 
manuscript as it appeared in the journal is in Appendix 7A. The text of this chapter is the 
same as the published version. This investigation describes frequency of comorbidities and 
their association with clinical disability and relapse in in people with MS. 
7.2 Abstract 
Background: MS patients may be at an increased risk of comorbidities due to the debilitating 
and chronic nature of the disease. An increased understanding of comorbidities and disease 
course in MS may provide new insights and enhance MS management. We aimed to 
investigate the frequency of comorbidities and their associations with clinical disability and 
relapse in MS. 
Methods: A prospective cohort of 198 MS patients, followed 2002–2005, and queried about 
specific doctor-diagnosed comorbidities. Prevalences of comorbidities in the MS cohort were 
compared to the 2007 general population in Australia. Multilevel mixed-effects linear 
regression was used to assess the difference in subsequent disability between those who 
reported comorbidities and those who did not. The association with hazard of relapse was 
assessed using survival analysis. 
Results: The age-standardised prevalences of hypertension, dyslipidaemia, asthma, psoriasis, 
eczema and anaemia were significantly higher in the MS cohort compared to the general 
Australian population. The level of disability (MSSS) in those who reported 
overweight/obesity (β: 0.76 (95%CI: 0.04, 1.48), p=0.037), or dyslipidaemia (β: 1.05 
(95%CI: 0.07, 2.02), p=0.036) was significantly higher compared to those who did not report 
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these comorbidities, even after adjustment for potential confounders. There were no 
significant associations between comorbidities and change in disability. For relapse analyses, 
rheumatoid arthritis and anaemia were associated with more than three-fold (HR: 3.70 (95% 
CI: 1.80, 7.58), p<0.001) and two-fold (HR: 2.04 (95% CI: 1.11, 3.74), p=0.022) increased 
risk of subsequent relapse respectively. 
Conclusions: The prevalences of some comorbidities were higher in MS patients and 
associated with greater disability and relapse risk. Treatment of these comorbidities in 
patients with MS has the potential to improve disease course and understanding of the 
prognosis and outcomes of MS. 
 
7.3 Introduction 
Comorbidities, referring to the presence of one or more additional diseases co-occurring 
with a primary disease, are relatively common in the general population
1, 2
 and their 
frequency increases with age.
3
 These comorbidities are associated with adverse health 
outcomes
1
, a negative impact on quality of life, increased health care use and concomitant 
increased medical costs.
4
  
In people with MS, increasing evidence suggests that cardiovascular and immune 
comorbidities are prevalent
5, 6
 and may be associated with the clinical course of the disease,
7
 
disability progression
5
 and health-related quality of life,
8
 and with increased mortality.
9
 The 
association of comorbidities with MS has prompted some authors to suggest that 
comorbidities may be partly responsible for the highly variable inter and intra-personal 
clinical course of MS.
5  
Despite their potential importance in understanding the aetiology and heterogeneity of MS, 
little and inconsistent information exists about the prevalence of cardiovascular and immune 
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comorbidities in MS patients and how they may affect the progression of the disease. From 
the existing literature it is also unclear whether people with MS are at increased or reduced 
risk of cardiovascular and immune comorbidities compared with the general population.
10
  
This analysis aimed to determine whether MS patients were at differential risk of 
comorbidities compared with that of the general Australian population. We also sought to 
determine whether reporting comorbidity was prospectively associated with subsequent level 
of disability and risk of relapse in participants with MS. 
7.4 Methodology 
7.4.1 Study design 
The Southern Tasmanian Multiple Sclerosis Longitudinal (MSL) Study was a prospective 
population-based cohort study, which followed a population of 203 persons with clinically 
definite MS
11
 living in southern Tasmania, Australia from 2002–2005. An estimated 78% 
(203/259) of eligible cases were included and the study retention rate was 90%. Ethics 
approval was obtained from the Southern Tasmania Human Research Ethics Committee and 
all participants provided informed consent. 
The study methodology has been previously described.
12 
Briefly, at each biannual review 
participants were asked about their lifestyle, including physical activity, smoking, vitamin D 
supplement use and dosage, and medication use. Using a questionnaire modelled on that used 
by the Australian Bureau of Statistics, participants were also asked whether a doctor had 
diagnosed them with a list of specific conditions and at what age the onset of the condition 
was. The comorbidities included in this study were based on those frequently reported in 
people with MS.
6
 Height and weight was measured at baseline. Expanded Disability Status 
Scale (EDSS)
13
 were assessed annually by a single physician and Multiple Sclerosis Severity 
Score (MSSS) was calculated from the EDSS and disease duration by comparing it to the 
global MSSS reference dataset.
14
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7.4.2 Measurement of relapses 
Using a real-time relapse notification system, participants telephoned the study centre if they 
thought they were experiencing a relapse. Additionally, at each biannual review, participants 
were queried about the occurrence of a relapse in the preceding 6 months. To ensure each 
relapse was a true relapse, the study nurse or physician administered a relapse questionnaire 
detailing relapse symptoms, medical practitioner review, treatment, and co-occurrence of 
infection or fever. For quality control, the study physician also performed a physical 
examination for those reporting a relapse by telephone. Throughout the study, each relapse 
was reviewed rigorously by the study physician and further by the study neurologist. 
7.4.3 Statistical analysis 
Prevalence of comorbidities in the MSL study were estimated and compared to that of the 
general Australian population estimates in the 2007 National Health Survey by the Australian 
Bureau of Statistics.
15
  
Information about the National Health Survey design and methodology, the quality and 
interpretation of results has been described.
15
 Briefly, approximately 22,000 people from all 
States and Territories and across all age groups were included in the survey. Estimates from 
the survey were obtained using a complex estimation procedure which ensures that survey 
estimates compares with independent population estimates by state, part of state, age and sex. 
The survey was designed to acquire national benchmarks on a range of health issues, and to 
allow changes in health to be surveyed over time. Information was also obtained about the 
health status of the population, health-related aspects of lifestyle and other health risk factors 
and the use of health services and other actions people had recently taken for their health. 
Log-binomial regression was used to estimate the prevalence ratio of comorbidities in people 
with MS at study entry compared with that of the general Australian population. Age 
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standardisation was calculated by the direct method.
16
 Associations between comorbidities 
and measured disability (EDSS, MSSS) or disability progression (annual change in EDSS) 
were assessed by multilevel mixed-effects linear regression to take into account the repeated 
measures. EDSS/MSSS was also dichotomised and its relationship comorbidities assessed 
using log-binomial regression. Associations with disability were adjusted for relevant 
confounders, including having a relapse at the time of disability assessment, age at study 
entry, sex, BMI (kg/m
2
), physical activity (Mets) and smoking status (no, yes). Log-binomial 
regression was used to assess the relationship between comorbidities and sustained disability 
progression. Sustained disability progression is defined as having a deterioration of at least 
0.5 in consecutive measures of EDSS compared to baseline EDSS. 
For relapse analyses, the effect of comorbidity on time-to-relapse was calculated using Cox 
proportional hazard models for repeated events, whereby multiple relapses by the same 
persons are treated as independent observations but accounted for at the intra-individual 
level, and the time until a prior event does not influence the composition of the risk set for a 
subsequent event.
17
 All covariates satisfied the proportional hazard assumption with the 
exception of the binary variable for sex and the categorical variable for baseline EDSS (0–<3, 
3–<5.5, 5.5–<7.5, 7.5–9). For this reason, all models were stratified to allow the baseline 
hazards to differ by sex and baseline EDSS category. Associations with relapse were adjusted 
for relevant confounders, including age at study entry, BMI (kg/m2), physical activity (Mets),  
vitamin D, smoking status (no, yes), statin use (yes/no) and immunomodulatory therapy use 
(yes/no). All analyses were done using STATA/IC for Windows (Version 12.1; StataCorp LP 
College Station USA). We did not conduct adjustment for multiple comparisons because 
although this reduces the likelihood of type I error, it increases the likelihood of type II 
error.
18
 We have used epidemiologic analysis to assist the assessment of whether an 
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association has causal features and to exclude non-causal explanations, such as confounding.  
Significance level was set at p <0.05. 
7.5 Results 
7.5.1 Participant characteristics 
 Table 7.1 summarises the clinical and demographic characteristics of the MS cohort at study 
entry. The cohort was 72% female, and 75.3% of participants were of relapsing-remitting MS 
type, 62.9% were overweight or obese (25 kg/m2), and 72.5% were on immunomodulatory 
therapy during the study, largely interferon-β-based medications. The median EDSS at study 
entry was 3.0 and median MS duration from diagnosis was six years. 
Table 7.1: Demographic and clinical characteristics of the MS cohort at study entry 
Characteristics                                                                 n/N (%) 
Female sex 128/198 (72) 
MS course at study entry  
   Relapsing-remitting MS 149/198 (75.3) 
   Secondary Progressive MS  40/198 (20.2) 
   Primary Progressive MS   9/198 (4.5) 
Used Immunomodulatory therapy during study? 132/198 (66.7) 
Smoker during study 53/198 (26.8) 
Body Mass Index (Kg/m
2
)  
   Normal 66/178 (37.1) 
   Overweight 75/178 (42.1) 
   Obese 37/178 (20.8) 
 Mean (SD; Range) 
Age at study entry 47.4 (11.21; 21-77) 
                                                                                           Median (IQR) 
MS duration from diagnosis (years) 6.0 (3.0, 12.0) 
EDSS at study entry 3.0 (2.0, 4.5) 
MSSS at study entry 3.8 (2.2, 5.7) 
Physical activity (Mets) 20.1 (6.0, 43.0) 
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Table 7.2: Prevalence of comorbidities in MS patients compared to the general population at study entry 
Comorbidities Total number (percentage)  Prevalence ratio (PR): (95% CI)  Prevalence ratio (PR): (95% CI) 
Sex-specific  
 
MS: (198) 
n (%) 
GP: 
(20,643,100) 
n ‘000 (%) 
          Crude  Age standardised Males Females p-value for 
interaction 
Overweight/obesity 112 (62.92)*  6908.4 (61.30)  1.03 ( 0.92-1.15 ) 
p=0.66 
0.96 ( 0.79,  1.16) 
p=0.49 
 0.94 (0.77, 1.16) 
p=0.60 
1.14 (1.00, 1.30) 
p=0.06 
p=0.14 
Hypertension 42 (21.21) 1945.8 (9.43)  2.25 (1.72, 2.94)  
p<0.001 
1.73 (1.25, 2.34)  
p<0.001 
 1.67 (0.91, 3.05) 
p=0.096 
2.41 (1.79, 3.24) 
p<0.001 
p=0.29 
Type 1 diabetes 2 (1.01) 81.8 (0.40)  2.55 (0.64, 10.12)  
p=0.18 
2.01 (0.23, 7.27) 
 p=0.31 
 4.08 (0.58, 28.52) 
p=0.16 
1.86 (0.26, 13.12) 
p=0.53 
p=0.58 
Type 2 diabetes 4 (2.02) 721.3 (3.49)  0.58 (0.22, 1.53)  
p=0.27 
0.71 (0.19, 1.83) 
 p=0.49 
 0.81 (0.21, 3.16) 
p=0.76 
0.50 (0.13, 1.97) 
p=0.001 
p=0.62 
Dyslipidaemia 29 (14.65) 1179.9 (5.72)  2.56 (1.83, 3.59)  
p<0.001 
1.83 (1.23, 2.63)  
p<0.001 
 2.45 (1.34, 4.48) 
p=0.004 
2.70 (1.80, 4.05) 
p<0.001 
p=0.79 
Psoriasis 15 (7.58) 472.2 (2.29)  3.31 (2.04, 5.39) 
 p<0.001 
2.65 (1.48, 4.38)  
p<0.001 
 4.19 (1.81, 9.71) 
p=0.001 
2.79 (1.54, 5.07) 
p=0.001 
p=0.44 
Rheumatoid arthritis 4 (2.02) 428.5 (2.08)  0.97 (0.37, 2.57)  
p=0.96 
0.69 (0.19, 1.76) 
 p=0.44 
 NC 1.13 (0.43, 2.96) 
p=0.81 
p=0.14 
Thyroid disease 11 (5.56) 486.4 (2.36)  2.36 (1.33, 4.19)  
p=0.003 
1.67 (0.83, 3.00)  
p=0.08 
 2.60 (0.37,18.16) 
p=0.34 
1.80 (0.99, 3.26) 
p=0.054 
p=0.72 
Asthma 37 (18.69) 2049.7 (9.93)  1.88 (1.41, 2.52)  
p<0.001 
1.85 (1.28, 2.58)  
p<0.001 
 2.59 (1.63, 4.10) 
p<0.001 
1.53 (1.05, 2.22) 
p=0.026 
p=0.08 
Hay fever 30 (15.15) 3107.2 (15.05)  1.01 (0.72, 1.40)  
p=0.97 
0.85 (0.57, 1.23)  
p=0.35 
 1.16 (0.66, 2.05) 
p=0.60 
0.91 (0.61, 1.37) 
p=0.66 
p= 0.50 
Eczema 26 (13.13) 189.5 (0.92)  14.31 (10.0, 20.47) 
p<0.001 
26.20 (17.11, 38.38) 
p<0.001 
 13.81(6.88,27.72) 
p<0.001 
13.82 (9.10, 20.97) 
p<0.001 
p= 1.00 
Anaemia 25 (12.63) 377.7 (1.83)  6.90 (4.78, 9.95)  
p<0.001 
5.68 (3.64, 8.45) 
 p<0.001 
 NC 5.74 (4.02, 8.18) 
p<0.001 
NA 
Crohn’s disease 1 (0.51) 29.0 (0.14)  3.60 (0.51, 25.40)  ND  NC 4.56 (0.65, 32.16) NA 
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p=0.20 p=0.13 
Ulcerative colitis 1 (0.51) 35.1 (0.17)  2.97 (0.42, 20.98)  
p=0.28 
ND  9.64 (1.38-67.37) 
p=0.022 
NC NA 
Coeliac disease 2 (1.01) 41.286 (0.20)  5.05 (1.27, 20.05) 
p=0.021 
ND  ND ND NA 
*178 of participants with BMI data, GP= General population, NA= Not applicable, NC= No case, ND= No data 
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7.5.2 Prevalences of comorbidities 
Table 7.2 presents the prevalence, prevalence ratio and standardisation of comorbidities by 
sex and age. In the age-standardised prevalence analysis, patients with MS were more likely 
than the general Australian population to have hypertension and dyslipidaemia. A 
significantly higher prevalence in the MS cohort than the general population was also 
observed for psoriasis, asthma, eczema and anaemia, with a particularly strong magnitude of 
association for eczema (PR: 26.20 (95% CI: 17.11, 38.38)). 
Prevalences of comorbidities were also stratified by sex. In these analyses, both male and 
female MS patients had higher prevalences of vascular comorbidities like hypertension and 
dyslipidaemia than males and females in the general population and the increased prevalence 
in the MS cohort was generally higher among females than males, but not statistically 
significantly. Similarly, the prevalence of psoriasis, eczema and asthma in both males and 
females were significantly higher in the MS cohort than males and females in the general 
population. 
7.5.3 Association between comorbidities and disability and progression in disability 
We next examined whether having particular comorbidities was associated with a higher 
disability and disability progression (Table 7.3).  From Model 1 (adjusted for relapse at the 
time of disability measurement), MS patients reporting overweight/obesity (β: 0.65 (95% CI: 
0.09, 1.21), p=0.024), hypertension (β: 1.25 (95% CI: 0.43, 2.06), p=0.003) and 
dyslipidaemia (β: 0.99 (95% CI: 0.05, 1.92) p=0.038), had higher EDSS compared to those 
who did not report these comorbidities. Further adjustment for sex, BMI, physical activity, 
MS duration and smoking status did not substantially reduce the association of disability with 
reporting hypertension (β: 1.15 (95% CI: 0.49, 1.81), p=0.001) and dyslipidaemia (β: 0.97 
(95% CI: 0.24, 1.69), p=0.009). However, further adjustment for age at study entry (Model 2) 
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attenuated the associations with overweight/obesity, hypertension and dyslipidaemia, 
suggesting that these associations were at least partly driven by older age. 
The results were similar when EDSS was dichotomized into EDSS<4.0 and EDSS>=4.0. 
From this adjusted analysis, dyslipidaemia (Adjusted Prevalence ratio (PR): 1.23 (95% CI: 
1.01, 1.50), p=0.041), hypertension (Adjusted PR: 1.24 (95% CI: 1.02, 1.51), p=0.034) and 
hay fever (Adjusted PR: 1.35 (95% CI: 1.09, 1.69), p=0.007) were associated with increased 
risk of higher disability compared to those who did not report these comorbidities. 
For associations with MSSS, similar results were found to those for EDSS. However, even 
after adjustment for confounders, MS patients reporting overweight/obesity (β: 0.76 (95% CI: 
0.04, 1.48), p=0.037) and dyslipidaemia (β: 1.05 (95% CI: 0.07, 2.02), p=0.036) had 
significantly higher MSSS compared to those who did not report these comorbidities. 
Additionally, the combined effect of reporting hypertension, diabetes and dyslipidaemia 
(vascular disease group) was associated with significantly higher EDSS (β: 0.64 (95% CI: 
0.14, 1.14), p=0.012) and MSSS (β: 0.90 (95% CI: 0.10, 1.69), p=0.027) compared to those 
who did not report these comorbidities, persisting on adjustment for confounders.  
When MSSS was dichotomized into MSSS<4.0 and MSSS>=4.0. From this adjusted 
analysis, dyslipidaemia (Adjusted Prevalence ratio (PR): 1.32 (95% CI: 1.11, 1.58), p=0.002), 
overweight/obesity (Adjusted PR: 1.31 (95% CI: 1.08, 1.59), p=0.006 and thyroid disease 
(Adjusted PR: 1.34 (95% CI: 1.09, 1.66), p=0.005) were associated with increased risk of 
higher disability compared to those who did not report these comorbidities. 
For other comorbidities, such as psoriasis, rheumatoid arthritis, thyroid dysfunction, asthma, 
hay fever, eczema, anaemia, the disability level of those who reported these comorbidities 
was not significantly different from those who did not.  
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We found no significant associations between comorbidities and annual change in EDSS 
(data not shown). 
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Table 7.3: Association between comorbidities and MS disability (EDSS & MSSS) 
Comorbidity EDSS: Model 1   EDSS: Model 2  MSSS: Model 1   MSSS: Model 2   
β (95% CI) p-value β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value 
Overweight/obesity 0.65 (0.09, 1.21)  p=0.024 0.35 (-0.09, 0.80)** p=0.12 0.82 (0.09, 1.55) p=0.027 0.76 (0.04, 1.48)** p=0.037 
Hypertension 1.25 (0.43, 2.06) p=0.003 0.46 (-0.12, 1.04) p= 0.12 0.83 (-0.12, 1.78) p=0.09 0.07 (-0.81, 0.96) p=0.87 
Dyslipidaemia 0.99 (0.05, 1.92)  p=0.038 0.44 (-0.16, 1.05)  p=0.15 1.03 (-0.08, 2.14) 
1.87 (0.61, 2.30) 
p=0.07 1.05 (0.07, 2.02) p=0.036 
Vascular disease 
group* 
1.52 (0.81, 2.23)  p<0.001 0.64 (0.14, 1.14) p=0.012 p=0.001 0.90 (0.10, 1.69) p=0.027 
Psoriasis 0.64 (-0.59, 1.88)  p=0.31 -0.03 (-0.85, 0.79)  p=0.94 0.89 (-0.58, 2.37) p=0.24 0.19 (-1.11, 1.49) p=0.78 
Rheumatoid arthritis 0.46 (-1.83, 2.75)  p=0.69 0.71 (-0.78, 2.19)  p=0.35 0.67 (-2.09, 3.43) p=0.63  0.69 (-1.63, 3.00) p=0.56  
Thyroid dysfunction 0.83 (-0.48, 2.14)  p=0.22 0.47 (-0.35, 1.30)  p=0.26 0.82 (-0.72, 2.36) p=0.30 1.00 (-0.33,2.33) p=0.14 
Asthma -0.65 (-1.38, 0.08)  p=0.08 0.02 (-0.51, 0.56)  p=0.93 -0.29 (-1.20, 0.63) p=0.54 0.04 (-0.76, 0.87) p=0.92 
Hay fever -0.40 (-1.22, 0.41)  p=0.34 0.21 (-0.36, 0.78)  p=0.48 -0.12 (-1.13, 0.89) p=0.82 0.36 (-0.53, 1.26) p=0.43 
Eczema -0.42 (-1.29, 0.44)  p=0.34 0.16 (-0.47, 0.78)  p= 0.62    0.21 (-0.89, 1.31) p=0.71 0.38 (-0.61, 1.37) p=0.45 
Anaemia 0.08 (-0.85, 1.01)  p=0.87 0.34 (-0.30, 0.98)  p=0.30 0.46 (-0.68, 1.60) p=0.43 0.79 (-0.24, 1.81) p=0.13 
*Vascular disease group: Hypertension, Types I & II Diabetes, Dyslipidaemia 
Model 1: Adjusted for relapse at the time disability measurement 
Model 2: Adjusted for relapse, age, sex, BMI, physical activity, smoking status (yes/no) and MS duration (MSSS analysis not adjusted for MS duration) 
**Adjusted for relapse, age, sex, physical activity, smoking status and MS duration 
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7.5.3.1 Sensitivity analysis 
 
We conducted a sensitivity analysis excluding those people whose disability was measured 
during a relapse. The findings were unchanged. The level of disability (MSSS) in those who 
reported overweight/obesity (β: 0.76 (95%CI: 0.03, 1.47), p=0.042), or dyslipidaemia (β: 1.04 
(95%CI: 0.05, 2.03), p=0.039) compared to those who did not report these comorbidities 
were not significantly affected. When the relationship between comorbidities and sustained 
disability progression was examined, there was a significant positive association with hay 
fever (Adjusted PR: 1.74 (95%CI: 1.45, 2.11), p<0.001) and a trend with overweight/obesity 
(Adjusted PR: 1.21 (95%CI: 0.97, 1.49), p=0.09). 
7.5.4 Association between comorbidities and risk of subsequent relapse 
During the study, a total of 122 confirmed relapses occurred in 70 out of the 149 patients with 
relapsing-remitting MS (RRMS). The mean age was 45.6 years, 75% were female, the 
average BMI was 26.8 kg/m2 and 82% was on immunomodulatory therapy. We found 
significant positive associations between rheumatoid arthritis, and anaemia and the risk of 
subsequent relapse. The association with rheumatoid arthritis was more than three-fold (HR: 
3.70 (95% CI: 1.80, 7.58), p<0.001) and that with anaemia was two-fold (HR: 2.04 (95% CI: 
1.11, 3.74), p=0.022). These associations were robust to the adjustment for potential 
confounders, including age at study entry, BMI, physical activity, smoking during study, 
vitamin D, statin use and use of immunomodulatory therapy during the study (Table 7.4).  
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7.6 Discussion 
Using a cohort of clinically definite MS patients, with the aim to determine whether they had 
different frequencies of comorbidities than that of the general population, we found that the 
age-standardised prevalence of hypertension, dyslipidaemia, psoriasis, eczema, asthma and 
anaemia was significantly higher in our MS cohort compared to the general Australian 
population. In the disability analysis, reporting overweight/obesity and dyslipidaemia was 
most consistently associated with a higher disability as measured by EDSS or MSSS 
measures. In the relapse analysis, rheumatoid arthritis and anaemia were associated with an 
increased risk of subsequent relapse. 
Table 7.4: Association between comorbidity and hazard of relapse 
 Unadjusted   Adjusted*  
 Hazard Ratio (95%CI) p-value  Hazard Ratio (95%CI) p-value 
Overweight/obesity 1.20 (0.78, 1.87)  0.41  1.16 (0.61, 2.22)  0.65 
Hypertension 1.09 (0.57, 2.09)   0.78  1.08 (0.53, 2.20)  0.84 
Dyslipidaemia 0.97 (0.50, 1.89)  0.93  0.79 (0.31, 2.01)  0.62 
Vascular disease group 1.12 (0.66, 1.91)   0.67  1.06 (0.57, 1.94)   0.86 
Psoriasis 0.62  (0.27, 1.44)   0.27  0.50 (0.18, 1.42)   0.20 
Rheumatoid arthritis 3.02 (1.94, 4.69)   0.001  3.70 (1.80, 7.58)   0.001 
Thyroid dysfunction 1.00 (0.46, 2.15)   1.00  1.12 (0.50, 2.49)   0.79 
Asthma 1.04 (0.63, 1.72)   0.88  1.09 (0.27, 1.44)   0.78 
Hay fever 1.22 (0.72, 2.07)   0.46  1.11 (0.62, 2.00)   0.72 
Eczema 1.31 (0.79, 2.17)   0.30  1.26 (0.74, 2.16)   0.40 
Anaemia 1.81 (1.05, 3.16)   0.034  2.04 (1.11, 3.74)   0.022 
*Adjusted for age, BMI, physical activity, smoking during study (yes/no), vitamin D, statin use (yes/no) & 
Immunomodulatory therapy use (yes/no) 
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In the regression analysis, the unadjusted analysis showed a significantly higher level of 
disability as measured by EDSS in MS patients who reported overweight/obesity, 
hypertension and dyslipidaemia compared to those who did not report these comorbidities. 
Adjustment for age at study entry substantially attenuated the associations, suggesting that 
advancing age of participants may explain a large part of the relationship between EDSS and 
these comorbidities. Despite this, age-independent associations were observed between 
overweight/obesity and dyslipidaemia and MSSS, which was also observed when we 
dichotomised MSSS. We also found a significant positive association between hay fever and 
sustained disability progression. Also, the combined effect of these vascular comorbidities 
was associated with significantly higher disability after adjusting for confounders including 
age at study entry and BMI. We found no association with annual change in disability. The 
findings on the level of disability were consistent with our previous work using this cohort 
where we reported significant positive associations between BMI (β: 0.06 (95%CI; 0.01, 
0.10) p=0.013), total cholesterol (β: 0.23 (95%CI; (0.01, 0.44)) p=0.037) and disability.19 Our 
findings are consistent with work by Weinstock-Guttman
20
 and colleagues who reported that 
dyslipidaemia is associated with higher disability in MS. Similarly, Marrie and colleagues
5
 
reported that people who reported comorbidities of diabetes, hypertension and dyslipidaemia 
have increased risk of ambulatory disability compared to those who did not. With reference 
to other comorbidities such as, psoriasis, rheumatoid arthritis, thyroid dysfunction, asthma, 
hay fever, eczema, and anaemia, the level of disability in those who reported developing 
these comorbidities was not significantly different from those who did not report these 
comorbidities although numbers were small. 
In the relapse analysis, rheumatoid arthritis was associated with a more than three-fold 
increased hazard of subsequent relapse and anaemia was associated with a two-fold increased 
hazard of relapse. To the best of our knowledge, we are the first to report a relationship 
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between these comorbidities and hazard of relapse. Similar to our study, Marrie and 
colleagues investigated the relationship between comorbidities and relapsing-remitting course 
at MS onset.
7
 In that study, both men and women who reported mental comorbidities had an 
increased odds of a relapsing-remitting course at MS onset compared to participants who did 
not report these comorbidities (OR: 1.48; 1.08–2.01) and also gastrointestinal comorbidities 
(OR 1.78; 1.25–2.52) and obesity (OR 2.08 1.53–2.82) at MS onset were associated with a 
relapsing-remitting course at onset in women but not in men. In the wake of the increasing 
prevalence of relapsing-remitting MS, finding a relationship between comorbidity and relapse 
raises the possibility that comorbid conditions could be a significant factor in this 
phenomenon. The association between relapse and rheumatoid arthritis however need to be 
interpreted with caution. This is because the small number of participants reporting 
rheumatoid arthritis limits the interpretation of this association.  
Our finding of higher prevalence of comorbidities in MS patients is generally consistent with 
the literature. For example, Kang and colleagues
21
 reported a higher prevalence of 
hypertension and dyslipidaemia in MS cases compared to matched controls. However, their 
finding of a higher prevalence of type 2 diabetes was not found in our study. For patients with 
MS compared to control groups, the prevalences of dyslipidaemia
21, 22
, diabetes
21, 22
 and 
hypertension
21, 22
 have been found to be higher in some studies, while other studies found 
similar prevalences
23
 or lower prevalence 
24, 25
 of these comorbidities among persons with 
MS compared to control groups. The prevalence of obesity has also been found to be 
higher
26
, similar
27
 or lower
24, 26
 in MS cases compared to a control group in different studies. 
However, evaluation of the whole body of evidence together suggests a slightly elevated 
prevalence of these cardiovascular comorbidities in MS than the general population.  
In relation to other comorbidities, our findings are in line with Kang and colleagues who 
reported a higher prevalence of asthma in MS cases compared to matched controls,
21
 and 
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Edwards and colleagues who found higher prevalences of asthma, eczema, and anaemia in 
MS patients compared to matched controls.
28
 In relation to autoimmune diseases, which are 
generally less common in the general population than more general comorbidities, our 
magnitudes of effect are in line with the findings of a recent meta-analysis,
29
 although our 
findings did not reach statistical significance. For example, in the meta-analysis, the pooled 
odds ratio for type 1 diabetes was 2.02 (95% CI: 1.22, 3.40) and the pooled odds ratio for 
thyroid dysfunction was 1.66 (95% CI: 1.35, 2.05), while in our study the prevalence ratio for 
type 1 diabetes was 2.01 (95% CI: 0.23, 7.27), and for thyroid dysfunction was 1.67 (95% CI: 
0.83, 3.00).
29
 Our estimate of effect for psoriasis was stronger and in the same direction 
(prevalence ratio 2.65 (95% CI: 1.48, 4.38) as the pooled estimate of 1.31 (95% CI: 1.09, 
1.57) in the meta-analysis.
29
  
Our study had significant strengths and limitations. The significant strengths include a 
rigorous ascertainment of MS diagnosis and relapses by neurologist. One limitation of our 
study is the small sample size which provided limited power for rare comorbidities and for 
interaction effects by sex and for effect on disability or relapse. As a longitudinal study, 
however, its sample size is balanced with the logistics inherent in prospective and 
comprehensive follow-up such as those here. Furthermore, the use of self-reported, doctor-
diagnosed comorbidity information, while valid for conditions which are readily diagnosed 
such as diabetes and hypertension (kappa >0.82), this is not the case for conditions such as 
arthritis and anaemia (kappa <0.40) which are not readily diagnosed.
30
  This has the potential 
of introducing misclassification bias which may have also reduced the power to identify an 
impact of comorbidities on the outcomes of interest. The probability that the diagnosis of 
these conditions may also be due to surveillance bias resulting from frequent health care 
utilizations cannot be completely ruled out. 
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The mechanisms by which comorbidities might influence MS disability and risk of relapse 
are not yet established. We are therefore hypothesizing that, the association between obesity, 
dyslipidaemia and clinical disability may act via the vitamin D pathway where obesity and 
dyslipidaemia may lead to reduced physical activity, which may also lead to reduced vitamin 
D to yield increased disability. The fact that obesity and dyslipidaemia may be associated 
with MS disability but not with relapses and likewise rheumatoid arthritis and anaemia may 
be associated with increased risk of relapse but not disability provides some insights as to 
how these comorbidities exert their effect. Proposed potential mechanisms assume that 
comorbidities may influence MS at the pathophysiologic level. Alternatively, independent 
etiologic effects of comorbidities on MS could additively or synergistically increase the risk 
of relapse and disability.  
MS is a chronic, debilitating, lifelong disease and therefore the risk of developing 
comorbidities in the course of the disease is high. While MS in itself may not cause 
cardiovascular or other comorbidities, people with MS may be subject to an increased risk of 
comorbidities due to a diminished ability to engage in physical activity due to symptoms or 
conditions associated with MS. Studies have confirmed that people with MS have reduced 
physical activity compared to healthy control group.
31, 32
 Less physical activity is associated 
with an increased risk of cardiovascular comorbidities.
33
 Consequently, MS patients may 
have increased morbidity and mortality from comorbidities despite the underlying 
pathophysiology potentially being unrelated. 
In conclusion, we found the age-standardised prevalence of hypertension, dyslipidaemia, 
psoriasis, eczema, asthma and anaemia to be significantly higher in our MS cohort compared 
to the general Australian population. Participants who reported rheumatoid arthritis and 
anaemia had a higher risk of relapse. Reports of being overweight/obese and having 
dyslipidaemia were associated with a higher level of disability when compared to those who 
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did not report these comorbidities. These associations were in part determined by the older 
age of participants; however, MSSS associations with comorbidities were robust to these 
adjustments, indicating a potential age-independent mechanism for these associations. We 
recommend long-term monitoring and treatment of comorbidities in MS in order to prevent 
increased morbidity as people age with their MS. Many of the comorbidities discussed here 
are treatable or preventable and therefore this is an area of MS management that can be 
emphasised, particularly in those with progressive disease where there are no effective 
treatment strategies to slow progression. Studies of comorbidity treatment and prevention in 
patients with MS have the potential to improve our understanding of the prognosis and 
outcomes of MS.  
7.7 Postscript 
This chapter has provided some data on the frequency of comorbidities in MS patients and 
their association with clinical disability and relapse. The next chapter describes the 
conclusions drawn from the various studies undertaken and the future direction of MS 
research I will be carrying out. 
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Chapter 8 Conclusions 
MS has so far proven to be a complex disease of the central nervous system. Even though the 
aetiology and the pathophysiology of the disease have been substantially studied, no reliable 
biomarker, diagnostic test, biological mechanism, or specific therapy has been identified for 
all MS patients.
1
 One of the reasons accounting for this failure is the considerable 
heterogeneity in clinical course and pathophysiological outcomes. The clinical course of MS 
is highly variable, including four different clinical phenotypes with various subcategories. 
Moreover, the pathophysiology of the disease is highly diverse and may be marked by 
various combination and degrees of inflammation, demyelination, axonal damage and loss, 
neurodegeneration and gliosis. 
MS is thought to be a multifactorial disease that results from the intricate, yet not well-
understood aetiology. From all the identified etiological factors of MS, not a single factor is 
in itself complete to initiate the onset or cause a substantial progression of the disease. 
Therefore, the identification of factors that can wholly predict the onset or progression by 
acting independently and in concert with each other would be a major success in MS 
research. Greater understanding of the aetiology of the disease will lead to early diagnosis 
and identification of individuals at risk of developing MS, prediction of disease course and 
monitoring of disease progression.
2
 
The search for these etiological factors has led to research into how serum lipids may 
influence the onset and progression of MS. Earlier laboratory investigations have identified 
oxidatively modified serum LDL cholesterol in the parenchyma of MS plaques.
3
 This finding 
has led to the question whether there is any relationship between presence of serum lipids in 
the brain parenchyma and MS onset, disability and disease progression. Further, the role of 
comorbidities in the onset and progression of MS was also investigated because of the 
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relationship between serum lipids and vascular comorbidities. For instance, it is a well-
established knowledge that elevated levels of serum lipids (dyslipidaemia) are associated 
with vascular diseases such as coronary heart disease, stroke, hypertension and diabetes. 
In this regard, findings from the various investigations on how lipid-related variables and 
comorbidities may influence the onset, severity of clinical disability and disease progression 
has been summarised below. 
8.1.1 Lipid-related variables and relapse 
To investigate whether there is a relationship between lipid-related variables and conversion 
or susceptibility to MS and time to next relapse, two datasets - the Tasmanian MS 
Longitudinal Study (MSL) and the Ausimmune Longitudinal Study (AusLong) were used. 
The AusLong study is an internationally unique cohort of participants with incident first 
clinical diagnosis of demyelination, which has been followed annually up to five-year review. 
The MSL study is made up of a cohort of prevalent MS patients living in southern Tasmania 
which was followed for a total of 2.5 years.   
The AusLong study was used to investigate the association between lipid-related variables 
and conversion to CDMS and time to subsequent relapse. In that investigation, we found that 
none of the serum lipid-related variables at study entry were significantly associated with 
conversion to CDMS. However, higher BMI and triglycerides were associated with increased 
risk of subsequent relapse. This disparity may be due to the fact that the association between 
lipid-related variables and risk of subsequent relapse has multiple outcomes per person, 
resulting in more power than the association between serum lipid-related variables and 
conversion to CDMS which has only one outcome per person. The MSL study was also used 
to examine the association between the lipid-related variables and time to subsequent relapse. 
From the analysis of the associations between lipid-related variables and the subsequent 
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hazard of relapse in MS patients using the MSL study, none of the lipid-related variables 
were associated with the hazard of relapse. 
While this finding needs further investigation, the lack of association between lipid-related 
variables and CDMS is suggesting that serum lipid-related variables may not be associated 
with the pathophysiological mechanisms that are involved in conversion or susceptibility to 
CDMS. The study for the factors which may significantly influence conversion to CDMS was 
motivated by the fact that significant minority of patients who develop first demyelinating 
event never progress to CDMS. Therefore identifying modifiable factors that can influence 
the progression of first demyelinating event to CDMS could provide both potential 
therapeutic and management target to either prevent conversion to CDMS or delay 
progression to CDMS. This therefore makes the window between first demyelinating event 
and conversion to CDMS an important research focus. 
The finding that higher BMI and triglycerides were associated with increased risk of 
subsequent relapse in the AusLong study do not align with the finding from the MSL study 
which did not report any significant finding with the lipid-related variables. The reason for 
this disparity may be due to the fact that participants of the AusLong study were incident first 
demyelinating event cases who are at a much earlier disease state compared to the 
participants of the MSL study who were prevalent cases of CDMS with longer disease 
duration and largely treated hence significantly reducing the relapse rate. In addition, the 
AusLong study has a larger sample size and more power than the MSL study. 
8.2 Lipid-related variables and disability and disability progression 
The MSL study and AusLong study datasets were used to examine the association between 
the lipid-related variables and disability and progression in disability. From the investigation 
whether an adverse lipid profile in people with MS is associated with disability and 
progression in disability in the MSL study, it was demonstrated that higher TC, ApoB and 
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ApoB/ApoA-I ratio were associated with higher disability and that higher TC/HDL ratio was 
associated with significant progression of disability. Moreover, we observed an effect of BMI 
on disability that was independent of the effect of lipids. In the disability progression analysis 
using the AusLong study dataset, higher BMI and TC/HDL ratio was associated with a higher 
annual change in clinical disability. 
There was a consistency in the finding of a significant association between TC/HDL ratio and 
a higher change in clinical disability in both AusLong and MSL study. However, the finding 
of a significant association between baseline BMI and change in disability in the AusLong 
study could not be replicated in the MSL study. The disparity may be due to the fact that the 
AusLong study used cases of first demyelinating event where disability was measured over a 
5 years period compared to the MSL study which used cases of established or prevalent, well-
treated MS patients where disability was measured over a shorter period of 2.5 years on 
average. The two-year change in disability is limited and a longer follow-up is preferable 
when measuring disability progression. The AusLong study would be followed up to 10 and 
15 years on average, making it a better study for the investigation of the progression of MS in 
relation to adverse lipid profile. It also makes it a better study to investigate whether the 
observed associations would persist further as the duration of the disease advances. 
The findings that BMI and adverse lipid levels were associated with disability progression 
raises the crucial question whether lipid-lowering interventions aimed at lowering adverse 
serum lipid levels into healthy ranges may reduce the accumulation of disability in people 
with MS. This research adds to the argument to test whether interventions aimed at increasing 
physical activity and improving diet is beneficial. It also opens up potential therapeutic 
opportunities for the use of lipid-lowering agents such as statins to lower serum lipid levels, 
but further investigation through clinical trial is needed to ascertain the benefit. From the data 
available, the use of statin in MS may be justified when the aim is to reduce a patient’s risk of 
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cardiovascular disease since the benefit of reducing the risk of cardiovascular disease has 
been established. However, the use of statins is not yet justified as an intervention to reduce 
the accumulation of disability in MS patients because clinical trials of statins as an 
intervention in MS have produced inconsistent evidence, including negative effects, which 
may be an indication that previous observational studies demonstrating associations may 
have been confounded. Adverse effects in people with MS are possibly explained by 
laboratory evidence showing negative impacts of statins on oligodendrocytes and myelin 
formation. Thus, care needs to be taken when considering the use of statins in the treatment 
of MS. 
8.3 Comorbidities and MS 
The MSL study was also used to examine whether the frequency of comorbidities was higher 
in MS patients compared to the Australian population and whether comorbidities were 
associated with clinical disability and relapse.  From the investigation, it was found that the 
age-standardised prevalence of hypertension, dyslipidaemia, psoriasis, eczema, asthma and 
anaemia was significantly higher in the MS cohort compared to the general Australian 
population. When disability data was analysed, it was found that reporting 
overweight/obesity and dyslipidaemia was associated with significantly higher disability after 
adjustment for potential confounders. These associations were in part determined by the 
advancing age of participants. We found, however, no significant association with annual 
change in disability. In the relapse analysis, rheumatoid arthritis and anaemia were associated 
with an increased risk of subsequent relapse. The association between relapse and rheumatoid 
arthritis, however, need to be interpreted with caution. This is because the small number of 
participants reporting rheumatoid arthritis limits the interpretation of this association. 
Although our study is a prospective population-based study, it is limited by the small sample 
size which provided limited power for rare comorbidities and for interaction effects by sex 
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and for effect on disability or relapse to be detected. The number of studies in this area of 
research is limited and therefore further investigation is warranted. The only sufficiently large 
study in this area with sufficient power is the NARCOMS study by Marrie and colleagues 
which found that vascular comorbidity in MS patients was associated with more rapid 
progression in ambulatory disability.
4
 
Studies of comorbidity treatment and prevention in patients with MS have the potential to 
improve our understanding of the prognosis and outcomes of MS. Many of the comorbidities 
examined here are treatable or preventable and therefore this is an area of MS management 
that can be emphasised, particularly in those with progressive disease where there are no 
effective treatment strategies to slow progression. 
8.4 Final conclusion of PhD 
Studies included in this thesis assessed the role of serum lipids and comorbidities in the onset 
and progression (clinical disability and relapse) of the disease. From these studies, the 
following conclusions regarding MS have been drawn: 
 None of the serum lipid-related variables were significantly associated with 
conversion to CDMS. 
 It was demonstrated that higher BMI, TC, ApoB and ApoB/ApoA-I ratio were 
associated with higher disability; and that a higher BMI and TC/HDL ratio was 
associated with progression of disability. 
 There was significant association between BMI, triglycerides and the hazard of 
relapse in the AusLong study but not in the MSL study. 
 The age-standardised prevalence of hypertension, dyslipidaemia, psoriasis, eczema, 
asthma and anaemia was significantly higher in the MSL study compared to the 
general Australian population.  
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 Overweight/obesity and dyslipidaemia as comorbidity in MS patients was associated 
with significantly higher disability.  
 Rheumatoid arthritis and anaemia as comorbidity in MS patients were associated with 
increased risk of subsequent relapse. 
  
8.5 Future directions 
A number of research questions that warrant further investigation have arisen from this work.  
Australian datasets such as the Australian Multiple Sclerosis Longitudinal Study (AMSLS) 
and Ausimmune Longitudinal Study (AusLong) datasets can be used to contribute to the 
body of evidence. I have secured a Post-Doctoral Fellowship which will enable me conduct 
large part of the research proposed below. 
8.5.1 Is a history of particular comorbidity associated with a higher risk of MS?  
In the general population, the occurrence of comorbid kidney disease,
5
 diabetes
6
 and 
hypertension
7
 has been associated with increased risk of cardiovascular disease. There is 
currently limited data as to whether history of particular comorbidity may be associated with 
a higher risk of MS. In a Danish population-based cohort study
8
 assessing the risk of MS in 
individuals with type 1 diabetes (T1D), the expected incidence rate for MS in patients with 
T1D was more than three-fold higher than what was expected based on available incidence 
rate data in Denmark. Further studies using these large datasets should be conducted to verify 
this finding. 
8.5.2 Are people with clinically definite MS at increased risk of developing 
comorbidities compared to the general population? 
In people with MS, increasing evidence suggests that comorbidities are prevalent
4, 9
 and may 
be associated with the clinical course of the disease.
10
 From the existing literature it is 
however unclear whether people with MS are at increased or reduced risk of comorbidities 
compared with the general population. In a study by Kang and colleagues, MS patients were 
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more likely to have rheumatoid arthritis, hypertension, hyperlipidaemia, diabetes, systemic 
lupus erythematosus, and peripheral vascular disorders. However in other studies, the 
prevalence of comorbid rheumatoid arthritis
11
, hypertension
12
, hyperlipidaemia and
13
 
diabetes
14
 were lower in MS patients compared to control group. Also, studies on the 
comorbidities in MS patients from the Australian region are lacking.  
 
8.5.3 Are people with MS worse off in their relapse and disability if they have 
comorbidities? 
While there is enough evidence in the general population that comorbidities are associated 
with increased disability,
15
 there is only one high quality study that investigated the 
relationship between comorbidities and level of disability in people with MS. In this 
particular study, Marrie and colleague reported that individuals with MS who developed 
vascular comorbidities at any point during their disease course had significantly increased 
risk of ambulatory disability compared with MS patients who did not report comorbidities.
4
 
Our study group has shown that anaemia and rheumatoid arthritis may be associated with 
increased risk of relapse. We will have the opportunity to investigate this further using larger 
datasets. 
8.5.4 Is there a relationship between comorbidities and reduced health-related quality 
of life in people with MS?  
While comorbidities are associated with reduced health-related quality of life (HRQOL) in 
the general population,
16, 17
 there is little information on the relationship between 
comorbidities and HRQOL in people with MS. In a study restricted to persons with relapsing-
remitting MS, patients with musculoskeletal and respiratory comorbidities were reported to 
have reduced physical HRQOL
18
 and another study reported that physical comorbidity is 
associated with substantially lower physical HRQOL in MS.
19
 Identification to what extent 
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comorbidities affect HRQOL could prioritise prevention efforts and improve the quality of 
lives of MS patients. 
 
8.5.5 Is the use of disease modifying therapies (DMTs) associated with increased risk of 
comorbidities? 
As demonstrated in the general population, there is accumulating evidence to suggest that 
DMTs may be associated with increased risk of comorbidity in MS. Treatment of MS 
patients with interferon beta has been associated with the risk of developing thyroid 
disorder
20
, psoriasis
21
 ulcerative colitis
22
 and systemic lupus erythematosus.
23
 Unpublished 
data from our Tasmanian Multiple Sclerosis Longitudinal Study showed that use of DMTs 
may be associated with significantly increased risk of developing thyroid dysfunction and 
eczema. The period of investigation in these studies is often too short to determine the long 
term effect of these agents. Large longitudinal datasets with data on DMTs and comorbidities 
should investigate any relationship between long term use of DMTs and risk of comorbidity.  
8.5.6 Are comorbidities associated with high health care costs? 
Comorbidities are known to have strong negative effects on health status and health services. 
In the general population, comorbidity have been associated with greater health care 
utilisation, including more hospital admissions, longer stays in hospital.
17
 In a recent study by 
Marrie and colleagues, MS patients with one or more comorbidities had a two-fold higher all-
cause hospitalization rate compared to MS patients without any comorbidity.
24
 Higher health 
care usage and treatments will lead to higher health care costs. A study in the general 
population attributed 36.4%% of health care expenditure for people with diabetes to 
comorbidities.
25
 There is currently no study on the relationship between comorbidities and 
health care cost in people with MS. Using the economic survey data from the AMSLS, we 
will be able to investigate the health care cost due to comorbidities.  
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